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ABSTRACT 
 
RONG ZHAO: Experimental Approaches to Measuring Brain Exposure:  
Rate, Extent and Regional Distribution 
(Under the direction of Gary M. Pollack, Ph.D.) 
 
The objective of this project was to understand the influence of physicochemical 
properties of compounds, biologic factors and physiologic factors on the kinetics (rate, 
extent and regional distribution) of brain uptake. The initial rate of brain uptake was 
determined using in situ brain perfusion in mice, and was found to vary widely among 
different compounds. Lipophilicity and ionization state, brain tissue unbound fraction, 
and P-gp-mediated efflux were important determinants of the rate of brain uptake. 
Fexofenadine was poorly permeable at the blood-brain barrier (BBB) and the slow 
equilibration of this compound between brain tissue and blood influenced the accuracy of 
measurement of kinetic parameters such as the P-gp efflux ratio. Pharmacokinetic 
simulations and continuous subcutaneous infusion with osmotic minipumps provided 
evidence of time-dependency in fexofenadine P-gp efflux ratio at the BBB. The more 
permeable precursor, terfenadine, was biotransformed to fexofenadine in brain tissue and 
increased fexofenadine brain exposure. The potential functional efficiency of breast 
cancer resistance protein (Bcrp), which shares similar expression pattern and substrate 
specificity with P-gp, was evaluated using in vitro, in situ and in vivo experimental 
approaches. While Bcrp effectively mediated substrate flux in vitro, it had limited impact 
on brain tissue exposure in situ or in vivo. The impact of local perfusion flow rate, 
iv 
capillary density, and P-gp activity on regional exposure to colchicine, quinidine, 
verapamil, diazepam and loperamide was evaluated in mdr1a(+/+) and mdr1a(-/-) mice 
using the in situ brain perfusion and in vivo administration together with brain 
microdissection technique. The regional perfusion rate varied 7.5-fold, and capillary 
density varied 3.7-fold, among the thirteen brain regions examined. Regional flow 
correlated with capillary density (R2=0.955). Regional P-gp-mediated efflux activity for 
colchicine and verapamil was directly proportional to local capillary density. Verapamil 
brain uptake was reduced with decreased blood perfusion rate, and P-gp-mediated efflux 
in less-perfused brain regions was influenced by changes in flow. In well-perfused brain 
structures, flow had no or little effect on P-gp activity. Taken together, these results 
provide a framework for understanding the multiplicity of interactive factors that 
determine regional brain exposure in intact animals. 
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CHAPTER 1 
INTRODUCTION 
2 
The time course of central nervous system (CNS) pharmacologic response is a complex 
function of CNS pharmacokinetics (drug exposure at the site of action) and 
pharmacodynamics (the relationship between the biologic response and drug 
concentration at the site of action). The presence of the blood-brain barrier (BBB) at the 
interface between the brain and the systemic circulation significantly restricts the entry of 
many molecules into the brain, including new chemical entities and potential drugs with 
intended central activity.  
Drug presentation to CNS sites of action also is a complex multi-process phenomenon 
dependent upon movement of therapeutic agents from the site of administration to the 
bloodstream (systemic pharmacokinetics) and then from the bloodstream to the site of 
action (CNS pharmacokinetics). Understanding how, and at what rate, drugs access CNS 
target sites often is problematic due to the complexity of the organ per se, as well as to 
the limitations inherent in available experimental methodologies. These limitations are 
especially evident, albeit understandable, in clinical pharmacology studies.  
The brain is a compartmentalized organ, in terms of both macro- and micro-architecture. 
The biophase (i.e., the specific location of the target receptor and the surrounding 
microenvironment) can be accessed from the extracellular fluid (ECF), intracellular fluid 
(ICF), or in some cases the cerebrospinal fluid (CSF). In addition, therapeutic targets are 
not distributed homogeneously throughout the brain. Thus, measurement of drug uptake 
into whole brain, which typically is performed in preclinical CNS pharmacokinetic 
studies, may not provide an accurate representation of drug exposure at the target site.  
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Recently, in vitro, in situ, and in vivo models have been developed to study many aspects 
of CNS pharmacokinetics, including the rate and extent of BBB penetration. Significant 
recent attention has been paid to the mechanisms that determine BBB permeation. 
However, factors that influence regional drug exposure in brain, and thereby determine 
drug presentation to the site of action following BBB penetration, are only beginning to 
be appreciated. Factors that influence the systemic (absorption, distribution, metabolism 
and elimination), and CNS (protein binding in plasma and brain tissue, BBB permeability, 
active transport and metabolism, CSF turnover, local cerebral blood flow rate, capillary 
density, and regional transporter and metabolizing enzymes expression level and 
functionality) all contribute to the determinants of drug exposure at the site of action and 
the resultant pharmacologic or toxic effect (Brodie et al., 1960; Fenstermacher et al., 
1981; Schinkel et al., 1994; Kalvass and Maurer, 2002; Liu et al., 2004; Liu and Chen, 
2005; Kalvass et al., 2007a). 
THE BLOOD-BRAN BARRIER (BBB) 
The BBB is the primary interface between the CNS and the systemic circulation. The 
BBB is formed by a continuous monolayer of brain capillary endothelial cells. The 
highly-developed tight junctions, as well as a lack of fenestrae and limited pinocytic or 
transcytotic activities, significantly limit brain penetration of many endogenous and 
exogenous compounds, including therapeutic agents. This physical barrier only allows 
compounds with lipid solubility to traverse it. Physicochemical properties such as 
molecular weight, pKa, lipophilicity, polar surface area, and the number of hydrogen 
bonds are important determinants of BBB penetration (Brodie et al., 1960).  
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The BBB is not only a structural barrier, but also a functional  barrier regulating the 
turnover of endogenous and exogenous substrates by active transport and metabolism in 
the brain (Strobel et al., 2001; Begley, 2003; Begley, 2004a; Graff and Pollack, 2004; 
Terasaki and Ohtsuki, 2005). The most important physiologic role of BBB functionality 
is to control precisely CNS homeostasis. The BBB supplies amino acids, glucose, and 
creatine to the brain through the action of specific carrier systems expressed at the brain 
capillary endothelial cells. The BBB also is involved in the brain-to-blood efflux 
transport of neurotransmitters (e.g., γ-aminobutyric acid, dopamine) and metabolites of 
neurotransmitters and neurosteroids (e.g., dehydroepiandrosterone sulfate) (Graff and 
Pollack, 2004; Ohtsuki, 2004; Terasaki and Ohtsuki, 2005). The BBB functionality is 
regulated by the surrounding astrocytes, neurons, pericytes and microglial cells. The 
expression of transporters, GLUT1, MCT1, P-gp and Mrps at the BBB is modulated by 
dietary and pathological conditions (Koehler-Stec et al., 1998; Terasaki and Pardridge, 
2000; Ohtsuki, 2004; Terasaki and Ohtsuki, 2005; Ohtsuki and Terasaki, 2007). An 
alteration in BBB function may lead to several CNS disease etiologies and 
neurodegenerative disorders, including recent speculation regarding Alzheimer’s disease 
(Vogelgesang et al., 2004; Zlokovic, 2004). 
THE BLOOD-CEREBROSPINAL FLUID BARRIER (BCSFB) 
The BCSFB is a composite barrier comprised of the choroid plexi, the arachnoid 
membrane, and the periventricular organs (including the area postrema, median eminence, 
neurohypophysis, and pineal gland) (de Lange, 2004; Strazielle et al., 2004). The choroid 
plexus epithelium is sealed by tight junctions, and expresses various efflux transporters 
and metabolizing enzymes, in a manner similar to the BBB. The BCSFB provides a 
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functional barrier between blood and CSF, just as the BBB serves as a functional barrier 
between blood and brain ECF. The surface area of BCSFB is about three orders of 
magnitude less than that of the BBB (de Lange, 2004), and to date the BCSFB is 
understudied. 
CSF is secreted by the choroid plexus, located anatomically in the lateral, third and fourth 
ventricles of the brain. The bulk flow of CSF moves from the site of formation, through 
the ventricles and subarachnoid spaces, then is reabsorbed into venous blood at the 
arachnoid villi. During this passage, CSF has direct communication with the brain ECF 
spaces close to the cortex surface (Shen et al., 2004). Little is known about the kinetics of 
solute exchange between these two fluid compartments. Such information is necessary to 
understand the distribution and clearance kinetics of drugs in the brain. The estimated 
bulk flow clearance in mice can be as high as 0.7 µl/min/g (Rudick et al., 1982). The CSF 
is turned over every 5-7 hr or about 4 times a day in human, whereas turnover is every 2 
hr (twelve times a day) in mice (Shen et al., 2004). CNS bulk flow and constant CSF 
turnover may act as a significant clearing mechanism for polar hydrophobic molecules 
with low BBB permeability (Liu and Chen, 2005). 
In the treatment of certain brain diseases such as meningitis, the therapeutic target is in 
close contact with the ventricular CSF. CSF concentrations therefore are directly related 
to the biophase concentration in these cases. Intracerebroventricular administration has 
been proposed to enhance the targeted delivery of therapeutic agents to specific brain 
regions (Johanson et al., 2005). For the treatment of most CNS diseases (e.g., 
Alzheimer’s disease, Parkinson’s disease, epilepsy, neurotropic pain), however, the brain 
ECF is assumed to be in direct contact or equilibrium with the unbound drug at the site of 
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action. The drug CSF concentration is sometimes taken as the surrogate measurement of 
brain ECF concentration due to easier accessibility and the assumption of direct 
communication and equilibrium between CSF and ECF. This assumption has been shown 
to be valid for many compounds, especially substrates with moderate to high lipophilicity 
(Liu et al., 2006). However, for drug targets distant from the ventricles, CSF 
concentrations will not necessarily provide useful information regarding drug 
presentation to the site of action due to the complexity of brain compartmentalization, 
especially for compounds that undergo active transport at the BBB and BCSFB. CSF 
concentrations may either under- or over-estimate brain ECF concentrations, depending 
on the specifics of the situation under examination (Wijnholds et al., 2000; Sun et al., 
2001a; de Lange and Danhof, 2002; Anthonypillai et al., 2004; Venkatakrishnan et al., 
2007).  
Knowledge regarding active transport at the BCSFB is relatively limited. Many of the 
transport proteins found at the BBB also are expressed in the BCSFB (Graff and Pollack, 
2004; Soontornmalai et al., 2006). P-gp and Mrp1 are reported to actively transport 
endogenous or exogenous compounds at the BCSFB. Mrp1 is expressed in the basolateral 
membrane of choroid plexus epithelial cells and transports the substrates towards the 
blood circulation, while P-gp is expressed in the apical side and has the opposite transport 
direction towards the CSF (de Lange, 2004). Transfer of endogenous thyroid hormones 
into the brain is mediated by P-gp and Oatps at the BCSFB (Kassem et al., 2007). 
Prevention of the entry of harmful compounds into the CSF and/or elimination of such 
compounds from the CSF potentially contribute to overall CNS protection.  
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The choroidal epithelial cells also express a high level of several metabolic enzymes. The 
coupled metabolism-efflux process results in synergistic protection of the choroids plexus. 
The metabolite of 1-naphthol, catalyzed via uridine diphosphate glucuronosyltransferase 
(UGT) conjugation, was actively transported into the blood circulation (Strazielle and 
Ghersi-Egea, 1999). Glutathione S-transferase and glutathione peroxidase have been 
found in high levels at the BCSFB. Epoxide hydrolase and UGTs also have been 
identified with high activities, similar to those in the liver. In addition, the BCSFB 
expresses high level of several cytochrome P450 isoenzymes, which might be important 
for the metabolism of therapeutic agents (Ghersi-Egea et al., 1994).  
CARRIER-MEDIATED TRANSPORT AT THE BBB 
Increasing evidence has shown that drug flux across the BBB is subject to active and 
facilitated transport processes, rather than simple passive diffusion alone (Taylor, 2002; 
Begley, 2003; Begley, 2004a; Ohtsuki and Terasaki, 2007). At least 15 mRNAs of drug 
transport proteins belonging to several subfamilies are expressed at the BBB (Bauer et al., 
2003). These drug transporters consist of uptake and efflux transport systems. The uptake 
transporters at the BBB facilitate the influx of nutrients and endogenously-generated 
compounds such as glucose and amino acids. Major efflux transporters at the BBB 
belong to the ATP-binding cassette (ABC) superfamily. These efflux transporters 
decrease the effective brain ECF concentrations by attenuating brain uptake and/or 
enhancing brain efflux (Golden and Pollack, 1998; Syvanen et al., 2006). The members 
of the ABC superfamily of transport proteins relevant to the BBB include P-glycoprotein 
(P-gp), breast cancer resistance protein (Bcrp), and multidrug resistance associated 
proteins (Mrps). Other transporters, such as organic anion transport peptides (Oatps) and 
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organic anion transporters (Oats) also have been reported to be expressed and functional 
in the transport of endogenous and exogenous compounds (e.g., thyroxine, fexofenadine) 
into and/or out of the brain (Cvetkovic et al., 1999; Tohyama et al., 2004). P-gp knockout 
mice, as well as animals naturally deficient in the protein, have been in use for more than 
a decade, and the impact of P-gp on brain exposure and pharmacologic response has been 
well established. With recently-developed knockout mouse models for other transport 
proteins, it should be possible to probe the role of other efflux transporters at the BBB. 
P-glycoprotein (P-gp) 
P-gp is a 170-kDa membrane-bound protein encoded by multidrug resistance gene 
ABCB1 (formerly, MDR1 in human, mdr1a and mdr1b in rodents). P-gp was first 
identified in multidrug resistant cancer cells, and mediates the efflux of anticancer drugs 
out of the cells and decreases their intracellular concentration (Kartner et al., 1983). P-gp 
subsequently was found to be expressed in normal tissues such as the small intestine, 
liver, kidney and brain. The functional efficiency of P-gp has been studied extensively 
using various in vitro cell-based models, in situ, and in vivo animal models, as well as in 
human clinical studies.  
P-gp is involved in many aspects of drug exposure in the body, including intestinal 
secretion, hepatobiliary excretion, and renal elimination. However, P-gp appears to have 
only a modest influence on systemic clearance and/or plasma concentrations following 
intravenous administration (studies comparing wild-type and gene-knockout mice), 
suggesting that P-gp has minimal effect on systemic disposition (Chen et al., 2003b). 
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However, P-gp has a profound influence on distribution into certain sanctuary or 
protected tissues or organs, including the brain.  
P-gp mediates the efflux of a wide range of substrates at the BBB, and net brain 
penetration of P-gp substrates has been reported to be decreased by 2- to nearly 100-fold 
in the presence of P-gp expression at the BBB (Schinkel et al., 1994; Kalvass et al., 2004). 
In the brain, P-gp is principally expressed at the luminal side of the brain capillary 
endothelial cells. Expression of the transport protein in microglia, astrocytic end feet and 
parenchymal neurons also has been demonstrated, especially under pathological 
condition when the transporter is upregulated (Seegers et al., 2002; Volk and Loscher, 
2005). Several studies have confirmed that the P-gp expression level is enriched in the 
brain endothelial cell fraction, while it is undetectable in the endothelial cell-negative 
fraction or whole brain homogenate (Demeule et al., 2001).  
P-gp is a gatekeeper at the BBB and limits the entry of many therapeutic agents into the 
brain. Direct evidence for this function came from drug distribution studies in genetic 
knockout or naturally-mutant P-gp-deficient mdr1a(-/-) and mdr1a/1b(-/-) mice (Schinkel 
et al., 1994; Kalvass et al., 2004), as well as selective or specific chemical inhibition (P-
gp modulators such as quinidine, PSC 833, cyclosporine A) (Choo et al., 2000). The 
resultant change of pharmacologic response following P-gp knockout also has been 
revealed. The first evidence for a P-gp-dependent modulation of biologic response in the 
CNS came from administration of the antihelminthic drug ivermectin, which caused 
significant neurotoxicity and deaths in P-gp-deficient animals (Schinkel et al., 1994). In 
addition, the antinociceptive effect of a µ-opioid peptide, DPDPE ,was found to be 
attenuated by P-gp-mediated efflux at the BBB (Chen and Pollack, 1997; Chen and 
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Pollack, 1999). Loperamide, a potent µ-opioid agonist, evidenced significant central 
antinociceptive effect in mdr1a(-/-) mice, but brain uptake in P-gp-competent mice was 
so limited that a central effect could not be elicited (Kalvass et al., 2004).  
The foregoing results suggested that the drug candidates for intended CNS therapy with 
adequate lipid solubility will stand a better chance of success in the drug development 
process if they are not substrates of P-gp. P-gp-mediated efflux was found to be one of 
the factors that differentiate CNS from non-CNS drugs using in vitro models (Mahar 
Doan et al., 2002). A recent review demonstrated that more than 20 marketed 
psychotropic drugs have no or very weak interaction with P-gp in vivo (Ejsing et al., 2007; 
Linnet and Ejsing, 2007). In contrast, for peripheral therapeutic targets, P-gp-mediated 
efflux at the BBB decreases the possibility of neurotoxic effects. As exemplified by the 
second-generation nonsedating antihistamines, fexofenadine and cetirizine, brain uptake 
limited by P-gp-mediated efflux can improve the therapeutic profile for a peripherally 
acting agent. In the case of anthistamines, efflux transport limits the potential for the 
undesirable sedative effect for second-generation drugs, while brain uptake of the first-
generation antihistamine hydoxyzine is not limited by BBB P-gp, resulting in marked 
sedative side effects (Chen et al., 2003a; Polli et al., 2003). Another relevant example is, 
domperidone, a highly efficient and specific dopamine antagonist in vitro. Domperidone 
cannot be used as an antipsychotic (neuroleptic) because it does not cross the BBB 
readily. However, it is used clinically as an antiemetic agent to counteract the unwanted 
dose-limiting peripheral side effects of dopamine-agonist drugs (e.g., bromocriptine and 
levodopa) used for the treatment of Parkinson’s disease, owing to its action on peripheral 
dopamine receptors (Schinkel et al., 1996).  
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The expression and function of P-gp at the BBB can be modulated by many factors, 
including pathological conditions and drug treatment (Bauer et al., 2005; Volk and 
Loscher, 2005). This is an important aspect of CNS therapy. However, only a few studies 
have addressed the importance of unintended functional BBB modulation. One relevant 
example is the up-regulation of P-gp at the BBB by rifampin treatment, which occurs via 
the human nuclear pregnane X receptor (PXR) pathway. In mice transfected with human 
PXR, up-regulation of P-gp by rifampin pretreatment reduced the central antinociceptive 
efficacy of methadone by ~70% (Bauer et al., 2006). 
Breast Cancer Resistance Protein (Bcrp) 
Bcrp is a recently-identified member of ABC efflux transporter encoded by gene Abcg2 
(Doyle et al., 1998). Bcrp is widely expressed in the intestine, liver, mammary gland, and 
placenta. The functional effects of Bcrp in these organs, such as intestinal secretion, fetal 
penetration, and secretion into breast milk of various compounds (e.g., topotecan, 
nitrofurantoin, and cimetidine) has been documented (Jonker et al., 2000; Jonker et al., 
2005). Bcrp also is expressed on the luminal side of brain capillary endothelial cells, 
sharing the same localization as that of P-gp, and the Bcrp mRNA expression level is 
similar to that of P-gp. Bcrp mediates the efflux of a wide variety of substrates, from 
sulfoconjugated organic anions to various organic cations (Maliepaard et al., 1999; 
Cooray et al., 2002; Eisenblatter and Galla, 2002; Eisenblatter et al., 2003; Cisternino et 
al., 2004; Aronica et al., 2005; Lee et al., 2005; Tanaka et al., 2005). The extensive 
overlap of Bcrp with P-gp in expression pattern and substrate specificity led to the 
speculation that Bcrp, like P-gp, might have significant impact on the pharmacologic 
handling of substrate drugs in animals and humans. However, studies to date have shown 
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that Bcrp function at the BBB is speculative. Some results have indicated that Bcrp is an 
important functional component of the BBB, e.g., Bcrp completely abolished brain 
penetration of three phytoestrogens (Enokizono et al., 2007). Imatinib mesylate brain 
penetration was decreased by 2.5-fold in wild-type mice compared to Bcrp-deficient mice 
(Breedveld et al., 2005). However, other experiments have been unable to ascribe an 
effect of Bcrp on substrate permeation across the BBB. The initial rate of brain uptake of 
imatinib mesylate was comparable between wild-type and Bcrp1(-/-) mice, and treatment 
with GF120918 (elacridar, a P-gp and Bcrp inhibitor) did not change brain uptake of 
imatinib in mdr1a/1b(-/-) mice (Bihorel et al., 2007). Bcrp appears to play only a minor 
role in mitoxantrone and DHEAS brain uptake (Lee et al., 2005). Bcrp has also been 
reported to be upregulated in the brain of epileptic patients (Vander Borght et al., 2006). 
The pharmacologic relevance of this modulation, however, remains unknown. 
Interestingly, compared to P-gp, Bcrp has a more significant role in limiting systemic 
bioavailability after oral administration (Jonker et al., 2000; Sparreboom et al., 2005). 
The discrepancies in apparent Bcrp effects (or lack thereof) at the BBB require further 
investigation.  
Multidrug Resistance Associated Proteins (Mrps) 
Mrps also are reported to be expressed at the human and rodent BBB (Sun et al., 2003; 
Strazielle et al., 2004). Little is known about the functional efficiency of brain Mrps, in 
part because they consist of nine isoforms (Mrp1-9). The Mrps primarily transport 
organic anions. Mrp1, 2, 4, and 5 are expressed in human and rodent brains, as 
demonstrated using isolated microvessels and tissue sections. However, the localization 
and functional efficiencies of the BBB Mrps remain controversial (Berezowski et al., 
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2004; Nies et al., 2004; Zhang et al., 2004). Mrp1 was found to be functional at the BBB 
by some (Sugiyama et al., 2003), but not by others (Cisternino et al., 2003; Sasabe et al., 
2004). Mrp2 has been demonstrated to be functional at the BBB using isolated brain 
capillaries or brain microdialysis (Miller et al., 2000; Miller et al., 2002; Potschka et al., 
2003), but several other groups failed to demonstrate Mrp2 expression or activity in the 
brain tissue (Sugiyama et al., 2003; Nies et al., 2004; Zhang et al., 2004). Recently, Mrp4 
at the BBB was reported to mediate the efflux of nucleotide drugs such as PMEA and 
puromycin, with 2- to 3-fold higher brain penetration of these substrates in gene knockout 
animals (Zhang et al., 2000; Adachi et al., 2002a; Adachi et al., 2002b; Sampath et al., 
2002). The difficulties associated with the study of Mrps at the BBB using gene knockout 
animals might be the development of compensatory mechanisms by one or more 
members of the same family. Similar problems are associated with chemical inhibition 
studies. MK571 was widely used to inhibit Mrps. However, no specific inhibitor for each 
member has been identified. Probenecid was considered as a selective Mrp inhibitor. 
However, probenecid has been found to inhibit Oatps and Oats as well as the Mrps 
(Wang et al., 1997), further emphasizing the difficulties inherent in the design and 
interpretation of transport inhibition studies in the intact BBB.  
BBB DRUG METABOLIZING ENZYMES 
The expression of drug metabolizing enzymes at the blood-brain and CSF-brain 
interfaces, glial cells and neurons indicates that the BBB can also be a metabolic barrier 
that provides an additional mechanism to protect the brain (Strobel et al., 2001; Miksys 
and Tyndale, 2002; Meyer et al., 2007). The importance of brain metabolism was not 
appreciated until recently because enzyme levels in the organ are relatively low compared 
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to the liver. However, the expression of metabolizing enzymes in the brain is region- and 
cell-specific. In some brain regions (e.g., choroid plexus), the expression level and 
functional activity of drug metabolizing enzymes are as high as, or even higher than, in 
liver (Ghersi-Egea et al., 1994).  
Cytochromes P450, epoxide hydrolase, as well as conjugating enzymes are expressed in 
the brain. More than 75% of marketed drugs are metabolized by P450s. So it is 
reasonable to speculate that the P450s expressed in brain might influence the local 
metabolism of therapeutic agents after penetration of the BBB. Brain P450s are not likely 
to influence the overall clearance of substrates from the body, due to the low absolute 
expression level (only about 1-10% of liver content). Nonetheless, these 
biotransformation reactions may be important determinants of substrate (or active 
metabolite) presentation to central sites of action. Mouse CYP3A11 and CYP3A13, the 
counterparts of human CYP3A4, were responsible for 6β-hydroxylation of testosterone in 
the brain, and activity was inducible by antiepileptic drug phenytoin treatment 
(Hagemeyer et al., 2003; Meyer et al., 2006). Early studies also showed that codeine is 
metabolized to morphine in the brain, thereby exerting an analgesic effect (Chen et al., 
1990). The data on regional metabolism in brain are scarce, however. The importance of 
local metabolism, regional modulation and perturbation on endogenous metabolic 
pathways due to drug treatment, are only beginning to be appreciated.  
CENTRAL NERVOUS SYSTEM KINETICS 
The onset and offset of CNS effect is determined by many factors that influence the 
movement of the drug from the site of administration to the site of action. It is assumed 
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that the unbound drug at the site of action drives the biologic effect. The rate and extent 
of drug presentation to the site of action are dependent on passive permeability at the 
BBB, nonspecific binding in blood and brain, and active transport and metabolism in the 
brain, any of which could be changed by pathophysiologic conditions (Klein et al., 1986; 
Kalvass and Maurer, 2002; Norinder and Haeberlein, 2002; Liu and Chen, 2005). For 
many centrally acting drugs, flux across the BBB is the rate-limiting step in the 
presentation of drug to the site of action. The importance of studying cerebral kinetics has 
been realized, especially for the analgesic drugs (Villesen et al., 2006a; Villesen et al., 
2006b; Kalvass et al., 2007b).  
The rate of brain uptake is dependent on the intrinsic permeability at the BBB, active 
transport and nonspecific binding in brain tissue (Hammarlund-Udenaes et al., 1997; Liu 
et al., 2005). The rate of brain equilibration is directly proportional to the product of 
permeability and unbound fraction (PS×fu,brain) under passive diffusion (Liu and Chen, 
2005; Liu et al., 2005). Low passive permeability does not necessarily indicate that a 
compound will have a poor CNS distribution. If fu,brain is large, then it is possible for a 
compound with low passive permeability (e.g., theobromine) to have unimpaired and 
adequate CNS distribution (Liu et al., 2005). 
The extent of brain penetration, commonly described by brain-to-plasma concentration 
ratio or brain partition coefficient kp,brain, is determined by the relative binding in blood 
and brain tissue, active transport and metabolism at the BBB, as well as the sink action of 
CSF bulk flow (Liu and Chen, 2005). The in vitro unbound fraction ratio (plasma to brain 
tissue) and P-gp efflux ratio have been used successfully to predict brain penetration 
(Kalvass and Maurer, 2002; Maurer et al., 2005; Summerfield et al., 2006; Kalvass et al., 
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2007a). However, it has been recognized that unbound brain concentration is the more 
relevant predictor of biological response (Martin, 2004; Pardridge, 2004). For compounds 
that undergo passive diffusion at the BBB, the unbound plasma and brain concentrations 
will be equal at steady-state or post distributional equilibrium. When CNS distribution is 
impaired by active efflux, metabolism, or CSF bulk flow, the unbound brain 
concentration will be normally lower than the unbound plasma concentration.  
The brain is a highly anatomically- and functionally-specialized organ. Blood flow varies 
~18-fold in different brain regions in rat (Fenstermacher et al., 1991). Brain capillary 
density, pharmacologic receptors, and expression of transporters are not homogeneously 
distributed in the brain (Sakurada et al., 1978; Duelli and Kuschinsky, 1993; Heiss and 
Herholz, 2006). To date, little is known about how drugs distribute within the brain to the 
site of action, and thus the ultimate fate of a given drug in the brain after the penetration 
through the BBB typically is unkown.  
From a pharmacokinetic standpoint, the brain can be viewed as being compartmentalized 
into cerebral capillary, CSF, extracellular fluid, and intracellular fluid compartments. 
Most CNS targets are membrane receptors, and in these cases the brain ECF 
concentration will drive the effect. In contrast, for the treatment of HIV and brain tumors, 
the relevant driving-force will be the intracellular concentration. CSF concentration 
might be representative of the biophase concentration when the target resides in the 
ventricular organs. Depending on the localization of the target site, the assessment of 
local unbound concentration at the target site needs to be considered in experimental 
design.  
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Other factors that might influence regional drug exposure also need to be considered in 
CNS therapy. Clinical practice has shown variations in sensitivity to therapeutic effect or 
CNS side effects when the target site resides in different brain regions. For example, the 
hippocampus is especially vulnerable to ischemia and colchicine cytotoxicity 
(Goldschmidt and Steward, 1980; Cavaglia et al., 2001). Chemotherapeutic agents in 
combination with transient reversible hyperosmotic opening of the BBB have been used 
to treat brain tumors. Both in vivo and in situ studies have demonstrated that variations 
exist in BBB disruption in different brain regions following hyperosmotic treatment, 
suggesting that clinical efficacy of hyperosmolar disruption therapy may be affected by 
the location of the tumor within the brain (Chiueh et al., 1978; Brown et al., 2004). 
Region-specific overexpression of P-gp decreased phenytoin concentration in the 
temporal hippocampus and parahippocampal cortex region in chronic epileptic rats (van 
Vliet et al., 2007). Previous studies demonstrated that P-gp-mediated efflux at the BBB 
influenced regional distribution of 3H-verapamil to different extents in different brain 
regions (Graff et al., 2005; Appendix). Knowledge of the regional cerebral vascular 
volume and blood flow rate, as well as regional P-gp activity, is of particular interest with 
regard to effective treatment of cerebral diseases. 
EXPERIMENTAL APPROACHES 
For CNS drug discovery and development, choosing the best experimental models for the 
BBB, as well as other aspects of drug distribution in the brain, depends on a variety of 
logistical issues (cost, time) as well as how closely a model needs to resemble in vivo 
conditions (Fenstermacher et al., 1981; Bonate, 1995). In vitro modeling of the BBB is a 
simplification of the in vivo situation. Cellular BBB assays are more cost-effective, and 
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represent high-throughput techniques in comparison to in situ and in vivo methods. There 
is, of course, concern as to how well such models mimic the structure and function of the 
BBB in the intact organism. In situ brain perfusion is an accurate method for studying the 
rate of BBB penetration, although it requires significant technical expertise. In vivo 
distribution studies provide direct measurement of BBB penetration, but are labor-
intensive. In situ and in vivo methods are especially useful to assess transporter kinetics 
in gene knockout animal models.  
In Vitro Models 
The development and application of in vitro systems have facilitated important progress 
in understanding the biochemical properties of the BBB (Gumbleton and Audus, 2001; 
Terasaki et al., 2003; Cecchelli et al., 2007). In vitro cell-based models have provided 
efficient screening in the early phase of drug development, in addition to allowing the 
efficient generation of large data sets. Cultured brain microvessel endothelial cells 
(BMECs) from different species, as well as non-cerebral-origin cell lines such as MDCK 
and LLC-PK1, have been developed over the past several years. In many evaluations of 
BBB function and transport, the relevance of in vitro BBB models is justified by 
comparison with data obtained through the use of in vivo methodologies. The limitations 
of primary BMECs or cultured cell lines lie predominantly in the “leaky” tight junctions 
characteristic of these models, and thus paracellular permeability that is higher than in 
vivo. In addition, the regulation of efflux transporters in cultured BMECs may be 
different than in the intact animal. These cell-based models nevertheless have been 
successfully used to rank order the passive permeability of the screening compounds 
(Hansen et al., 2002; Mahar Doan et al., 2002).  
19 
A variety of in vitro assays have been developed to assess the potential for compounds to 
act as P-gp substrates, inhibitors and/or inducers, such as the monolayer efflux assay, the 
ATPase assay, and the calcein-AM fluorescence assay (Gumbleton and Audus, 2001; 
Carrara et al., 2007). Among these methods, the monolayer efflux assay employing P-gp-
expressing polarized cell monolayers is considered a standard method for identifying 
compounds as P-gp substrates and/or inhibitors. This approach also can provide 
important information on drug transport kinetics. Efflux transporters such as P-gp, Mrps, 
and Bcrp stably single-, double-, and triple-transfected cell lines based on MCDK or 
LLC-PK1 cells have been developed for studying transport kinetics, especially in the 
identification and characterization of P-gp substrates and/or inhibitors, as well as 
potential drug-drug interactions at the level of active transport at the BBB (Polli et al., 
2001; Rautio et al., 2006). 
Isolated brain microvessels also have been used for the study of carrier-mediated 
transport at the BBB (Miller et al., 2000). However, this method is more technically 
challenging and time-consuming, and is not suitable for drug screening. 
Gene Knockout vs. Chemical Inhibition 
In situ or in vivo studies using gene knockout animal models have provided the most 
convincing evidence of active transport at the BBB (Schinkel et al., 1994; Sugiyama et al., 
2003; Assem et al., 2004; Breedveld et al., 2005; Doran et al., 2005; Zelcer et al., 2005; 
Johnson et al., 2006). Gene knockout mice do not display clear physiologic abnormalities 
or a decreased life span (Schinkel, 1999). Single gene (P-gp, Mrp1, 2, 3, 4, or Bcrp) or 
double gene Abcg2/Mrp4(-/-) knockout mouse models have been developed and used in 
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the study of drug transport at the BBB (Chen et al., 2003b; Sugiyama et al., 2003; Lee et 
al., 2005; Takenaka et al., 2007). P-gp knockout, or the natural mutant P-gp-deficient 
mice mdr1a(-/-) and mdr1a/1b(-/-). have been in use for more than a decade, and P-gp is 
the most well studied efflux transporter at the BBB to date. P-gp knockout mice have 
become important tools used in the drug screening process (Cisternino et al., 2001; Chen 
et al., 2003b; Doran et al., 2005). P-gp can have a profound effect in attenuating the rate 
and extent of brain penetration, although the transport protein appears to have only a 
limited contribution to the systemic clearance of P-gp substrates (Chen et al., 2003b). The 
impact of a specific efflux transporter on the in vivo CNS distribution can be described by 
the ratio of kp,brain or uptake clearance (Clup) in gene-deficient mice relative to gene-
competent mice (Kalvass and Pollack, 2007). The knockout of a single efflux transporter 
gene (Mrps, Bcrp or P-gp) significantly increased the brain penetration of substrates by 2- 
to nearly 100-fold (Chen et al., 2003b; Enokizono et al., 2007; Kalvass et al., 2007a; 
Takenaka et al., 2007). 
One important disadvantage to gene knockout models is that compensatory mechanisms 
can develop in these animals that influence substrate flux (Cisternino et al., 2004; 
Takenaka et al., 2007). In addition to the modulation of transport proteins, the activity of 
other compensatory systems (metabolic enzymes, receptors, or post-receptor signaling) 
might change in response to loss of the target gene. Thus, careful control experiments 
must be conducted to rule out specific and non-specific changes in substrate 
pharmacokinetics and pharmacodynamics in response to the genetic perturbation.  
Chemical inhibition with specific transport modulators also has provided useful 
information regarding the function and pharmacologic consequences of efflux transport at 
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the BBB (Kemper et al., 2003; Elsinga et al., 2004; Kemper et al., 2004). The most 
important problem associated with chemical inhibition as a probe of transport-mediated 
drug distribution across the BBB is the degree to which chemical inhibitors are specific 
for the target transporter. Verapamil and quinidine inhibit P-gp function, but also inhibit 
metabolic enzymes (Sikic et al., 1997). Cyclosporine A and GF120918 inhibit both P-gp 
and Bcrp (Breedveld et al., 2006). The degree to which inhibitors of efflux transport also 
might modulate uptake transporters suach as the Oatps is unclear, but obviously would 
yield confounded data that would be very difficult to interpret. It is good general practice 
to utilize both genetic models of transport deficiency and selective chemical inhibition as 
a cross-check. 
Systemic Administration 
Systemic administration [intravenous (i.v.), subcutaneous (s.c.), intraperitoneal (i.p.), or 
oral (p.o)] of a test compound is the most widely used approach for studying systemic 
pharmacokinetics. In terms of CNS kinetics, the rate and extent of brain uptake, as well 
as the regional distribution of test compounds, can be determined by sampling brain 
tissue at a specific time or several time points. The concentrations of substrate in whole 
brain homogenate or dissected specific brain regions can be determined. Systemic 
administration approaches can provide information at steady-state (during continuous 
presentation or multiple discrete dosing) or following the attainment of distribution 
equilibrium (after multiple passages through the systemic circulation). To determine drug 
distribution at steady-state, multiple dosing or continuous i.v. infusion through a venous 
cannula often is used. An alternative method that is particularly useful for compounds 
with long terminal elimination half-lives, or agents that require a long time to achieve 
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distribution equilibrium, is drug administration via osmotic minipumps. These pumps can 
be implanted intraperitoneally or subcutaneously, and release drug continuously at a 
constant rate over an extended time (up to 4 weeks) (www.alzet.com). The surgery 
procedure is relatively simple and time-efficient compared to other techniques. 
Following systemic administration, the extent of brain uptake can be quantitated as the 
brain-to-plasma concentration ratio at steady-state or post distribution equilibrium. An 
equivalent metric, although one that requires a different information set, is the brain-to-
plasma area under the concentration-time curve (AUC) ratio. Unbound drug 
concentrations can be determined based on the unbound fraction measured using in vitro 
equilibrium dialysis (Kalvass and Maurer, 2002; Kalvass et al., 2007a). In silico 
predictive models and high-throughput screening of brain tissue binding have been 
developed (Wan et al., 2007). The systemic administration approach also can be used to 
assess the rate of brain penetration, with a pharmacokinetic modeling approach (Liu et al., 
2005; Kalvass et al., 2007b).  
The effect of active transport at the BBB also can be evaluated using this approach in 
gene knockout animal models or in the presence of chemical inhibitors. The P-gp efflux 
ratio is defined as the ratio of uptake clearance or kp,brain in P-gp-deficient to P-gp-
competent mice. In addition, the concentration dependence due to saturable processes at 
the BBB also can be evaluated using escalating dosing (substrate or inhibitor) regimens 
(Bart et al., 2005; Hsiao et al., 2006).  
Regional drug distribution in different brain structures can be determined by 
microdissection or imaging techniques. Regional physiologic parameters such as blood 
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flow rate and capillary vascular space also can be determined using this method (Ohno et 
al., 1979; Duelli and Kuschinsky, 1993; Dagenais et al., 2000a). For example, the 
regional blood-to-brain glucose transfer in the rat was determined following systemic 
administration of double tracers (Gjedde and Diemer, 1985). 
Among all of the preclinical methodologies, this method most closely resembles the 
clinical situation. However, it is not useful in understanding the specific mechanisms 
underlying brain uptake of a given substrate since the uptake process is a multi-factorial 
event including systemic disposition, nonspecific binding in brain tissue and blood, CSF 
bulk flow, and active transport and metabolism in the CNS. 
Brain Uptake Index (BUI) 
The BUI technique was first introduced for the study of drug penetration of the BBB 
(Oldendorf, 1970). A small-volume bolus of buffered saline or plasma containing tracer 
concentrations of test compound and a permeable reference (e.g., 3H-H2O) is injected 
rapidly into the carotid artery of an anesthetized animal. At a fixed time (~ 5 s) after 
injection, the brain is removed for substrate analysis. The BUI of the test compound then 
is determined as the fraction of test compound extracted from the injection mixture 
relative to the extraction fraction of the permeable reference. 
The BUI method has been used for rank-ordering BBB permeability of a wide variety of 
compounds (Bonate, 1995). A good correlation between BUI and compound lipophilicity 
in adult rat BBB has been reported (Oldendorf, 1974). In addition, this technique can be 
used to examine concentration-dependent efflux transport at the BBB, or in conjunction 
with gene knockout animals or co-injection of chemical inhibitors to assess the impact of 
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loss of efflux transport activity on single-pass substrate uptake into brain. Regional 
distribution in different brain structures can be assessed after single-pass uptake 
following brain microdissection. The main disadvantage of this method is that, by 
definition, it focuses on single-pass permeability, and thus is insensitive for compounds 
with low BBB permeability. These are the very compounds of interest from the 
perspective of significant efflux transport. 
In Situ Brain Perfusion 
In situ brain perfusion was first developed to determine the intrinsic BBB permeability in 
rats (Takasato et al., 1984). In the original method, the brain hemisphere was perfused 
with physiologic buffer or artificial blood via retrograde perfusion through the external 
carotid artery for a time period up to 3 minutes. The rate of brain uptake is calculated as 
uptake clearance based on the initial unidirectional phase of brain uptake. Modification of 
the surgical procedure has been developed. The brain hemisphere of guinea pigs, for 
example, has been perfused for 30 minutes through the internal carotid artery. Subsequent 
capillary depletion allows assessment of drug trapped inside the capillary endothelium 
(Zlokovic et al., 1986). The first in situ mouse brain perfusion in mdr1a(-/-) animals 
extended the use of brain perfusion to the screening of P-gp substrates (Dagenais et al., 
2000a). The in situ brain perfusion approach in rats and mice provided similar 
information regarding BBB penetration for over 20 compounds, suggesting that BBB 
characteristics are conserved across those two species (Murakami et al., 2000). In 
addition, with the commercial availability of various genetic knockout mouse models, the 
in situ mouse brain perfusion technique received increasing attention (Dagenais et al., 
2001a; Cisternino et al., 2003; Dagenais et al., 2004; Lee et al., 2005). The effect of 
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plasma protein binding on brain drug uptake also can be determined by changing the 
composition of perfusion buffer (Mandula et al., 2006; Summerfield et al., 2006; 
Summerfield et al., 2007). Combined with microdissection, in situ brain perfusion also 
has been used to study the regional cerebral hemodynamics and drug distribution in the 
brain (Takasato et al., 1984; Suzuki et al., 1998; Youdim et al., 2004; Parepally et al., 
2006). 
Brain Microdialysis 
Intracerebral microdialysis is a sampling technique that allows continuous measurement 
of brain ECF concentration in rodents, as well as in critically ill patients with severe brain 
injury (de Lange et al., 1997; Boschi and Scherrmann, 2000; Tunblad et al., 2003; 
Rambeck et al., 2006). This technique has been used successfully to assess CNS 
pharmacokinetics of many substrates (Clinckers et al., 2005; Helmy et al., 2007). 
Simultaneous microdialysis in blood and brain provides information on transport kinetics 
of unbound drug (Hammarlund-Udenaes et al., 1997; Evrard et al., 1998). Use of recently 
developed transporter or enzyme gene knockout animal models or chemical inhibitors 
provides useful information on the mechanisms of in vivo brain uptake of various 
therapeutic agents (Sun et al., 2001b; Potschka et al., 2003). This approach has been used 
in humans during the anhepatic phase of liver transplantation to study the brain 
metabolism (Tofteng et al., 2002; Tofteng and Larsen, 2002; Battezzati and Bertoli, 
2004). The regional brain ECF concentration is accessible because the microdialysis 
probe can be implanted virtually in any brain region of interest such as tumors (Apparaju 
et al., 2007).  
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The limitations of this technique include extensive surgical preparation and requirement 
of specialized equipment and expertise. Probe implantation is invasive and may perturb 
the integrity of the BBB at the implantation site. An extremely sensitive assay for the 
molecule of interest is required. The difficulties associated with the determination of in 
vivo microdialysis probe efficiency also need to be considered. In the absence of a robust 
approach to estimating recovery efficiency, microdialysis data can only provide the 
temporal pattern of changes in concentration, and not actual concentrations per se. The 
technique also is quite difficult to implement in mice, making use of gene knockout 
models problematic. 
CSF Sampling 
In clinical settings, where brain ECF concentrations are not accessible, CSF often is taken 
as a surrogate measurement under the assumptions that BCSFB shares similar 
characteristics with BBB with regard to drug transport and that CSF is in equilibrium 
with brain ECF. The relevance of CSF concentration to unbound brain concentration has 
been demonstrated for various therapeutic agents (Liu et al., 2006). However, for targets 
that are distant from CSF passage, the CSF concentration does not necessarily represent 
the relevant biophase concentration because the underlying assumptions are not 
universally reasonable (de Lange and Danhof, 2002; Shen et al., 2004). Significantly 
lower brain ECF concentrations as compared to CSF concentrations have been 
demonstrated for several antiepileptic drugs (i.e., carbamazepine, topiramate, phenytoin) 
in patients with intractable epilepsy (Rambeck et al., 2006) and an investigational drug 
candidate CP-615,003 in rats and dogs (Venkatakrishnan et al., 2007). Active carrier-
mediated efflux transport at these two barriers also is different. Inhibition of P-gp with 
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zosuquidar increased brain penetration by ~ 146-fold, while decreasing CSF penetration 
by 5-fold (Kaddoumi et al., 2007). 
Imaging Techniques 
Non-invasive imaging techniques (e.g., positron emission tomography [PET]) have been 
used in the drug discovery and development process (Gee, 2003; Salvadori, 2007). This 
approach has been applied successfully in biodistribution studies of drugs both in human 
and preclinical species, as well as in identification and characterization of pharmacologic 
targets (Elsinga et al., 2004). The isotopes typically used in PET studies (i.e., 11C, 13N, 
15O or 18F) have short half-lives and can be administered to human subjects at sub-
pharmacologic doses. The experiments can be repeated in the same subject over a short 
period of time. Recent studies with the P-gp substrates 11C-carvedilol and 11C-verapamil 
have demonstrated that PET can be used to assess the functions of P-gp at the BBB (Bart 
et al., 2005; Ikoma et al., 2006). Studies in mdr1a(-/-) mice and rats demonstrated that P-
gp function at the BBB is modulated by the P-gp inhibitor cyclosporine A in a 
concentration-dependent manner (Hendrikse et al., 1998; Bart et al., 2003). A good 
interspecies correlation has been obtained with imaging techniques between rat and 
human BBB with regard to P-gp inhibition by cyclosporine A (Hsiao et al., 2006). 
Additional studies in healthy human subjects or patients provide invaluable information 
regarding the function of P-gp at the BBB (Takano et al., 2006; Langer et al., 2007; 
Lubberink et al., 2007).  
PET studies are especially useful in investigating the spatial heterogeneity of drug uptake 
in the brain. The regional blood flow rate and amino acid uptake vary substantially in 
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gliomas in patients (Wyss et al., 2007). 11C-verapamil uptake in epileptogenic and non-
epileptogenic brain regions was studied in medically refractory patients with temporal 
lobe epilepsy (Langer et al., 2007). The heterogeneous distribution of target receptors and 
cerebral hemodynamic parameters also can be determined using PET or other 
noninvasive imaging techniques (e.g., single photon emission tomography [SPECT], 
magnetic resonance imaging [MRI]) (Rosen et al., 1991; Frankle and Laruelle, 2002; 
Heiss and Herholz, 2006). Careful experimental design is required because PET imaging 
measures the total parent and metabolite levels and cannot differentiate between 
metabolite and parent (Lubberink et al., 2007). 
IN VITRO-IN VIVO CORRELATION 
A complete understanding of in vitro/in vivo relationships in preclinical species makes 
extrapolation to human studies possible. It has been demonstrated that BBB 
characteristics are conserved between species. Immense effort has been devoted to 
making predictions of in vivo BBB penetration from physicochemical properties (e.g., 
molecular weight, lipophilicity, pKa, the number of hydrogen bonds) of investigational 
molecules. Passive permeability at the BBB has been predicted successfully by in silico 
models (Norinder and Haeberlein, 2002; Clark, 2003; Hou and Xu, 2003b; Hou and Xu, 
2003a; Liu et al., 2004; Goodwin and Clark, 2005). Nonspecific brain tissue binding, 
which is related to lipophilicity, and correlated to blood protein binding, also can be 
predicted using in silico models (Wan et al., 2007). However, the prediction of substrates, 
inducers and/or inhibitors for specific transporter protein or metabolizing enzymes is 
relatively less successful because the mechanism of action has not been fully understood.  
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Novel in vitro and in vivo models have been or need to be developed to study many 
different aspects of CNS kinetics. Under most situations well-designed experiments with 
different models can yield consistent results with regard to CNS transport. In vitro cell-
based models have been used in rank-ordering passive permeability as well as in 
mechanistic studies of carrier-mediated transport at the BBB (Hansen et al., 2002; Mahar 
Doan et al., 2002). Quantitative analyses of the P-gp effect on in vivo pharmacokinetics 
and pharmacodynamics have been performed for many clinically important drugs 
(Summerfield et al., 2006; Kalvass et al., 2007b). In vitro models have been used to 
identify P-gp substrates and/or inhibitors, which has become a key issue in the drug 
discovery and development process (Polli et al., 2001; Rautio et al., 2006). The in vitro P-
gp-mediated efflux studies [ratio of apparent permeability in basolateral-to-apical 
direction to apical-to-basolateral direction] can be quantitatively predictive of in vivo P-
gp effect at the BBB [ratio of uptake clearance or brain partition coefficient in P-gp 
deficient mice to P-gp competent mice] (Adachi et al., 2001; Yamazaki et al., 2001; 
Hochman et al., 2002; Chen et al., 2003b; Summerfield et al., 2006; Kalvass and Pollack, 
2007). 
Not surprisingly, apparent discrepancies have been observed between in vitro and in vivo 
BBB penetration kinetics. There are several limitations associated with in vitro models 
that might explain these discrepancies. The tight junctions of cultured cell monolayers are 
usually “leakier” than in the intact BBB in vivo. It is not known how close the expression 
level of transporters and metabolizing enzymes in cultured cells is to that in vivo. 
Transporter expression level is a confounding factor in the study of intrinsic transport 
parameters (Balakrishnan et al., 2007; Korjamo et al., 2007). More importantly, in vitro 
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cellular models are a simplification of the dynamic blood-brain interface, and the three-
dimensional architecture, blood flow and protein profiles cannot be reproduced in in vitro 
models. The molecular mechanism of transport of P-gp and other efflux transporters is 
still unknown (Ambudkar et al., 2003). Development of structure-activity relationships to 
identify or describe P-gp substrates and inhibitors have been unsuccessful (Pajeva and 
Wiese, 2002; Wang et al., 2003; Pajeva et al., 2004), in part due to the interplay of 
passive permeability and P-gp-mediated efflux (Lentz et al., 2000). The emergence of 
gene knockout animals facilitated the understanding of transport kinetics. However, gene 
knockout animals have not been fully characterized for potential compensatory 
mechanisms (Cisternino et al., 2004). Some “specific” chemical inhibitors were found to 
be not specific (Gupta et al., 2006), so chemical inhibition studies using these inhibitors 
need to be re-examined. Sex, strain and species differences and pathological conditions 
might modulate the expression and functional efficiency of transport proteins (Hochman 
et al., 2002; Merino et al., 2005; Tanaka et al., 2005; Zhang et al., 2005a; Soontornmalai 
et al., 2006; Vander Borght et al., 2006). The flavonoids chrysin and benzoflavone are 
potent inhibitors of human BCRP, but only weak inhibitors for rodent Bcrp (Zhang et al., 
2005a). In addition, regional heterogeneity of active transport and metabolism in the 
brain has not been mapped (Reichel, 2006). 
PROJECT OVERVIEW 
BBB penetration represents an important bottleneck in CNS drug design and 
development. The rate, extent and regional distribution of drug to the site of action are 
important aspects of CNS pharmacokinetics. The goal of this dissertation project was to 
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assess the determinants of brain distribution using in vitro, in situ and in vivo 
experimental approaches. 
First, the in situ brain perfusion technique was used to study the BBB permeability of 
twelve therapeutic compounds with a wide range of physicochemical properties, together 
with in vitro equilibrium dialysis to measure plasma and brain tissue binding. The 
influence of lipophilicity, intrinsic permeability, and brain tissue binding on the rate of 
brain:blood equilibration was investigated. The brain distribution equilibrium of 
alfentanil (high permeability, low brain tissue binding), sufentanil (intermediate 
permeability, intermediate brain tissue binding) and fexofenadine (low permeability, 
extensive brain tissue binding) was compared. In addition, the influence of P-gp-
mediated efflux at the BBB was assessed using mdr1a(-/-) mouse model (Chapter 2).  
Fexofenadine and terfenadine are both effective antihistamines. Fexofenadine is an active 
metabolite of terfenadine, with formation catalyzed by hepatic CYP3A4 in humans. 
Fexofenadine is poorly permeable at the BBB, while terfenadine readily crosses the BBB. 
Both antihistamines are P-gp substrates. In the current study, local brain metabolism was 
evaluated as a potential source of influence on the disposition of terfenadine and 
fexofenadine. Due to the slow approach to distribution equilibrium, these experiments 
were performed with subcutaneous osmotic minipump continuous infusion of 
fexofenadine or terfenadine. The brain metabolism of terfenadine to fexofenadine was 
studied using in situ brain perfusion and whole brain homogenate incubation methods. 
The time-dependency of fexofenadine brain penetration and P-gp effect at the BBB was 
examined. A two-compartment pharmacokinetic model was used to simulate the time 
course of fexofenadine brain uptake (Chapter 3). 
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The ABC transporters (e.g., P-gp, Bcrp, Mrps) are the major efflux transporters at the 
BBB. To date, P-gp-mediated efflux at the BBB to extrude the therapeutic agents out of 
the brain has been widely accepted. However, studies on other efflux transporters remain 
unclear, and the results have been controversial. Bcrp and P-gp have a similar expression 
pattern and overlapping substrates. Thus, it was speculated that Bcrp might play as 
important role as P-gp in defending the brain from exposure to exogenous compounds. 
Bcrp-overexpressed MDCKII cell line was grown in transwell devices, and many 
compounds were screened for Bcrp substrate characteristics. Cimetidine, alfuzosin, 
dipyridamole and LY2228820 were four Bcrp substrates selected based on the in vitro 
cell model. Then, the in situ brain perfusion and in vivo osmotic minipump administration 
studies were carried out to test the relevance of Bcrp at the murine BBB using mdr1a(-/-) 
and Abcg2(-/-) mouse models (Chapter 4). 
There are broad differences in physiology and function in the mammal brain. Therapeutic 
targets are not homogeneously distributed in the brain. The effectiveness of therapy 
depends on adequate delivery of drugs to the site of action within specific brain structures. 
Regional drug exposure is a complex function of local cerebral blood flow rate, brain 
capillary surface area, transit time in the brain, cerebrospinal fluid (CSF) bulk flow, blood 
protein binding and nonspecific brain tissue binding, as well as the transport of drugs 
across the BBB and metabolism in the specific brain region. In the current project, the in 
situ brain perfusion technique was used to study the local cerebral blood flow rate, 
capillary vascular volume, and the influence of these physiologic parameters on regional 
drug exposure. In addition, the effect of lipophilicity and P-gp interaction also was 
investigated using colchicine, quinidine and verapamil as model compounds. The 
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relevance of this in situ brain perfusion technique was evaluated by in vivo regional 
pharmacokinetics of loperamide (Chapter 5). 
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CHAPTER 2 
ASSESSMENT OF BLOOD-BRAIN BARRIER PERMEABILITY USING THE IN 
SITU MOUSE BRAIN PERFUSION TECHNIQUE 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted for publication in Pharmaceutical Research and is 
presented in the style of that journal.  
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Abstract 
Purpose To assess the blood-brain barrier (BBB) permeability of twelve clinically-used 
drugs in mdr1a(+/+) and mdr1a(-/-) mice, and investigate the influence of lipophilicity, 
nonspecific brain tissue binding, and P-gp-mediated efflux in the rate of brain uptake. 
Methods The BBB partition coefficient (PS) was determined using the in situ mouse 
brain perfusion technique. The net brain uptake for twelve compounds, and the time 
course of brain uptake for selected compounds ranging in BBB equilibration kinetics 
from rapidly-equilibrating (e.g., alfentanil, sufentanil) to slowly-equilibrating 
(fexofenadine) was determined and compared. The inter-relationship between PS, fu,brain, 
PS×fu,brain and the calculated octanol-water partition coefficient (clogD7.4) were examined. 
Results There was a sigmoidal relationship in mdr1a(-/-) mice between the logPS 
[logPS(-/-)] and clogD7.4 in the range of 0-6. For compounds with clogD7.4 less than 1, 
the initial rate of brain uptake was low and limited by permeability; for compounds with 
clogD7.4 higher than 3, the rate of brain uptake was limited by perfusion rate. In the 
clogD7.4 range of 1-3, the brain uptake clearance was a function of both permeability and 
blood flow rate. The brain unbound fraction was inversely proportional to the 
lipophilicity. Alfentanil achieved brain equilibrium approximately 4000-fold faster than 
fexofenadine, based on the magnitude of PS×fu,brain. 
Conclusions In situ brain perfusion is a useful technique to determine BBB permeability. 
Lipophilicity, ionization state, molecular weight and polar surface area are all important 
determinants for brain penetration. The time to blood-to-brain equilibrium varies widely 
for different compounds, and is determined by a multiplicity of pharmacokinetic factors. 
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Introduction 
The blood-brain barrier (BBB) is a continuous layer of brain capillary endothelial cells, 
connected by highly-developed tight junctions, that expresses numerous efflux 
transporters and metabolizing enzymes. The BBB represents a formidable barrier to the 
access of therapeutic targets for agents intended to have central nervous system (CNS) 
activity (1-4). Physicochemical properties (e.g., molecular weight, pKa, lipophilicity, 
polar surface area, and the number of hydrogen bonds) as well as biological factors (e.g., 
plasma and brain tissue binding, affinity to transporter systems at the BBB) are known 
determinants of substrate flux across the luminal and abluminal membranes of the brain 
capillary endothelial cells (5-8). Whereas the role of other efflux transporters at the BBB 
remains unclear, P-glycoprotein (P-gp)-mediated efflux of many therapeutic agents has 
been widely accepted (4, 9). P-gp is a 170-kDa membrane protein encoded by multidrug 
resistance gene MDR1 in human and mdr1a and mdr1b in rodents. P-gp-mediated 
reduction in brain exposure has been linked to the decreased CNS pharmacologic or toxic 
effects (9, 10). 
The logarithm of the brain-to-blood (or brain-to-plasma) concentration ratio (logBB) 
often is used to characterize and predict brain penetration. However, it is recognized that 
the unbound brain concentration is the relevant driving force for most pharmacologic 
events in the CNS. Because logBB is a hybrid parameter that is determined by 
permeability, plasma and brain tissue binding, and active transport mechanisms, it may 
provide misleading information regarding potential in vivo pharmacologic response, 
thereby excluding potentially useful drug candidates from further consideration (11, 12). 
The log of the permeability-surface area coefficient (logPS), in contrast, measures the 
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ability of a drug to cross the BBB and move into brain tissue over time, and is a more 
relevant metric of BBB penetration per se. Consequently, logPS has been proposed to 
replace logBB for assessment and prediction of drug brain penetration (11-13).  
PS can be measured using an in vivo or in situ short-duration vascular perfusion method, 
e.g., brain uptake index, indicatior dilution, or in situ brain perfusion (14). In situ brain 
perfusion was developed to provide a simpler and more accurate method to determine 
BBB permeability compared to other techniques (15). Furthermore, changes in perfusate 
composition or use of gene knockout animals enable study of variables such as protein 
binding and efflux transporter mechanisms, and the resultant influence of these variables 
on CNS distributional kinetics. This method has been applied to study the CNS uptake of 
compounds (16-19), and the data generated were used successfully to develop 
computational models to predict the BBB permeation (13).  
Nonspecific brain tissue binding not only influences measures of drug exposure in the 
brain (7), but also impacts the rate of brain uptake (20). Mathematical modeling of this 
system showed that the rate to brain equilibrium is determined by the product of PS and 
fu,brain (PS×fu,brain). The equilibrium half-life calculated based on PS×fu,brain was found to 
be significantly correlated with the experimentally measured distributional half-life (20). 
CNS drug discovery and development have been relatively unsuccessful due to the 
complexity of the BBB and the difficulties associated with the assessment and prediction 
of CNS penetration (21). Understanding the parameters favorable for CNS penetration is 
critically important for CNS drug design and optimization, and ultimately for 
understanding and treating CNS diseases. In the present study, the BBB permeation of 5 
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compounds with CNS activity, and 7 non-CNS-active drugs, representing a small 
compound set with substantial structural diversity covering various therapeutic categories 
and a wide range of physicochemical characteristics, was investigated with the in situ 
mouse brain perfusion technique. The effect of P-gp on net brain uptake, the relationship 
between the brain permeability coefficient (PS), the unbound drug fraction in mouse 
brain tissue (fu,brain), PS×fu,brain and the calculated octanol-water partition coefficient at pH 
7.4 (clogD7.4) were examined. In addition, alfentanil and sufentanil are known to reach 
plasma-biophase equilibration in minutes (22), while fexofenadine is poorly- and slowly-
permeable at the BBB (23, 24). The time course of equilibration for these rapidly- and 
slowly-equilibrating compounds was determined, and the influence of PS and fu,brain on 
the rate of brain uptake of these compounds was compared.
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Materials and Methods 
Adult CF-1 mdr1a(+/+) and mdr1a(-/-) mice (30-40 g, 6-8 weeks of age) were obtained 
from Charles River Laboratories (Wilmington, MA). All mice were maintained on a 12-h 
light/dark cycle with access to water and food ad libitum. All experimental procedures 
were performed under full anesthesia induced with ketamine/xylazine (100/10 mg/kg, 
i.p.), were approved by the Institutional Animal Care and Use Committee at the 
University of North Carolina at Chapel Hill, and were conducted in accordance with 
“Principles with Laboratory Animal Care” (NIH publication No. 85-23, revised in 1985). 
3H-cimetidine (25.0 Ci/mmol) and 14C-diazepam (56.0 mCi/mmol) were purchased from 
Amersham Biosciences (Buckinghamshire, UK), 14C-inulin (2.1 mCi/g) from American 
Radiolabeled Chemical Inc. (St Louis, MO), 3H-inulin (180.0 mCi/g), 3H-colchicine (80.4 
Ci/mmol), 3H-verapamil (74.2 Ci/mmol) and 3H-phenytoin (53.1 mCi/mmol) from 
PerkinElmer (Waltham, MA), 3H-quinidine (20 Ci/mmol) from American Radiolabeled 
Chemicals Inc (St. Louis, MO), 3H-valproic acid (55 Ci/mmol) from Moravek 
Biochemicals Inc(Brea, CA). Alfentanil, sufentanil, cimetidine, terfenadine, fexofenadine, 
loperamide, phenytoin and valproic acid were purchased from Sigma-Aldrich (St. Louis, 
MO). All other chemicals were commercially available and of reagent grade or better.  
In situ Mouse Brain Perfusion 
The details of the in situ mouse brain perfusion have been described elsewhere (18). 
Briefly, CF-1 mdr1a(+/+) and mdr1a(-/-) mice were anesthetized with ketamine/xylazine 
(100/10 mg/kg, i.p.). The perfusion buffer (Krebs-bicarbonate buffer, with 9 mM of D-
glucose, pH 7.4) was oxygenated with 95% O2 and 5% CO2 and maintained at 37°C. 14C-
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diazepam and 3H- or 14C-inulin were used as blood flow rate and vascular space markers, 
respectively. Test compounds (2 μM) with or without radiolabeled tracer (0.1-1.6 µCi/mL) 
were added to the perfusate. The right common carotid artery was cannulated with 
polyethylene tubing (0.30-mm inner diameter × 0.70-mm outer diameter; Biotrol 
Diagnostic, Chennevières-les-Louvres, France) following ligation of the external carotid 
artery. The cardiac ventricles were severed immediately before perfusion at 2.5 mL/min 
for 60 s (all compounds except alfentanil, sufentanil and fexofenadine) via a syringe 
pump (Harvard Apparatus, Holliston, MA). Alfentanil and sufentanil (2 µM) were 
perfused for 10 (alfentanil only), 20, 40 and 60 s, and fexofenadine for 60, 90, and 120 s 
in mdr1a(+/+) and mdr1a(-/-) mice, respectively. For additional groups of mdr1a(+/+) 
and mdr1a(-/-) mice, fexofenadine was perfused for a single time-point at 60 s, followed 
by an additional 15-s drug-free saline perfusion to wash out the remaining fexofenadine 
in the capillary space. All of the experiments were terminated by decapitation, and the 
right cerebral hemisphere was collected. Aliquots of perfusate were collected through the 
syringe and tubing for determination of perfusate concentrations. When radiotracers were 
used, brain samples were digested with 0.7 mL of Solvable® (Packard, Boston, MA) at 50 
°C overnight. Five mL of UltimaGold® scintillation cocktail (PerkinElmer, Wellesley, 
MA) was added and mixed by vortex. Total radioactivity (3H and/or 14C) was determined 
in a Packard Tri-carb TR 1900 liquid scintillation analyzer (Packard, Boston, MA). For 
non-radioactive samples, the hemisphere was homogenized with two volumes of distilled 
water by brief probe sonication. The perfusate and brain samples were stored at -20°C 
until analysis by HPLC/MS/MS.  
64 
Parameters related to the in situ brain perfusion, i.e., the cerebral vascular volume 
(mL/100 g brain), was calculated using equation:  
inulin
inulin
vasc C
X
V = . 
At any single time point, the initial brain uptake clearance (Clup, mL/min/100 g brain) 
was calculated as:  
perf
brain
up
C
/TXCl = , 
and the apparent distributional volume (Vd, mL/100 g brain) was calculated as:  
perf
brain
d
C
XV =  
where the amount of substrate in brain Xbrain was corrected for blood vessel 
contamination by subtraction of vascular volume or a final 15-s washout with drug-free 
saline. For compounds that were perfused for several different times, the Vd values were 
plotted against perfusion time, the Clup was calculated as the slope of the initial linear 
phase (14, 18). The permeability surface product (PS) values were calculated based on 
Crone-Renkin equation (15):  
)/FCl1ln(FPS pfuppf −×−= . 
Fpf is the perfusion flow rate measured using 14C-diazepam as the flow rate marker. 
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Equilibrium Dialysis 
Plasma and brain unbound fractions were determined in a 96-well equilibrium dialysis 
apparatus (HTDialysis, Gales Ferry, CT) using a previously reported method (7). Briefly, 
fresh CF-1 mouse plasma and brain tissue were obtained the same day of the study. 
Spectra-Por 2 membranes obtained from Spectrum Laboratories Inc. (Rancho Dominguez, 
CA) were conditioned in HPLC-grade water for 15 min, followed by 30% ethanol for 15 
min, and 100 mM sodium phosphate buffer (pH 7.4) for 15 min. Brain tissue was diluted 
3-fold with 100 mM sodium phosphate buffer (pH 7.4) and homogenized with a sonic 
probe. The drug of interest was added to brain homogenate to achieve a final 
concentration of 3 and 1 µM, respectively; 150-µl aliquots (n = 6) were loaded into the 
96-well equilibrium dialysis apparatus and dialyzed against an equal volume of 100 mM 
sodium phosphate buffer (pH 7.4). The 96-well equilibrium dialysis apparatus was 
incubated for 4.5 h in a 155-rpm shaking incubator maintained at 37°C. For non-
radioactive samples, after 4.5 h 10 µl of brain homogenate sample and 50 µl of buffer 
sample were removed from the apparatus and added directly to HPLC vials containing 
100 µl of methanol with an appropriate internal standard. A 50-µl aliquot of control 
buffer was added to the brain homogenate sample, and either a 10-µl aliquot of control 
brain homogenate was added to the buffer samples to yield identical sample composition 
between buffer and non-buffer samples. The samples were vortex-mixed, centrifuged, and 
the supernatant was analyzed by HPLC/MS/MS. For radioactive samples, 5 mL of 
UltimaGold® scintillation cocktail (PerkinElmer, Wellesley, MA) was added and vortex-
mixed. Total radioactivity (3H and/or 14C) was determined in a Packard Tri-carb TR 1900 
66 
liquid scintillation analyzer (Packard, Boston, MA). The brain unbound fraction was 
calculated according to the equation: 
Df
f
1)1)((1/
D1   Undiluted
measuredu,
u +−=   
where D represents the -fold dilution of brain tissue, and fu,measured  was the ratio of 
concentrations determined from the buffer and brain homogenate samples. 
HPLC/MS/MS Assay  
Non-radioactive samples were analyzed by HPLC/MS/MS (API 4000 triple quadrupole 
with TurboIonSpray interface; Applied Biosystems/MDS Sciex, Concord, ON, Canada). 
A 25-µL aliquot of the cerebral hemisphere homogenate was transferred to an HPLC vial, 
and protein was precipitated with 100 µl of methanol containing internal standard (10 
ng/mL loperamide), and a 25-µl aliquot of DMSO was added. The sample was vortex-
mixed and centrifuged. Standard solutions ranged from 0.5 -5000 nM and were prepared 
in a similar way, i.e., 25 µl of blank plasma or brain matrix, 100 µl of methanol 
containing internal standard, and 25 µl of serially-diluted standard solution were mixed 
and centrifuged. A 3-µl aliquot of supernatant was injected into autosampler (Leap, 
Carrboro, NC). Test compounds and the internal standard were eluted from an Aquasil 
C18 column (2.1 x 50 mm, dp = 5 µm; Thermo Electron Corporation, Waltham, MA) 
using a mobile phase gradient (A, 0.1% formic acid in water; B, 0.1% formic acid in 
methanol; 0-0.70-min hold at 0% B, 0.70-3.12-min linear gradient to 90% B, 3.12-4.10 
min hold at 90% B, 4.10-4.20-min linear gradient to 0% B, 4.20-4.90-min hold at 0% B; 
solvent delivery system (Shimadzu, at a flow rate of 0.75 ml/min; from 0.8 ttto 4 min, 
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flow was directed to the  mass spectrometer) and were detected in positive ion mode 
using multiple reaction monitoring: alfentanil: 417.3 ? 268.3 m/z, fexofenadine: 502.4 
? 466.4 m/z, ritonavir: 721.5 ? 296.4 m/z, sufentanil: 387.2 ? 238.4 m/z, terfenadine, 
472.3 ? 436.5 m/z, loperamide, 477.4 ? 266.0 m/z. All analytes were quantified with 
standard curves (0.05-5000 ng/ml) prepared in the appropriate matrix. The lower limit of 
detection was 0.5 ng/ml; inter-and intraday CVs were <15% for each of the analytes 
examined in this study.  
Statistical Analysis 
Data are reported as mean ± SD for 3 mice per condition. One-way or two-way ANOVA, 
where appropriate, was used to determine the statistical significance of differences among 
two or more groups. The level of significance was corrected for multiple comparisons 
(e.g., Bonferroni test) or adjusted for unequal variance when necessary. In all cases, p < 
0.05 was considered to be statistically significant. 
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Results  
14C- or 3H-inulin was used as the cerebral capillary space marker (Vvasc) to measure BBB 
physical integrity. Vvasc was 1.69±0.10 and 1.68±0.11 mL/100 g in mdr1a(+/+) and 
mdr1a(-/-) mice, respectively (two-tailed Student’s t-test, p>0.05). Functional perfusion 
rate (14C-diazepam Clup) was 250±41 mL/min/100 g brain in both mdr1a(+/+) and 
mdr1a(-/-) mice. 
The octanol-water partition coefficients in the unionized state or at pH 7.4 (clogP or 
clogD7.4) for each compound were calculated using Marvin and calculator plugin 
freeware (www.chemaxon.com, ChemAxon Kft, Budapest, Hungary). The calculated 
clogP, clogD7.4, initial brain uptake clearance Clup in mdr1a(+/+) and mdr1a(-/-) mice, 
PS×fu,brain and the unbound fractions in mouse brain for all compounds determined using 
equilibrium dialysis or obtained from the literature (25, 26) are summarized in Table 2.1. 
Based on comparisons of Clup in mdr1a(+/+) and mdr1a(-/-) mice, P-gp-mediated efflux 
decreased the initial rate of brain uptake by up to 14-fold for quinidine in mdr1a(+/+) 
mice. Figure 2.1 demonstrates a sigmoidal relationship between logPS in mdr1a(-/-) mice 
[logPS(-/-)] and clogD7.4 in the range of 0-6. Valproic acid and ritonavir were excluded 
from the regression because the uptake of valproic acid at the BBB is known to be 
facilitated by a medium-chain fatty acid transporter (27), and ritonavir is extensively 
bound and sequestrated in the brain capillary endothelium (28). The log of the unbound 
fraction in mouse brain for these 12 compounds is inversely correlated to clogD7.4 (Figure 
2.2). 
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The relationship between PS×fu,brain and clogD7.4 is shown in Figure 2.3. The PS×fu,brain  
was calculated based on the regression in Figures 2.1 and 2.2. This relationship suggests 
that the rate of blood-to-brain equilibration is not a simple function of lipophilicity, 
permeability or brain unbound fraction. In addition, the PS×fu,brain varied widely among 
the compounds studied, with the highest value of 196 for alfentanil and lowest value of 
0.05 for colchicine. 
The time course of sufentanil and alfentanil brain uptake is presented in Figure 2.4. The 
apparent distributional volume (Vd) for sufentanil was linear over all of the perfusion 
times evaluated in both mdr1a(+/+) and mdr1a(-/-) mice (Figure 2.4A). Alfentanil brain 
uptake was linear over 20 s in both mdr1a(+/+) and mdr1a(-/-) mice (Figure 2.4C). The 
calculated uptake clearance (Clup) at each time point is shown in Figure 2.4B and 2.4D. 
Clup values for sufentanil were constant over the perfusion period and were comparable in 
mdr1a(+/+) and mdr1a(-/-) mice (two-way ANOVA, p>0.05). Clup values for alfentanil 
were constant for the first 20 s and then decreased significantly at 60 s from ~229 
mL/min/100 g to ~102 mL/min/100 g. The Clup in mdr1a(-/-) mice was about 1.4-fold 
higher than that in mdr1a(+/+) mice (two-way ANOVA, p<0.05). 
Fexofenadine brain uptake was linear over 120 s in mdr1a(+/+) and mdr1a(-/-) mice 
(Figure 2.5A). The initial uptake clearance of fexofenadine, determined with versus 
without the final washout step, did not differ in either mdr1a(+/+) or mdr1a(-/-) mice. 
The brain uptake was 4.4- and 4.6-fold higher in mdr1a(-/-) mice than in mdr1a(+/+) 
mice in the absence and presence of final washout step, respectively (Figure 2.5B, two-
way ANOVA, p<0.05). 
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Discussion 
Previous studies have suggested that lipophilicity is one of the most important 
determinants of brain penetration (29, 30), and that logPS in rat brain is related linearly 
with cLogP (for octanol:water) over 6 orders of magnitude (15, 30). However, the 
compounds studied previously are, for the most part, non-CNS-therapeutic agents with 
limited presentation to brain tissue. In the present study, BBB penetration of 12 
clinically-used drugs in several therapeutic classes, covering a clogD7.4 range of 0-6, was 
investigated. PS ranged nearly 600-fold, and fu,brain  ranged almost 1000-fold, among 
these compounds. Thus, the selected compound set contained sufficient physicochemical 
diversity to allow dissection of the contributors to net brain uptake. 
The relationship between the logPS in mdr1a(-/-) mice [logPS(-/-)] and clogD7.4 was 
generally sigmoidal (Figure 2.1). The logPS for valproic acid fell above this relationship, 
consistent with the observation that its brain uptake is facilitated by a medium-chain fatty 
acid transporter (27). Ritonavir brain uptake is slow, although it is highly lipophilic and 
not ionized at pH 7.4. This slow uptake is explained by the molecular weight of 720.9, 
and polar surface area of 202 Å2, whereas a molecular weight less than 450 and polar 
surface area less than 90 Å2 are typically considered to be favorable for brain penetration 
(31). In addition, capillary depletion techniques have been used to demonstrate that 
ritonavir is extensively bound to or sequestrated inside the brain capillary endothelium 
after crossing the luminal membrane, (28). The regression of logPS(-/-) versus clogP 
showed a similar relationship, with fexofenadine as an outlier. Fexofenadine has a high 
lipophilicity (logP=5.68) when unionized. However, it is both positively- (due to the 
tertiary amine group) and negatively- (due to its carboxylic acid group) charged at pH 7.4 
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(clogD7.4=0.92), which explains the very low brain penetration of fexofenadine at the 
BBB, consistent with lipophilicity and ionization state as important factors for brain 
penetration (29). LogPS(-/-) is limited by permeability for more hydrophilic compounds 
(cimetidine, fexofenadine and colchicine); and increases with clogD7.4 when clogD7.4  is 
in the range of 1-3 (quinidine, sufentanil, quinidine and verapamil). When clogD7.4 
exceeds a value of 3 (alfentanil, diazepam and terfenadine), BBB permeability does not 
increase further and becomes limited by capillary perfusion rate. 
Interestingly, in the dataset generated for drugs active against CNS targets (CNS+) in vivo 
drugs (i.e., diazepam, phenytoin, alfentanil, sufentanil, and valproate), the mean clogD7.4 
was 2.11, and the mean Clup values were 93.0 and 101.0 in mdr1a(+/+) and mdr1a(-/-) 
mice, respectively. For non-CNS therapeutic (CNS-) agents (i.e., cimetidine, colchicine, 
fexofenadine, quinidine, ritonavir, and verapamil), the mean clogD7.4 was 1.86, and the 
mean Clup values were 6.2 and 34.1 in mdr1a(+/+) and mdr1a(-/-) mice, respectively. 
Terfenadine was not included in the CNS- group because it is known to be a CNS 
penetrant (23, 32) and it is metabolized rapidly systemically and in the brain (Chapter 3). 
This comparison clearly shows that CNS+ drugs tend to have higher Clup with minimal or 
no P-gp-mediated efflux. In contrast, CNS- drugs have lower Clup in the absence of P-gp, 
with Clup decreased further by P-gp-mediated efflux at the BBB. For these P-gp 
substrates, P-gp-mediated efflux decreased brain uptake by 1.5-, 2.1-, 3.5-, 4.4-, 5.0-, and 
13.6-fold for cimetidine, colchicine, ritonavir, fexofenadine, verapamil, and quinidine, 
respectively. A similar observation, i.e.,  that the passive permeability and P-gp-mediated 
efflux could differentiate the CNS and non-CNS drugs, also was observed using in vitro 
cell-based models (33).  
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No statistical differences were detected between mdr1a(+/+) and mdr1a(-/-) mice for 
sufentanil, and alfentanil brain uptake was only 1.4-fold higher in mdr1a(-/-) mice than in 
mdr1a(+/+) mice. Sufentanil and alfentanil were reported previously as weak P-gp 
substrates, with in vivo P-gp efflux ratios of 3.0 and 2.8, respectively (34, 35). Previous 
work also has demonstrated that the P-gp efflux ratio measured in situ correlates well 
with that determined in vivo, but with lower apparent P-gp effects at the BBB using the in 
situ brain perfusion technique (19). This result also has been supported by mathematical 
analysis recently: a smaller ERB (in situ P-gp efflux ratio) compared to ERα (in vivo P-gp 
efflux ratio) is expected for the same experimental system (i.e., same substrate and same 
animal species) (25). For other P-gp substrates in the present compound set, P-gp-
mediated efflux decreased the brain uptake by 1.5- to 13.6-fold; suggesting that the in situ 
brain perfusion technique is a sensitive method to test the efflux transporter kinetics at the 
BBB. 
In the absence of active transport, the rate of brain equilibration is a function of both PS 
and unbound brain fraction (fu,brain), and is directly proportional to the PS×fu,brain  product 
(5, 20). Lipophilic compounds tend to cross the BBB (high PS; Figure 2.1) and bind to 
brain tissue more extensively (low fu,brain; Figure 2.2). The apparent inverse relationship 
between PS and fu,brain  leads to the common assumption that the rate of equilibration 
across the BBB might be similar for most drugs (36). However, in vivo experiments and 
mathematical modeling indicate that the time to brain equilibrium varied widely among 
compounds (20). A mathematical simulation based on the sigmoidal relationship between 
PS and clogD7.4 and the linear relationship between fu,brain  and clogD7.4 showed the trend 
of the rate to brain equilibrium (PS×fu,brain) increases with the lipophilicity of compounds 
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up to clogD7.4 of 3, and then decreases after the compounds become too lipophilic (Figure 
2.3). The compounds in the clogD7.4 range of 2-3 evidenced the most rapid brain 
penetration. Alfentanil reached an equilibrium condition about 200-fold faster than 
sufentanil, and about 2000-fold faster than fexofenadine and ritonavir. This difference is 
consistent with the clinically-observed onset of alfentanil anaesthetic effect, which is 
more rapid than that observed for sufentanil (22, 34). In contrast, ritonavir brain uptake 
has been shown previously to be quite slow, failing to reach equilibrium within 30 min 
during perfusion in guinea pigs (28). 
The in situ brain perfusion technique measures the initial rate of brain uptake during a 
time period when there is no significant back flux from the brain to the perfusate. Care 
should be taken when a single-time-point method is used with this technique. In many 
cases, a single time-point at 30- or 60-s can provide an accurate estimate of Clup (17, 37). 
However, a curvilinear relationship between net brain uptake and time has been 
demonstrated for some compounds such as iodoantipyrine (16) that equilibrate rapidly 
(less than 60 s) across the BBB. In the present study, a similar result was observed for 
alfentanil, which shares some physicochemical characteristics with iodoantipyrine (high 
PS and high fu,brain). Alfentanil achieved equilibrium in 20 s in both mdr1a(+/+) and 
mdr1a(-/-) mice. By 60 s, Vd had reached a plateau due to significant back flux from the 
brain to the perfusate. The calculated Clup values therefore decreased about 50-60% at 60 
s compared to other time points. Only Clup calculated based on unidirectional flux from 
perfusate to brain will reflect the actual rate of alfentanil brain uptake (Figure 2.4C and 
2.4D). Sufentanil Clup was ~8-fold lower than that for alfentanil, corresponding to a lower 
clogD7.4 value. Sufentanil binds to brain tissue ~10-fold more extensively than alfentanil, 
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limiting the back-flux of sufentanil from the brain to the perfusate during perfusion 
(essentially creating a sink condition with respect to unbound substrate in brain tissue 
available for back-diffusion). Sufentanil brain uptake therefore is linear over the entire 60 
s perfusion, and Clup is time-independent.  
Fexofenadine brain uptake was unidirectional over 120 s (Figure 2.5). Fexofenadine is a 
very low-permeability compound and has high nonspecific binding in brain tissue. 
Combined with a 15-s drug-free saline washout at the end of the perfusion, the single-
time-point method for calculating Clup yielded results similar to those obtained from the 
three time-point linear phase slope method. Because the variability in vascular volume 
might appreciably affect the Clup calculation, particularly for compounds with poor BBB 
permeability, the washout step increased the accuracy of measurement of the brain 
permeability when using a single-time-point method (14, 38). 
In silico models have become more common in the early phase of the drug discovery 
process to predict the BBB penetration of new chemical entities and drug candidates. The 
predictive accuracy of the models depends on the quality of the experimentally measured 
data and the chemical space covered in the selected molecules. A mechanistic 
understanding of the generated data, and an expanded high-quality database, are very 
important for in silico model development and validation, and ultimately aid and 
accelerate the drug design process for the treatment of CNS diseases. The in situ brain 
perfusion technique is a useful method to determine the BBB permeability. However, 
caution needs to be taken when using a single-time-point method. The time point should 
sit in the initial linear (unidirectional) phase of brain uptake and a final washout step 
might increase the accuracy of measuring brain permeability for poorly-permeable 
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compounds. Brain penetration is a balance between the permeability and nonspecific 
brain tissue binding. Other variables, i.e., polar surface area, molecular weight, the 
number of hydrogen bonds, and P-gp-mediated efflux also contribute to measurements of 
brain penetration. Highly lipophilic compounds tend to have high permeability and high 
brain tissue binding, which causes the PS×fu,brain  product to vary across a wide range. 
This variability is apparent when comparing a compound such as alfentanil, which 
reaches equilibrium very quickly, to a compound such as fexofenadine, which reaches 
equilibrium very slowly.  
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Table 2.1:  Calculated clogP, clogD7.4, uptake clearance in mdr1a(+/+) and mdr1a(-/-) 
mice, and brain unbound fraction for selected compounds. 
Name clogP clogD7.4 Clup(+/+) Clup(-/-) PS× 
fu,brain 
fu,brain 
(reference) 
Alfentanil 3.55 3.20 194 ± 38 229 ± 46 196 0.32 (27) 
Colchicine 1.08 1.08 0.9 ± 0.1 1.9 ± 0.1 0.05 0.024 
Cimetidine 0.24 0.12 0.7 ± 0.2 1.1 ± 0.4 0.6 0.53 (27) 
Diazepam 3.01 3.01 250 ± 41 250 ± 41 12.5 0.05 (28) 
Fexofenadine 5.68 0.92 0.3 ± 0.1 1.3 ± 0.4 0.1 0.077 (27) 
Phenytoin 2.28 2.27 33.4 ± 1.2 34.7 ± 9.9 3.1 0.082 
Quinidine 2.32 1.46 3.4 ± 0.4 54.1 ± 12.2 1.6 0.037 (27) 
Ritonavir 5.04 5.04 2.3 ± 0.7 8.0 ± 2.7 0.1 0.0106 (27) 
Sufentanil 3.17 1.69 34.0 ± 6.6 29.5 ± 9.0 1.1 0.034 (27) 
Terfenadine 6.45 4.82 174 ± 52 202 ± 85 0.5 0.0011 
Valproate 2.61 0.37 24.3 ± 0.7 18.1 ± 4.5 18.8 1.0 
Verapamil 4.30 2.56 31.5 ± 3.0 137 ± 23 7.7 0.033 (27) 
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Figure 2.1:  Relationship between PS and clogD7.4.
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Figure 2.2:  Relationship between brain unbound fraction fu,brain  and clogD7.4. 
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Figure 2.3:  Relationship between PS×fu,brain  and clogD7.4. 
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Figure 2.4:  The time course of apparent brain distributional volume of (A) sufentanil 
and (C) alfentanil, and the initial brain uptake clearance of (B) sufentanil and (D) 
alfentanil, in mdr1a(+/+) (solid symbol) and mdr1a(-/-) (open symbol) mice following 
60 s perfusion at 2.5 mL/min (n=3). 
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Figure 2.5:  (A), The apparent distributional volume at 60-, 90-, and 120-s of perfusion 
for fexofenadine in mdr1a(+/+) (solid circle) and mdr1a(-/-) (open circle) mice; and (B), 
initial brain uptake clearance of fexofenadine in mdr1a(+/+) (solid bar) and mdr1a(-/-) 
(open bar) mice in the absence or presence of additional 15-s drug-free saline washout 
following brain perfusion at 2.5 mL/min for 60 s. Fexofenadine brain uptake increased 
approximately 5-fold in mdr1a(-/-) mice than in mdr1a(+/+) mice. 
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CHAPTER 3 
FEXOFENADINE BRAIN EXPOSURE AND THE INFLUENCE OF BLOOD-
BRAIN BARRIER P-GLYCOPROTEIN FOLLOWING FEXOFENADINE AND 
TERFENADINE ADMINISTRATION 
 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted for publication in Drug Metabolism and Disposition  and 
is presented in the style of that journal.  
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Abstract 
P-glycoprotein (P-gp) plays an important role in determining net brain uptake of 
fexofenadine. Initial in vivo experiments with 24-hr subcutaneous osmotic minipump 
administration demonstrated that fexofenadine brain penetration was 48-fold higher in 
mdr1a(-/-) mice than in mdr1a(+/+) mice. In constrast, the P-gp efflux ratio at the blood-
brain barrier (BBB) for fexofenadine was only ~4 using an in situ brain perfusion 
technique. Pharmacokinetic modeling based on the experimental results indicated that the 
apparent fexofenadine P-gp efflux ratio is time-dependent due to low passive 
permeability at the BBB. Fexofenadine brain penetration following terfenadine 
administration was ~25-27-fold higher than following fexofenadine administration in 
both mdr1a(+/+) and mdr1a(-/-) mice, consistent with terfenadine metabolism to 
fexofenadine in murine brain tissue. Fexofenadine formation rate following terfenadine in 
situ brain perfusion was comparable to that in a 2-hr brain tissue homogenate in vitro 
incubation. Fexofenadine formation rate increased ~5-fold during a 2-hr brain tissue 
homogenate incubation with hydroxyl-terfenadine, suggesting that the hydroxylation of 
terfenadine is the rate-limiting step in fexofenadine formation. Moreover, regional brain 
metabolism appears to be an important factor in terfenadine brain disposition, and 
consequently fexofenadine brain exposure. Taken together, these results indicate that the 
fexofenadine BBB P-gp efflux ratio has been underestimated previously due to lack of 
complete equilibration of fexofenadine across the blood-brain interface under typical 
experimental paradigms.  
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Introduction 
The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) are the 
major interfaces and barriers between the central nervous system (CNS) and the 
peripheral circulation. The BBB and BCSFB are formed by a continuous layer of brain 
capillary endothelial cells (BBB) or epithelial cells that line the choroid plexus (BCSFB). 
The highly-developed tight junctions and expression of numerous efflux transporters and 
metabolizing enzymes limit brain penetration of many endogenous compounds and 
therapeutic agents (Begley, 2003; Graff and Pollack, 2004).  
Brain penetration can be beneficial or detrimental depending on the target site of therapy 
and the potential for untoward side effects. Adequate exposure in the brain is essential for 
the treatment of cerebral diseases. However, brain exposure ideally would be minimized 
for compounds intended to treat peripheral disorders. BBB permeability, a primary 
determinant of substrate exposure in brain tissue, is influenced by many physicochemical 
properties such as molecular weight, pKa, lipophilicity, polar surface area, and the 
number of hydrogen bonds (Brodie et al., 1960; Liu et al., 2004). The extent of brain 
exposure, and thus the CNS pharmacologic or toxic effect, is determined by passive 
permeability, plasma and brain tissue binding, uptake or efflux transport activity, CSF 
bulk flow and biotransformation in the CNS (Fenstermacher et al., 1981; Schinkel et al., 
1994; Kalvass and Maurer, 2002; Liu and Chen, 2005; Kalvass et al., 2007a). Accurate 
prediction of CNS penetration is difficult because of these complex mechanisms and 
parameters.  
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Recently, non-specific protein binding (i.e., capacity-limited binding to proteins other 
than the target receptor) in brain tissue and plasma was first used to predict in vivo CNS 
drug penetration (Kalvass and Maurer, 2002). These predictions were based in part on the 
assumption that, when compounds distribute between brain and blood solely by passive 
diffusion, the unbound brain and plasma concentrations are equal at distribution 
equilibrium. Under these conditions, the brain-to-plasma concentration ratio (brain 
partition coefficient; brainpK , ) is simply a function of the relative plasma and tissue 
unbound fractions brainuplasmaubrainp ffK ,,, = . For many compounds that are subject to P-
gp mediated efflux at the BBB, brain penetration has been predicted successfully based 
on this approach as modified to account for the P-gp-mediated efflux activity 
(Summerfield et al., 2006; Kalvass et al., 2007a).  
Non-sedating antihistamines represent an interesting class of compounds because the lack 
of a sedative effect is due primarily to exclusion from the brain at the blood-brain 
interface. Fexofenadine, for example, has been identified as a substrate of P-gp in Caco-2 
cells and MDR1 overexpressing LLC-PK1 cells (Cvetkovic et al., 1999; Petri et al., 
2004). P-gp subsequently was demonstrated to decrease intestinal absorption and brain 
exposure of fexofenadine by comparing wild-type mice to mdr1a/1b(-/-) animals (Tahara 
et al., 2005).  
The extent of fexofenadine brain penetration in normal rats and mice is minimal (Mahar 
Doan et al., 2004; Tahara et al., 2005). In contrast, terfenadine enters the brain rapidly 
(Mahar Doan et al., 2004; Obradovic et al., 2007). Terfenadine is metabolized to 
hydroxyl-terfenadine and then to the active metabolite fexofenadine by hepatic CYP3A4 
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in human (Ling et al., 1995; Markham and Wagstaff, 1998). Metabolic enzymes such as 
P450s are also expressed in human and rodent brain (Strobel et al., 2001; Miksys and 
Tyndale, 2002; Meyer et al., 2007). Brain P450s play an important role in local 
metabolism of endogenous compounds and xenobiotics, though brain P450s is only about 
1-10% of liver content and not likely to influence the overall metabolism of the body. 
Mouse CYP3A11 and CYP3A13, the counterpart of human CYP3A4, were responsible 
for 6β-hydroxylation of testosterone in the brain and were induced by antiepileptic drug 
phenytoin treatment (Hagemeyer et al., 2003; Meyer et al., 2006). In the current study, 
the brain metabolism of terfenadine to fexofenadine was examined. 
Despite the ability to predict brain exposure of many compounds, the P-gp effect coupled 
with relative protein binding in blood and brain tissue can explain only partially the 
impaired brain penetration of fexofenadine and cetirizine (Kalvass et al., 2007a), two 
nonsedating antihistamines with poor permeability at the BBB. Fexofenadine brain 
penetration is ~35-fold overestimated based on the plasma-to-brain unbound fraction 
ratio assumption; this magnitude of overestimation cannot be explained by the ~3-fold P-
gp effect at the BBB that has been reported (Cvetkovic et al., 1999; Tahara et al., 2005). 
Efflux protein(s) other than P-gp that may serve as barrier transport systems at the blood-
brain interface have been proposed (Kalvass et al., 2007a). However, the functional 
efficiency and biologic significance of other BBB efflux transporters remain unclear, and 
no evidence is available to suggest an interaction between fexofenadine and other efflux 
transporters in brain capillary endothelium. The purpose of this study, therefore, was to 
understand the underlying mechanism(s) governing fexofenadine exposure in brain tissue, 
and to re-examine P-gp mediated fexofenadine efflux at the BBB. The central hypothesis 
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underlying this effort is that studies to date have underestimated the actual BBB P-gp 
effect on fexofenadine brain uptake. 
In the current study, the rate and extent of fexofenadine brain uptake and P-gp-mediated 
efflux activity at the BBB was determined using an in situ brain perfusion technique and 
subcutaneous osmotic minipump containing fexofenadine or terfenadine in mdr1a(+/+) 
and mdr1a(-/-) mice, continuously release drug over 24 to 168 hours. A pharmacokinetic 
model was used to simulate the time-dependence of P-gp efflux ratio for fexofenadine 
and other compounds that have different passive permeability at the BBB. In addition, the 
influence of local metabolism on terfenadine brain disposition and consequent 
fexofenadine brain exposure was investigated. 
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Materials and Methods 
Adult CF-1 mdr1a(+/+) mice and their natural mutant mdr1a (-/-) counterparts (30-40 g, 
6-8 weeks of age) were purchased from Charles River Laboratories (Wilmington, MA). 
All mice were maintained on a 12-h light/dark cycle with access to water and food ad 
libitum. All experimental procedures were performed under full anesthesia induced with 
ketamine/xylazine (100/10 mg/kg, i.p.). All procedures were approved by the Institutional 
Animal Care and Use Committee at the University of North Carolina at Chapel Hill and 
were conducted in accordance with “Principles with Laboratory Animal Care” (NIH 
publication No. 85-23, revised in 1985). 
14C-diazepam (56.0 mCi/mmol) was purchased from Amersham Biosciences 
(Buckinghamshire, UK). 3H-inulin (180.0 mCi/g) was purchased from PerkinElmer 
(Waltham, MA). Terfenadine, fexofenadine hydrochloride and loperamide were 
purchased from Sigma-Aldrich (St. Louis, MO). All of the other chemicals were 
commercially available and of reagent grade.  
In Situ Mouse Brain Perfusion 
The details of the in situ mouse brain perfusion have been described elsewhere (Dagenais 
et al., 2000a). Briefly, mice were anesthetized with ketamine/xylazine (100/10 mg/kg, 
i.p.). The perfusion buffer (Krebs-bicarbonate buffer, with 9 mM of D-glucose, pH 7.4) 
was oxygenated with 95% O2 and 5% CO2 and maintained at 37°C. 14C-diazepam and 
3H-inulin were used as blood flow rate and vascular space markers, respectively. 
Fexofenadine or terfenadine at a final concentration of 2 μM was added to the perfusate. 
The right common carotid artery was cannulated with PE-10 tubing (Braintree Scientific 
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Inc., Braintree, MA) following ligation of the external carotid artery. The cardiac 
ventricles were severed immediately before perfusion at 2.5 mL/min for 60 s via a 
syringe pump (Harvard Apparatus, Holliston, MA). The experiment was terminated by 
decapitation And the right cerebral hemisphere was collected. Aliquots of perfusate were 
collected through the syringe and tubing for determination of substrate concentrations in 
perfusate. The perfusate and brain samples were stored at -20°C until analysis by 
HPLC/MS/MS. The radioactive brain samples were digested with 0.7 mL of Solvable® 
((Packard, Boston, MA) at 50°C overnight. Five mL of UltimaGold® scintillation cocktail 
(PerkinElmer, Wellesley, MA) was added and vortex-mixed. Total radioactivity (3H 
and/or 14C) was determined in a Packard Tri-carb TR 1900 liquid scintillation analyzer 
(Packard, Boston, MA). 
Parameters related to the in situ brain perfusion, i.e., the cerebral vascular volume 
(mL/100 g brain), was calculated using equation:  
inulin
inulin
vasc C
X
V = . 
the initial brain uptake clearance (Clup, mL/min/100 g brain) was calculated as:  
perf
brain
up
C
/TXCl = , 
and the apparent distributional volume (Vd, mL/100 g brain) was calculated as:  
perf
brain
d
C
XV =  
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where the amount of substrate in brain Xbrain was corrected for blood vessel 
contamination by subtraction of vascular volume or a final 15-s washout with drug-free 
saline. The permeability surface product (PS) values were calculated based on Crone-
Renkin equation (Takasato et al., 1984):  
)/FCl1ln(FPS pfuppf −×−= . 
Fpf is the perfusion flow rate measured using 14C-diazepam as the flow rate marker. 
Mathematical Modeling and Simulations 
The time to equilibrium of brain penetration is dependent on the passive permeability, 
brain unbound fraction and BBB P-gp-mediated efflux (Liu et al., 2005; Kalvass et al., 
2007b). The time course of P-gp efflux ratio following continuous infusion was simulated 
based on a similar model structure with additional P-gp-mediated efflux activity. As the 
structure shown in Figure 3.1, the model contains one central (blood) compartment and 
one brain compartment; Vc and Vbr are the physiologic blood and brain volumes, 
respectively. Cld represents the passive permeability between blood and brain 
compartments, Cleff is the P-gp-mediated efflux clearance, Cl is the systemic clearance, 
and fu,p and fu,br are plasma and brain unbound fraction, respectively. Modeling was based 
in part on the assumption that only unbound drug is able to cross the BBB. The passive 
permeability Cld for fexofenadine is very low relative to the blood flow rate, and 
therefore was assumed to be equal to the permeability coefficient PS determined by the in 
situ brain perfusion technique. Numerical values for these parameters were assigned as 
follows: Vp=49 mL/kg, Vbr=17 mL/kg (Brown et al., 1997), Cl=30 mL/min/kg (Tahara et 
al., 2005), fu,p =0.35 and fu,br =0.077 (Kalvass et al., 2007a), The infusion rate k0 was set 
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to a value of 1 (unit dose). Fexofenadine PS=0.22 mL/min/100 g brain based on the in 
situ brain perfusion data. Three pairs of Cld and Cleff were assigned: Cld1=0.022, 
Cld2=0.22, Cld3=2.22 mL/min/kg; the corresponding Cleff1=0.54; Cleff2=5.39, Cleff3=53.90 
mL/min/kg for P-gp-competent mice assuming a steady-state P-gp efflux ratio of 25. 
Cleff=0 for all P-gp deficient mice. The P-gp efflux ratio was calculated as the ratio of 
brain partition coefficient in P-gp deficient mice to P-gp competent mice. The differential 
equations used for simulations were: 
bru,brpu,
br
br
bru,brpu,c
CCleff)(CldCCld
dt
dC
V
CCleff)(CldCCld)(Clk0
dt
dCV
ff
ff
××+−××=×
××++××+−=×
 
where C and Cbr are the total plasma and brain concentrations, respectively.  
In vivo Osmotic Minipump Studies 
CF-1 mice (n=3 per group) were anesthetized with ketamine/xylazine (100/10 mg/kg, 
i.p.). Alzet® model # 2001 osmotic minipump (release rate 1 μl/h over one week, Alza 
Corporation, Palo Alto, CA) was selected. Initial experiments were directed at 
determining fexofenadine brain penetration and P-gp efflux ratio following fexofenadine 
and terfenadine administration. To produce similar plasma concentrations of 
fexofenadine for comparison, pumps were filled with fexofenadine hydrochloride (80 
μg/pump) or terfenadine (900 μg/pump) dissolved in 50% DMSO (200 μl/pump) and 
placed subcutaneously in the back of mdr1a(+/+) and mdr1a(-/-) mice. The experiment 
was terminated by decapitation 24 hr following implantation. Additional experiments 
were performed to study the time course of fexofenadine P-gp efflux ratio at the BBB. To 
96 
accomplish this goal, additional groups of mdr1a(+/+) and mdr1a(-/-) mice received 
fexofenadine hydrochloride (872 μg/pump) to produce plasma concentrations similar to 
those reported by Tahara et al. (2005). The mice were sacrificed at 24, 72 and 168 hr 
post-implantation. Trunk blood was collected in heparinized 1.5-mL microcentrifuge 
tubes, and plasma was harvested following centrifugation at 3,000 rpm for 5 min. The 
plasma and brain samples were stored at -20°C until analysis by HPLC/MS/MS. The 
contribution of residual blood in the brain tissue to the brain partition coefficient was 
corrected by subtracting 1.8% from the calculated brain-to-plasma concentration ratio 
(Brown et al., 1997; Dagenais et al., 2000a). 
Mouse Brain Metabolism 
Terfenadine brain metabolism was determined under two different experimental 
conditions. First, mdr1a(+/+) and mdr1a(-/-) mouse brain hemispheres were perfused 
with 2 μM terfenadine for 1 min (n=3, with a procedure identical to that described in “In 
situ Mouse Brain Perfusion”). The concentrations of fexofenadine formed in the perfused 
brain hemisphere were determined by HPLC/MS/MS. Second, fresh mdr1a(+/+) mouse 
brains were harvested, washed with 0.15 M KCl, and homogenized in two volumes of 
phosphate buffer (pH 7.4, 1.15% KCl). Terfenadine or hydroxyl-terfenadine at a final 
concentration of 200 nM was incubated with brain homogenate (10 mg/mL) in the 
presence of potassium phosphate buffer (0.1 M, pH 7.4) and magnesium chloride (5 mM). 
The reaction was initiated by addition of freshly prepared NADPH (2 mM) (Ling et al., 
1995; Holleran et al., 2004). After 2 hr incubation at 37 oC in shaking water bath, the 
reaction was terminated by addition of ice-cold methanol to precipitate protein. The 
samples were centrifuged at 10,000 g for 10 min. The supernatant was transferred to a 
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fresh tube and evaporated under a stream of dry nitrogen. The residue was reconstituted 
with 50% methanol in water, and an internal standard was added. The formation of 
fexofenadine from terfenadine or hydroxyl-terfenadine was determined by HPLC/MS/MS. 
Sample Preparation and Quantitation 
The brain tissue was homogenized with addition of two volumes of distilled water 
following brief probe sonication. The perfusate was diluted with two volumes of 
methanol. A 25-µl aliquot of plasma or brain homogenate was transferred to an HPLC 
vial, and protein was precipitated with 100 µl of methanol containing internal standard 
(10 ng/mL loperamide) followed by a 25-µl aliquot of DMSO. The sample was vortex-
mixed and centrifuged. Standard solutions ranging from 0.5 to 5000 nM were prepared in 
a similar manner. Briefly, 25 µl of blank plasma or brain homogenate, 100 µl of methanol 
containing internal standard, and 25 µl of serially-diluted standard solution were mixed 
and centrifuged. The supernatant was analyzed by HPLC-tandem mass spectrometry 
(API 4000 triple quadrupole with TurboIonSpray interface; Applied Biosystems/MDS 
Sciex, Concord, ON, Canada). Three microliters of sample solutions were injected via an 
autosampler (Leap, Carrboro, NC). Fexofenadine, terfenadine, terfenadine-OH, and the 
internal standard loperamide were eluted from an Aquasil C18 column (2.1 x 50 mm, dp = 
5 µm; Thermo Electron Corporation, Waltham, MA) using a mobile phase gradient (A, 
0.1% formic acid in water; B, 0.1% formic acid in methanol; 0-0.70-min hold at 0% B, 
0.70-3.12-min linear gradient to 90% B, 3.12-4.10 min hold at 90% B, 4.10-4.20-min 
linear gradient to 0% B, 4.20-4.90-min hold at 0% B; solvent delivery system [Shimadzu]; 
flow rate = 0.75 ml/min; 0.8-4 min directed to mass spectrometer) and were detected in 
positive ion mode using multiple reaction monitoring: fexofenadine: 502.4?466.4 m/z, 
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terfenadine, 472.3?436.5 m/z; terfenadine-OH, 488.3?452.5 m/z; loperamide, 
477.4?266.0 m/z. All analytes were quantified with standard curves in the linear range of 
the relationship between detector response and analyte concentration prepared in the 
appropriate matrix. The lower limit of detection was 0.5 ng/ml; inter-and intraday CVs 
were <15%.  
Statistical Analysis 
Data are reported as mean ± standard deviation (SD) for 3 mice per condition. A two-
tailed student’s t-test, or either a one-way or two-way ANOVA, where appropriate, was 
used to determine the statistical significance of differences among two or more groups. 
The level of significance was corrected for multiple comparisons (e.g., Bonferroni test) or 
adjusted for unequal variance when necessary. In all cases, p < 0.05 was considered to be 
statistically significant.
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Results 
In Situ Mouse Brain Perfusion 
3H-inulin was used as the brain capillary space marker to measure the BBB physical 
integrity. 14C-diazepam was perfused as a marker of functional perfusate flow rate. The 
vascular volume was 1.69±0.10 mL/100 g and functional flow rate was 250±41 
mL/min/100 g brain. P-gp gene deficiency had no influence on the vascular volume or 
functional perfusion rate. The initial brain uptake clearance (Clup, mL/min/100 g brain 
tissue) of fexofenadine and terfenadine in mdr1a(+/+) and mdr1a(-/-) mice is shown in 
Figure 3.2. The P-gp efflux ratio, calculated as the ratio of Clup in mdr1a(-/-) mice to 
mdr1a(+/+) mice, was 4.4 and 1.1 for fexofenadine and terfenadine, respectively. 
Mathematical Modeling and Simulation 
Simulations were conducted with three different sets of values for the passive 
permeability (Cld) and P-gp-mediated efflux clearance (Cleff) (Figure 3.3). The time 
course of the apparent fexofenadine P-gp efflux ratio was simulated when Cld was equal 
to the actual value determined from the in situ brain perfusion experiment (1×PS). All of 
the other variables were physiologic or biologic parameters (i.e., Vc, Vbr, fu,p, and fu,br) or 
estimates of fexofenadine pharmacokinetic parameters (i.e., Cl) obtained from the 
literature (Brown et al., 1997; Tahara et al., 2005; Kalvass et al., 2007a). The simulations 
predicted that 12 hr and 36 hr would be required for fexofenadine to achieve 50% and 
90% of the steady-state P-gp efflux ratio, respectively. When Cld was increased 10-fold, 
the time to achieve the maximum P-gp efflux ratio shortened. In contrast, when Cld was 
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10-fold lower than the actual experimental value obtained for fexofenadine, the P-gp 
efflux ratio did not plateau during the time frame of the simulation. 
In Vivo Osmotic Minipump Studies 
Fexofenadine brain-to-plasma concentration ratios at 24 hr following administration of 
either fexofenadine or terfenadine in mdr1a(+/+) and mdr1a(-/-) mice are displayed in 
Figure 3.4. Steady-state fexofenadine plasma concentrations were 28.5 ± 8.3 and 45.5 ± 
3.1 nM in mdr1a(+/+) and mdr1a(-/-) mice during fexofenadine administration, 
respectively. During terfenadine administration, concentrations of terfenadine in plasma 
and brain tissue were below the limit of quantitation. However, plasma concentrations of 
fexofenadine derived from terfenadine were identical in mdr1a(+/+) (7.1±2.8 nM) and 
mdr1a(-/-) (7.1±1.7 nM) mice. Fexofenadine brain-to-plasma concentration ratios after 
24 hr of fexofenadine administration were 0.0056 ± 0.010 and 0.27 ± 0.08 in mdr1a(+/+) 
and mdr1a(-/-) mice, respectively. In contrast, the fexofenadine brain-to-plasma 
concentration ratio after 24 hr of terfenadine administration were 0.14 ± 0.03 and 7.44 ± 
2.12 in mdr1a(+/+) and mdr1a(-/-) mice, respectively. The fexofenadine brain-to-plasma 
ratios therefore were ~25- and 27-fold higher in mdr1a(+/+) and mdr1a(-/-) mice, 
respectively, after terfenadine administration as compared to after fexofenadine 
administration. The calculated fexofenadine P-gp efflux ratios following fexofenadine 
and terfenadine administration are 48 and 55, respectively. 
Fexofenadine hydrochloride at dose of 872 µg/pump, selected to produce plasma 
concentrations (380-480 nM) similar to those in a previous study by Tahara et al. (2005), 
was administered in mdr1a(+/+) and mdr1a(-/-) mice for 24, 72 and 168 hr. Plasma 
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concentrations of fexofenadine achieved with this approach were 305 ± 74 and 836 ± 138 
nM in mdr1a(+/+) and mdr1a(-/-) mice, respectively, and did not vary with time during 
this period. The brain-to-plasma concentration ratios of fexofenadine during prolonged 
continuous infusion by subcutaneous osmotic minipumps are shown in Figure 3.5. The P-
gp efflux ratios were 17, 23 and 25, at 24, 72, and168 hr, respectively. The calculated P-
gp efflux ratio values, together with the P-gp efflux ratio at 2.5 hr from Tahara et al. 
(2005), are shown in Figure 3.3. These experimentally-derived values correspond closely 
with the predicted values based on the mathematical simulation. 
Mouse Brain Metabolism 
Fexofenadine formation rate in brain tissue during in situ brain perfusion with 2 µM of 
terfenadine for 1 min in mdr1a(+/+) and mdr1a(-/-) mice; and after 2-hr incubation of 
200 nM of terfenadine or hydroxyl-terfenadine with whole brain tissue homogenate, is 
displayed in Figure 3.6. The fexofenadine formation rate during 1-min terfenadine brain 
perfusion was 17.0 ± 3.1 and 12.0 ± 5.4 nmole/min/kg brain tissue in mdr1a(+/+) and 
mdr1a(-/-) mice, respectively. Fexofenadine formation rate during a 2-hr incubation of 
whole brain homogenate with terfenadine or hydroxyl-terfenadine was 12.9 ± 3.5 or 74.9 
± 11.8 nmole/min/kg brain tissue, respectively. 
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Discussion 
Lipophilicity and ionization at physiologic pH are important determinants of brain 
penetration (Brodie et al., 1960). Fexofenadine is ionized at physiologic pH and crosses 
the BBB to only a minimal extent. In contrast to pre-formed fexofenadine, the 
fexofenadine prodrug terfenadine, a very lipophilic molecule, evidenced a brain uptake 
that approximated perfusate flow. This very high uptake clearance was similar between 
mdr1a(+/+) and mdr1a(-/-) mice, even though terfenadine has been reported to be a P-gp 
substrate (Mahar Doan et al., 2004; Obradovic et al., 2007). The lack of a discernible P-
gp effect for this substrate was consistent with the efficient unidirectional uptake of 
terfenadine during short-term brain perfusion.  
P-gp has been reported to be involved in fexofenadine intestinal secretion, and thus in the 
systemic disposition of this compound. [14C]-fexofenadine plasma concentrations in 
mdr1a knockout mice were ~4.6-fold higher than that in wild-type mice after intravenous 
administration (Cvetkovic et al., 1999). In the current study, fexofenadine plasma 
concentrations in mdr1a(-/-) mice were approximately 60-206% higher than in 
mdr1a(+/+) mice. These observations are in contrast to a previous report by Tahara et al 
(2005), which indicated that plasma concentrations of fexofenadine were similar in P-gp-
competent and P-gp-deficient bile duct cannulated mice..  
P-gp also is involved in fexofenadine penetration of the BBB. The influence of P-gp on 
brain uptake of fexofenadine was demonstrated for the first time with the in situ brain 
perfusion technique, using the mdr1a(-/-) mouse model of P-gp deficiency. The P-gp 
effect during short-term brain perfusion (4.4-fold) was modest. In vivo administration 
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under conditions that produce steady-state provides a more sensitive approach to 
quantitating the BBB P-gp effect than short-term brain perfusion when substrate 
equilibration across the blood-brain interface is slow. Continuous infusion with a 
subcutaneous osmotic minipump provides useful steady-state information from a simple 
experimental system. This approach was used in the current study. As anticipated, the in 
vivo P-gp efflux ratio exceeded that determined by the in situ brain perfusion, which has 
been demonstrated experimentally in the present study and previously (Dagenais et al., 
2001). The present results also are consistent with previous mathematical predictions 
based on a simple three-compartment model (representing plasma, endothelial cell layer, 
and brain) that showed ERα (in vivo P-gp efflux ratio) must be higher than ERB (in situ P-
gp efflux ratio) for the same substrate and efflux transporter system (Kalvass and Pollack, 
2007).  
Fexofenadine brain-to-plasma concentration ratio at 24 hr (i.e., during continuous 
minipump administration) was 25- to 27-fold higher following terfenadine administration 
than fexofenadine administration in both mdr1a(+/+) and mdr1a(-/-) mice. This 
difference might be due to the low permeability of fexofenadine. In the presence of such 
a low uptake clearance, a significantly longer period of time would be required to reach 
distribution equilibrium across the BBB, and so the apparent brain-to-plasma ratio at 24 
hr may be an underprediction of the true equilibrium value. Indeed, this situation has 
been demonstrated previously by Liu et al. (2005) using a simulation approach. 
Alternatively, the precursor of fexofenadine, terfenadine, is permeable at the BBB. If 
terfenadine is metabolized in the brain after crossing the BBB, an increase in 
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fexofenadine brain exposure, relative to administration of preformed fexofenadine, would 
be predicted. 
To test the first possible mechanism, simulation studies were conducted in parallel with 
animal experiments. Mathematical modeling demonstrated that the P-gp efflux ratio must 
be time-dependent. Moreover, these simulations successfully predicted the P-gp efflux 
ratios measured at the selected experimental time points. The interpretation of the 
simulation results is both straightforward and logical: because it takes longer for slowly-
permeable compounds to equilibrate across the BBB, the experimentally-determined P-gp 
efflux ratio also will take a longer time to reach its equilibrium (theoretically maximum) 
condition. Experimentally, fexofenadine was administered for a prolonged time period up 
to 168 hr. The present results demonstrate a clear time-dependence of fexofenadine P-gp 
efflux ratio during this time range of 24 to 168 hr. The determined P-gp efflux ratio 
values, together with the P-gp efflux ratio of ~3.3 at 2.5 hr taken from Tahara et. al. 
(2005), were almost superimposable with the predicted values based on the model 
simulation.  
In order to assess the influence of P-gp on fexofenadine brain exposure when 
fexofenadine is formed from terfenadine, versus when fexofenadine is administered 
directly, fexofenadine plasma concentrations must be similar between the two 
administration modalities. To achieve similar fexofenadine concentrations from pre-
formed fexofenadine as compared to fexofenadine concentrations following terfenadine 
administration, fexofenadine hydrochloride was administered via osmotic minipump at a 
continuous rate of 1.5 nmoles/hr. The fexofenadine P-gp efflux ratios determined in vivo 
at distribution equilibrium were similar (55 vs. 48) regardless of whether fexofenadine 
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was formed from terfenadine or administered directly. The P-gp efflux ratio decreased 
when fexofenadine plasma concentration was ~10-fold higher (305 nM) in the time-
course studies, consistent with at least partial saturation of the transport process. 
Based on the impaired brain penetration of fexofenadine in both mdr1a(+/+) and 
mdr1a(-/-) mice at all time points following fexofenadine administration, the 25-27-fold 
increase of fexofenadine brain penetration following terfenadine administration could not 
be explained by simply attaining distribution equilibrium more rapidly with the prodrug. 
Thus, it was important to address the possibility that local metabolism of terfenadine to 
fexofenadine in the brain was responsible for the observed difference. Terfenadine is 
metabolized to hydroxyl-terfenadine, then to the carboxylic acid metabolite fexofenadine, 
by hepatic CYP3A4 in humans. CYP3A11 and 3A13 are the murine counterparts of 
human 3A4, and are expressed in mouse liver and brain (Hagemeyer et al., 2003; Meyer 
et al., 2006). Following terfenadine administration, terfenadine plasma and brain 
concentrations were below the limit of quantitation, although fexofenadine concentrations 
in plasma and brain were substantial. These observations confirm efficient metabolism of 
terfenadine in the mouse. Fexofenadine plasma concentrations were identical in 
mdr1a(+/+) and mdr1a(-/-) mice, indicating that the formation rate of fexofenadine from 
terfenadine did not differ between mouse strains. Terfenadine appeared to be metabolized 
to fexofenadine in mouse brain during a short (1-min) brain perfusion, as well as during a 
2-hr in vitro incubation with brain tissue homogenate (Figure 3.6).  
Fexofenadine formation rate in the brain during terfenadine brain perfusion was 
comparable between mdr1a(+/+) and mdr1a(-/-) mice, suggesting that the correspondent 
enzyme(s) activity in brain was not modulated  by P-gp. These novel observations 
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provided supporting evidence, consistent with the pharmacokinetic arguments, that 
terfenadine must be metabolized to fexofenadine both systemically and regionally in the 
brain. The local metabolism significantly increased fexofenadine brain exposure 
compared to what would be expected if fexofenadine was simply formed from 
terfenadine systemically.  
The enzyme(s) responsible for terfenadine-to-fexofenadine biotransformation in murine 
brain is unknown, although it is reasonable to speculate that CYP3A11 and/or CYP3A13 
may be responsible. This metabolic situation may have pharmacologic consequences. 
Fexofenadine is a non-sedating antihistamine, at least in part because it does not penetrate 
the BBB efficiently. In contrast, high-dose terfenadine administration has been associated 
with sedative effects (Mattila and Paakkari, 1999). It is possible that terfenadine itself is 
the causative agent for sedation. Alternatively, terfenadine may be inert, but provide 
sufficient fexofenadine to the brain, via local metabolism, to allow fexofenadine to cause 
sedation.  
Antihistamines represent an interesting pharmacologic class from the standpoint of BBB 
permeation and central nervous system responsivity. Fexofenadine and cetirizine are both 
non-sedating antihistamines due to poor BBB permeability secondary to P-gp-mediated 
efflux at the BBB (Polli et al., 2003). Hydroxyzine is sedating, as is terfenadine at high 
doses (Mattila and Paakkari, 1999). A comprehensive pharmacokinetic study of cetirizine 
following intravenous administration of cetirizine and hydroxyzine has been conducted 
(Chen et al., 2003a). Re-examination of these published results demonstrated that the 
cetirizine P-gp efflux ratio was ~4.4 after administration of preformed cetirizine. 
However, the cetirizine P-gp efflux ratio following administration of hydroxyzine, the 
107 
more permeable precursor of cetirizine, was ≥125 at 240 min. This experimentally-
determined efflux ratio is remarkably similar to the predicted value of 111 based on the 
unbound fraction of cetirizine in plasma versus brain and the intrinsic transport activity of 
cetirizine by P-gp (Kalvass et al., 2007a). Thus, the overall prediction of antihistamine 
brain penetration could be substantially improved by using accurately determined P-gp 
efflux ratios (that is, the efflux ratios determined after complete equilibration across the 
BBB). Such an approach would effectively address the two outliers – fexofenadine and 
cetirizine - identified in a previous compound set (Kalvass et al., 2007a).  
An additional consideration for these compounds is that the cetirizine brain-to-plasma 
concentration ratio at 240 min was ~7-fold higher following hydroxyzine administration 
as compared to ceterizine administration. This situation is analogous to that for the 
terfenadine-fexofenadine precursor-metabolite pair as shown in the present series of 
experiments.. The specific enzyme(s) responsible for hydroxyzine metabolism are 
unknown. However, it is conceivable that hydroxyzine enters the brain and subsequently 
is metabolized to cetirizine, thus increasing cetirizine local exposure following 
hydroxyzine administration. Clearly, additional experimentation would be required to 
confirm this speculation. 
Based on the current study with the terfenadine/fexofenadine pair, together with 
published results for the hydroxyzine/cetirizine pair, administration of a permeable 
prodrug seems to provide useful information about the true P-gp efflux ratio for a poorly 
permeable metabolite. For many slow-equilibrating compounds, partitioning through the 
BBB is the rate-limiting step in brain uptake. In this situation, the assumption that simple 
diffusion of unbound substrate across the BBB leads to equivalent unbound 
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concentrations in brain and plasma is violated because distribution equilibrium might not 
be achieved within the confines of a given experiment, thus result in a lower extent of 
brain penetration than predicted based on the equilibrium assumption. Such a situation 
has been demonstrated for NFPS (N[3-(4’-fluorophenyl)-3-(4’-
phenylphenoxy)propyl]sarcosine), which failed to reach equilibrium within a 24-hr 
experiment (Liu et al., 2005).  
Following prodrug administration, a poorly-permeable metabolite formed in the brain 
(i.e., in capillary endothelial cells, neurons, or glial cells) might evidence access to the P-
gp binding site that is different from access that could be achieved from the luminal side 
(i.e., after systemic formation of the metabolite or direct administration of the pre-formed 
compound). The relative rate of metabolite formation in systemic circulation versus brain 
certainly would influence brain exposure, apparent brain-to-blood partitioning, and 
calculated P-gp efflux ratios. These experimental aspects warrant further investigation. 
Taken together, brain exposure is an integrative effect of passive permeability, protein 
binding in plasma and brain, interaction with active transporters at the BBB, and, in the 
special case of poorly permeable metabolites, the systemic and regional brain metabolism. 
Finally, brain exposure for poorly permeable compounds is complicated further by CSF 
bulk flow, which in the mouse is ~0.071 mL/min/100 g (Rudick et al., 1982). CSF bulk 
flow also poses a significant influence on the brain exposure of low-permeability 
compounds (Liu and Chen, 2005). 
In conclusion, the current study investigated fexofenadine brain penetration and P-gp 
efflux ratio following fexofenadine and terfenadine administration. The results 
demonstrated that P-gp is an important determinant of fexofenadine efflux at the BBB 
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and, consequently, the presentation of fexofenadine to brain tissue. Studies to date have 
underestimated the actual P-gp efflux ratio of fexofenadine at the BBB because the P-gp 
efflux ratio is time-sensitive, and previous experiments were not sufficiently long to 
uncover the true efflux ratio. The present experiments also demonstrated for the first time 
the metabolism of terfenadine to fexofenadine in murine brain. The enzyme(s) 
responsible for terfenadine metabolism in the brain require further investigation. These 
latter results underscore the fact that enzymes in the brain or the BBB not only represent 
a metabolic barrier for substrate presentation to the brain, but also might activate some 
drugs to cause CNS responses (either therapeutic or toxic). Modulation of brain 
metabolic enzymes by co-administered drugs might represent a source of drug-drug 
interaction. 
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Figure 3.1:  Scheme for the mathematical model used to simulate the P-gp efflux ratio 
over time. Parameter definitions are included in the Materials and Methods section.  
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Figure 3.2:  Initial brain uptake clearance (Clup, mL/min/100 g) for fexofenadine and 
terfenadine in mdr1a(+/+) (solid bar) and mdr1a(-/-) (open bar) mice. The mouse brain 
hemisphere was perfused via the common carotid artery at 2.5 mL/min for 60 s. Data are 
presented as mean ± SD (n=3). Student’s t-test was used to determine the statistical 
significance of P-gp effect between mdr1a(+/+) and mdr1a(-/-) mice. Asterisk (*) 
represents a statistical difference (p<0.05) between mdr1a(+/+) and mdr1a(-/-) mice. 
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Figure 3.3:  Simulated P-gp efflux ratios over time for varying passive permeability (Cld) 
and P-gp-mediated efflux clearance (Cleff) (―, Cld=2.24, Cleff=53.90; ----, Cld=0.22, 
Cleff=5.39; ······, Cld=0.022, Cleff=0.54; Cleff=0 for P-gp-deficient mice). The P-gp efflux 
ratio was calculated as the ratio of brain-to-plasma concentration ratio in mdr1a(-/-) mice 
to mdr1a(+/+) mice. The solid circles (●) represent fexofenadine P-gp efflux ratios 
determined at 24, 72, and 168 hr during subcutaneous osmotic minipump administration. 
The open circle (○) is the P-gp efflux ratio determined at 2.5 hr in Tahara et al., (2005).  
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Figure 3.4:  Fexofenadine brain-to-plasma concentration ratio at 24 hr in mdr1a(+/+) 
(solid bar) and mdr1a(-/-) (open bar) mice following subcutaneous osmotic minipump 
administration of fexofenadine or terfenadine. Data are presented as mean ± SD (n=3). 
Student’s t-tests were used to compare brain-to-plasma concentration ratios between 
mdr1a(+/+) and mdr1a(-/-) mice. Asterisk (*) represents a statistical difference (p<0.05) 
between mdr1a(+/+) and mdr1a(-/-) mice. 
*
*
118 
24 h 72 h 168 h
Fe
xo
fe
na
di
ne
 K
p,
br
ai
n
0.0
0.1
0.2
0.3 mdr1a(+/+)
mdr1a(-/-)
 
Figure 3.5:  Fexofenadine brain-to-plasma concentration ratio in mdr1a(+/+) (solid bar) 
and mdr1a(-/-) (opne bar) mice at 24, 72 and 168 hr following subcutaneous osmotic 
minipump administration of fexofenadine. Data are presented as mean ± SD (n=3). Two-
way ANOVA was used to compare brain-to-plasma concentration ratios between 
mdr1a(+/+) and mdr1a(-/-) mice; and among the time points, respectively. Asterisk (*) 
represents a statistical difference (p<0.05) between mdr1a(+/+) and mdr1a(-/-) mice. 
There was no differences for fexofenadine brain partition coefficients at different time 
points.
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Figure 3.6:  Fexofenadine formation rate in the brain hemisphere following 60 s 
terfenadine in situ mouse brain perfusion in mdr1a(+/+) and mdr1a(-/-) mice, or a 2-hr 
incubation of terfenadine (Terf) or terfenadine-OH (Terf-OH) with whole brain tissue 
homogenate. Data are presented as mean ± SD (n=3). One-way ANOVA statistical 
analysis corrected for multiple comparisons (Bonferroni test) demonstrated that 
fexofenadine formation rate in the brain was significantly higher when incubated with 
terfenadine-OH than incubation with terfenadine or one-minute terfenadine brain 
perfusion (*, p<0.05). 
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CHAPTER 4 
BREAST CANCER RESISTANCE PROTEIN INTERACTS WITH VARIOUS 
COMPOUNDS IN VITRO, BUT PLAYS A MINOR ROLE IN SUBSTRATE 
EFFLUX AT THE BLOOD-BRAIN BARRIER 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted for publication in Drug Metabolism and Disposition and is 
presented in the style of that journal.  
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Abstract 
Expression of breast cancer resistance protein (Bcrp) at the blood-brain barrier (BBB) has 
been revealed recently. In order to investigate comprehensively the potential role of Bcrp 
at the murine BBB, a chemically-diverse set of model compounds (cimetidine, alfuzosin, 
dipyridamole and LY2228820) was evaluated utilizing a multiexperimental design. Bcrp1 
stably-transfected MDCKII cell monolayer transport studies demonstrated that each 
compound had affinity for Bcrp, and that polarized transport by Bcrp was abolished 
completely by the Bcrp inhibitor chrysin. However, none of the compounds differed in 
brain uptake between Bcrp wild-type and knockout Abcg2(-/-) mice under either an in 
situ brain perfusion or a 24-hr subcutaneous osmotic minipump continuous infusion 
experimental paradigm. In addition, alfuzosin and dipyridamole were shown to undergo 
transport by P-gp in an MDCKII-MDR1 cell monolayer model. Alfuzosin brain uptake 
was four-fold higher in mdr1a(-/-) mice than in mdr1a(+/+) mice in in situ and in vivo 
studies, demonstrating for the first time that it undergoes P-gp-mediated efflux at the 
BBB. In contrast, P-gp had no effect on dipyridamole brain penetration in situ or in vivo. 
Dipyridamole brain penetration was appreciable, with brain concentrations that 
approximated plasma concentrations. In summary, Bcrp mediates in vitro transport of 
various compounds, but appears to play a minimal role at the BBB in vivo. Correlation 
analyses indicate that in situ brain permeability is dependent on the lipophilicity of 
compounds in the absence of efflux transport. In addition, in situ brain uptake clearance 
correlates with the apparent passive permeability in in vitro transport and cellular 
accumulation studies. 
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Introduction 
The blood-brain barrier (BBB) is composed of brain capillary endothelial cells, which are 
characterized by highly-developed tight junctions, lack of fenestrations and paucity of 
pinocytic and transcytotic activities. Expression of metabolic enzymes and efflux 
transporters in these and associated glial cells provide additional limiting factors at the 
BBB. Insufficient drug exposure at the pharmacologic target within the brain, as a 
consequence of limited flux from blood to brain, represents a major obstacle for effective 
treatment of CNS disorders (Begley, 2004b; Pardridge, 2005). It is widely accepted that 
P-glycoprotein (P-gp) is expressed abundantly at the BBB and functions as an efflux 
pump thay extrude toxic substances and therapeutic agents in the brain-to-blood direction, 
representing a functional barrier to brain uptake (Schinkel, 1999). The potential role of 
other members of ATP-binding cassette (ABC) efflux transporters, such as multidrug 
resistance-associated proteins (Mrps) and breast cancer resistance protein (Bcrp), at the 
BBB is less clear, although the proteins appear to be expressed at the BBB in various 
species (Soontornmalai et al., 2006; Yousif et al., 2007). 
Bcrp is a recently-identified member of ABC efflux transporter encoded by gene Abcg2 
(Doyle et al., 1998). Bcrp is widely expressed in the intestine, liver, mammary gland, and 
placenta. The functional efficiency of Bcrp in these organs, such as intestinal secretion, 
fetal penetration and breast milk secretion of various compounds (e.g., topotecan, 
nitrofurantoin and cimetidine), has been documented clearly (Jonker et al., 2000; Jonker 
et al., 2005). In addition, Bcrp is expressed on the luminal side of brain capillary 
endothelial cells in mice, rats, pig and human, with localization similar to that of P-gp; 
mRNA expression level for Bcrp also is similar to that of P-gp (Maliepaard et al., 1999; 
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Cooray et al., 2002; Eisenblatter and Galla, 2002; Eisenblatter et al., 2003; Cisternino et 
al., 2004; Aronica et al., 2005; Lee et al., 2005; Tanaka et al., 2005).  
Bcrp mediates the transport of a wide variety of substrates, from sulfoconjugated organic 
anions to various organic cations. The extensive overlap of Bcrp with P-gp in expression 
pattern and substrate specificity leads to the hypothesis that Bcrp, like P-gp, might have 
an important role in the handling of substrate drugs, with subsequent regulation of 
pharmacologic response, in animals and humans (Tanaka et al., 2005). However, studies 
to date have not clarified Bcrp function at the BBB, which remains very controversial. 
Brain penetration of imatinib mesylate was 2.5-fold higher in Bcrp-deficient mice as 
compared to wild-type animals, suggesting that Bcrp represents a functional barrier to 
brain uptake of this compound (Breedveld et al., 2005). In contrast, the initial rate of 
brain uptake of imatinib mesylate did not differ between wild-type and Bcrp1(-/-) mice 
during in situ brain perfusion, and GF120918 (elacridar), an inhibitor of P-gp and Bcrp, 
did not alter brain uptake of imatinib in mdr1a/1b(-/-) mice, suggesting that Bcrp was not 
involved in imatinib brain uptake (Bihorel et al., 2007). 
Exploring the role of Bcrp at the BBB may provide important information on the design 
of efficient drug delivery to CNS, and may add to the understanding CNS toxicity, for 
Bcrp substrates. In the present study, four compounds with different physicochemical 
properties, cimetidine, alfuzosin, dipyridamole, and LY2228820, four compounds were 
selected as model substrates based on the in vitro screening in an MDCKII-Bcrp cell 
monolayer transport assay to evaluate comprehensively the role of Bcrp at the murine 
BBB. Cimetidine, a prototypical histamine H2 receptor antagonist, recently was 
demonstrated to possess anti-tumor activity against a variety of cancers and malignant 
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brain glioma (Lefranc et al., 2006). Cimetidine is a hydrophilic compound that has poor 
brain penetration (Hough et al., 1986) and is actively secreted from rat mammary gland 
and placenta by Bcrp (Jonker et al., 2005; Staud et al., 2006). Alfuzosin is a clinical 
uroselective alpha1-adrenergic receptor antagonist with proven efficacy and safety in the 
treatment of benign prostatic hyperplasia (BPH). Alfuzosin is a structural analog of 
prazosin, which is a prototypical Bcrp substrate (Marbury et al., 2002; Guay, 2004; Staud 
et al., 2006). Dipyridamole is a platelet inhibitor used for treatment of stroke. It is a P-gp 
inhibitor and was identified recently as a human BCRP substrate (Hervey and Goa, 1999; 
Verstuyft et al., 2003; Zhang et al., 2005b). LY2228820 is a P38 mitogen-activated 
protein kinase (MAPK) inhibitor discovered by Eli Lilly and Company. In the present 
study, bidirectional transport of these model compounds across the MDCKII-Bcrp and 
MDCKII-MDR1 cell monolayers was evaluated. The initial brain uptake clearance (Clup) 
was determined using in situ brain perfusion with Bcrp-competent [C57BL/6, Abcg2(+/-)] 
and Bcrp -deficient [Abcg2(-/-)], P-gp-competent [mdr1a(+/+)] and P-gp -deficient 
[mdr1a(-/-)] mouse models. In addition, the P-gp and Bcrp inhibitor GF120918 was co-
perfused with test compounds in the brain perfusion paradigm to generate a chemical 
knockout model. Finally, in vivo brain penetration of substrates was measured at 24 hr 
during continuous subcutaneous infusion with an osmotic minipump. 
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Materials and Methods 
Animals  
Adult mdr1a(+/+) mice and its natural mutant mdr1a (-/-) mice (30-40 g, 6-8 weeks of 
age) were obtained from Charles River Laboratories. Male C57BL/6 wild-type 
[Abcg2(+/-)], Abcg2(+/+) and Abcg2(-/-) mice (25-35 g) were a gift from Eli Lilly and 
Company. Details regarding the background, generation, and breeding of these mice have 
been described elsewhere (Zamek-Gliszczynski et al., 2006). All mice were maintained 
on a 12-h light/dark cycle with access to water and food ad libitum. All experimental 
procedures were performed under full anesthesia induced with ketamine/xylazine (100/10 
mg/kg, i.p.). All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill and were conducted in 
accordance with “Principles with Laboratory Animal Care” (NIH publication No. 85-23, 
revised in 1985). 
Materials  
Cimetidine and dipyridamole were purchased from Sigma-Aldrich (St. Louis, MO). 
Alfuzosin was obtained from Toronto Research Chemicals Inc (New York, ON, Canada). 
LY2228820 and 14C-LY2228820 were kind gifts from Eli Lilly and Company 
(Indianapolis, IN). GF120918 [N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-
isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide] 
was a kind gift from GlaxoSmithKline (Research Triangle Park, NC). 3H-cimetidine 
(25.0 Ci/mmol) and 14C-diazepam (56.0 mCi/mmol) were purchased from Amersham 
Biosciences (Buckinghamshire, UK). 14C-inulin (2.1 mCi/g) was purchased from 
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American Radiolabeled Chemical Inc. (St Louis, MO). 3H-inulin (180.0 mCi/g) and 3H-
colchicine (80.4 Ci/mmol) were purchased from PerkinElmer (Waltham, MA). All of the 
other chemicals were commercially available and of reagent grade.  
Cell Culture 
Madin-Darby canine kidney (MDCKII) cells stably expressing either murine wild-type 
Abcg2 (Bcrp1) or human wild-type ABCB1 (P-gp) were obtained from the Netherlands 
Cancer Institute under a Materials Transfer Agreement. MDCK cells were maintained at 
37oC in humidified 5% CO2/95% air using Eagle’s MEM culture medium supplemented 
with 10% (v/v) fetal bovine serum, penicillin, and streptomycin. A 1:10 split was done 
twice per week and cells at passage 7-10 (Bcrp) or 20-30 (P-gp) were plated at 50,000 
cells/cm2 in 12-well Transwell filter inserts (1.13 cm2 surface area). Medium was 
changed on days 3 and 5 and the cell monolayers used on day 6. 
Bi-directional Flux Experiments In vitro 
Cells were rinsed twice with Dulbecco’s phosphate-buffered saline (PBS) containing 10 
mM Hepes, pH 7.4. Some cells were pretreated twice for 15 min each with PBS 
containing either 2.5 μM of LSN335984, a close structural analog to zosuquidar 
(LY335979), to potently and selectively inhibit P-gp, or 20 μM chrysin, to specifically 
inhibit Bcrp. Transport was measured in both directions across uninhibited and inhibited 
cell monolayers using a substrate concentration of 5 μM diluted from a 10 mM DMSO 
stock solution (final DMSO concentration of 0.05%) and a single 60-min time interval 
(screening mode). The upper chamber (A) contained 0.5 mL PBS and the lower chamber 
(B) contained 1.0 mL PBS without and with inhibitor. The system was mixed using a 
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Clay-Adams Nutator® and kept at 37 C in room atmosphere. Solute concentration was 
determined for the donor and receiver solutions, and mass balance was achieved by 
extracting the cells with methanol. The apparent permeability coefficients (Papp) were 
estimated as the slope of the mass transported per 60 min relative to the total recovered 
mass according to Ho et al. (2000). BA/AB Papp ratios were calculated for each cell line. 
Cell monolayer integrity was monitored with percent leakage of 14C-mannitol in the 
absence and presence of solute and DMSO. Positive controls run periodically included 
amprenavir for P-gp and prazosin for Bcrp with triamterene as control for a non-substrate. 
Experiments were done in duplicate at least twice. All test solutes were quantified by 
reverse-phase high performance liquid chromatography with detection by tandem mass 
spectrometry (HPLC/MS/MS) as detailed below. 
In situ Mouse Brain Perfusion 
The details of the in situ mouse brain perfusion have been described elsewhere (Dagenais 
et al., 2000a). Briefly, mice were anesthetized with ketamine/xylazine (100/10 mg/kg, 
i.p.). The right common carotid artery was cannulated with polyethylene tubing (0.30-
mm inner diameter × 0.70-mm outer diameter; Biotrol Diagnostic, Chennevières-les-
Louvres, France) following ligation of the external carotid artery. The cardiac ventricles 
were severed immediately before perfusion at 2.5 mL/min for 60 s via a syringe pump 
(Harvard Apparatus, Holliston, MA). The perfusion buffer (Krebs-bicarbonate buffer, 
with 9 mM of D-glucose, pH 7.4) was oxygenated with 95% O2 and 5% CO2 and 
maintained at 37°C. 14C-diazepam and 3H- or 14C-inulin were used as blood flow rate and 
vascular space markers, respectively. The test compounds, 3H-cimetidine (1.6 μCi/mL), 
14C-LY2228820 (0.1 μCi/mL), alfuzosin (2 μM) or dipyridamole (1, 2, 5 μM) was added 
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to the perfusate to achieve appropriate concentrations. GF120918 and dipyridamole were 
dissolved in DMSO. The final concentration of DMSO in the perfusate was less than 2%. 
GF120918 (2 μM) was co-perfused with alfuzosin and dipyridamole to inhibit P-gp and 
Bcrp. The experiment was terminated by decapitation. The brain was carefully removed 
from the skull, cleaned of meninges and choroids plexus, the cerebellum was excised and 
the right brain hemisphere was collected. Aliquots of perfusate were collected from the 
catheter and weighed for determination of perfusate concentration. 
All non-radioactive samples were analyzed by HPLC/MS/MS. Radioactive brain samples 
were digested in 0.7 mL Solvable® (Packard, Boston, MA) at 50 °C overnight. Five mL 
of UltimaGold® scintillation cocktail (PerkinElmer, Wellesley, MA) was added and 
vortex-mixed. Total radioactivity (3H and/or 14C) was determined in a Packard Tri-carb 
TR 1900 liquid scintillation analyzer (Packard, Boston, MA). Parameters related to the in 
situ mice brain perfusion, i.e., the cerebral vascular volume (mL/100 g brain) was 
calculated using equation: 
inulin
inulin
vasc C
XV = ; the initial brain uptake clearance (Clup, 
mL/min/100 g brain) were calculated as: 
perf
brain
up
C
/TXCl = , where the amount of substrate in 
brain Xbrain was corrected for residual blood contamination (Dagenais et al., 2000a). 
Osmotic Minipump Studies 
Mdr1a(+/+), mdr1a(-/-), C57BL/6, and Abcg2(-/-) mice (n=3) were anesthetized with 
ketamine/xylazine (100/10 mg/kg, i.p.). An Alzet 2001D® osmotic minipump (Alza 
Corporation, Palo Alto, CA) was selected to release the drug continuously over 24 hr at a 
flow rate of 8 μl/h. The concentration of dosing solution was adjusted to the average 
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animal body weight and mean pump rate to deliver an appropriate dose. Cimetidine, 
alfuzosin and dipyridamole were dissolved in 50% DMSO and loaded into the 
minipumps. Cimetidine (200 μg/pump, approximately 6.4 mg/kg/day) was implanted 
subcutaneously in the back of C57BL/6 and Abcg2(-/-) mice. Alfuzosin (200 μg/pump, 
approximately 6.4 mg/kg/day) and two doses of dipyridamole (40 and 400 μg/pump, 
approximately 1.28 and 12.8 mg/kg/day, respectively, with the higher dose dissolved in 
80% DMSO to ensure adequate solubility) were implanted subcutaneously in 
mdr1a(+/+), mdr1a(-/-), C57BL/6, and Abcg2(-/-) mice. The experiments were 
terminated at 24 hr by decapitation. The brain was removed carefully from the skull and 
weighed. Trunk blood was collected in heparinized 1.5-mL microcentrifuge tubes. 
Plasma was harvested following centrifugation at 3,000 rpm for 5 minutes. The plasma 
and brain samples were stored at -20°C until analysis by HPLC/MS/MS. To ensure a 
reliable drug release during the dosing period, the minipump was removed from the body 
and the residual volume was measured. 
HPLC/MS/MS Assay  
Two volumes of distilled water were added to brain samples and homogenized with brief 
probe sonication. Plasma, brain homogenate and perfusate samples were analyzed by 
HPLC/MS/MS (API 4000 triple quadrupole with TurboIonSpray interface; Applied 
Biosystems/MDS Sciex, Concord, ON, Canada). A 25-µL aliquot of brain hemisphere 
homogenate or plasma was transferred to an HPLC vial, and protein was precipitated 
with 100 µl of methanol containing internal standard (10 ng/mL loperamide), followed by 
a 25-µl aliquot of DMSO. The sample was vortex-mixed and centrifuged. Three 
microliters of sample solutions were injected via an autosampler (Leap, Carrboro, NC). 
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Cimetidine, alfuzosin, dipyridamole and the internal standard, loperamide, were eluted 
from an Aquasil C18 column (2.1 x 50 mm, dp = 5 µm; Thermo Electron Corporation, 
Waltham, MA) using a mobile phase gradient (A, 0.1% formic acid in water; B, 0.1% 
formic acid in methanol; 0-0.70-min hold at 0% B, 0.70-3.12-min linear gradient to 90% 
B, 3.12-4.10 min hold at 90% B, 4.10-4.20-min linear gradient to 0% B, 4.20-4.90-min 
hold at 0% B; solvent delivery system (Shimadzu); flow rate = 0.75 ml/min; 0.8-4 min 
directed to mass spectrometer) and were detected in positive ion mode using multiple 
reaction monitoring: cimetidine: 253.1?117.0 m/z, alfuzosin, 390.2?235.2 m/z; 
dipyridamole, 505.5?429.3 m/z. All analytes were quantified with standard curves (0.05-
5000 ng/ml) prepared in the appropriate matrix. The lower limit of detection was 0.1 
ng/ml for all analytes; inter-and intraday CVs were <15%.  
Statistical Analysis 
Data are reported as mean ± SD for 3 mice per condition. Two-tailed student’s t-test, one-
way or two-way ANOVA, where appropriate, was used to determine the statistical 
significance of differences among two or more groups. The level of significance was 
corrected for multiple comparisons (e.g., Bonferroni test) or adjusted for unequal 
variance when necessary. In all cases, p < 0.05 was considered to be statistically 
significant. 
 131 
Results 
In vitro Transport 
The basolateral-to-apical / apical-to-basolateral (B-A / A-B) Papp ratios for each of the 
four compounds tested ranged from 16 to 37, suggesting that each compound underwent 
carrier-mediated efflux across MDCKII-Bcrp cell monolayers. The positive control 
prazosin had a ratio of 27, which compared favorably to historical data (mean ± standard 
deviation) of 22 ± 7 (n=17). In addition, the B-A / A-B Papp ratios were decreased 
substantially (to 1.1 ~ 2.0) in the presence of the Bcrp inhibitor chrysin (Table 4.1). 
Prazosin efflux by MDCKII-Bcrp was not inhibited by the specific P-gp inhibitor 
LSN335984 (data not shown). Cellular substrate concentrations at equilibrium, estimated 
by methanol wash, of alfuzosin, dipyridamole, and 14C-LY2228820, were decreased ~4 
fold in Bcrp-expressing cells because of active efflux, whereas cellular cimetidine 
concentrations were very low and unaffected by Bcrp. Alfuzosin and dipyridamole also 
were identified as P-gp substrates when substrate flux was evaluated in the MDCK-
MDR1 cell monolayer model, with P-gp-mediated transport inhibited by the P-gp 
inhibitor LSN335984 (Figure 4.1). In these cases, cellular concentrations at equilibrium 
were decreased 4- to 6-fold in the presence of Bcrp-mediated efflux. Amprenavir efflux 
by MDCKII-MDR1 wans not inhibited by the Bcrp inhibitor chrysin (data not shown). 
In situ Brain Perfusion 
14C-inulin was used as a brain capillary space marker to assess BBB physical integrity. 
BBB integrity was not changed by knockout of the mdr1a or Abcg2 gene or by co-
perfusion with 2 µM GF120918. In addition, the brain capillary volumes in C57BL/6 and 
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Abcg2(-/-) mice were comparable to those in CF-1 mice.  The cerebral blood flow rates in 
C57BL/6 and Abcg2(-/-) mice also were similar to that in CF-1 mice, measured using 
14C-diazepam as the marker (data not shown). 
The values of initial brain uptake clearance of 3H-cimetidine and 14C-LY2228820 in all 
four mouse strains, i.e., C57BL/6 and Abcg2(-/-), mdr1a(+/+) and mdr1a(-/-) mice, are 
presented in Table 4.2. Cimetidine does not cross the BBB to an appreciable extent. 
Cimetidine Clup increased by 33%, but did not reach statistical difference (1.1 ± 0.4 vs. 
0.8 ± 0.3 mL/min/100 g, p>0.05) when co-perfused with 2 µM GF120918 in C57BL/6 
mice. 14C-LY2228820 is very permeable at the BBB. The initial rate of brain uptake in 
mdr1a(-/-) mice was close to the functional perfusate flow rate (250 ± 41 mL/min/100 g), 
and was 2.3-fold higher than that in mdr1a(+/+) mice (p<0.05). 14C-LY2228820 was also 
perfused in Abcg2(+/+) mice and the Clup was 120 ± 9 mL/min/100g brain, which did not 
differ significantly from that in C57BL/6 and Abcg2(-/-) mice (136 ± 3 and 131 ± 26 
mL/min/100 g, one-way ANOVA, p>0.05). 
Alfuzosin brain uptake was moderate in all mouse strains. The inhibitory effect of 
GF120918 on P-gp- and/or Bcrp-mediated alfuzosin efflux is illustrated in Figure 4.3. 
Figure 4.3A showed alfuzosin brain uptake is comparable in C57BL/6 and Abcg2(-/-) 
mice in the absence of GF120918 (p>0.05). Co-perfusion with GF120918 significantly 
increased alfuzosin brain uptake in both C57BL/6 and Abcg2(-/-) mice (p<0.05, 
inhibitory effect), but to a greater extent in Abcg2 (-/-) mice (p<0.05, strain difference). 
The increased alfuzosin brain uptake can be ascribed to P-gp inhibition in the BBB by 
GF120918. Figure 4.3B demonstrates that alfuzosin brain uptake increased ~3.7-fold in 
mdr1a(-/-) mice compared to mdr1a(+/+) mice (p<0.05). Consistently, alfuzosin brain 
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uptake increased about 4.4-fold with GF120918 co-perfusion in mdr1a(+/+) mice 
(p<0.05). GF120918 had no effect on alfuzosin brain uptake in mdr1a(-/-) mice. 
Three concentrations (1, 2, and 5 µM) of dipyridamole were perfused in C57BL/6 and 
Abcg2(-/-) mice, respectively (Figure 4.4). Two-way ANOVA analysis indicated that 
there was no statistical differences between these two mouse strains at any of the 
concentrations tested, or among concentrations in any mouse strain (p>0.05). 
Figure 4.5 depicts dipyridamole brain uptake when perfused at 2 µM in the absence or 
presence of 2 µM GF120918 in all four mouse strains. Dipyridamole brain uptake did not 
differ between C57BL/6 and Abcg2(-/-) mice, or between mdr1a(+/+) and mdr1a(-/-) 
mice. Figure 4.5A illustrates dipyridamole brain uptake was increased by 2.2-fold in the 
presence of 2 µM GF120918 co-perfusion in both C57BL/6 and Abcg2(-/-), respectively 
(two-way ANOVA, p<0.05). Co-perfusion of GF120918 increased dipyridamole brain 
uptake by 1.4-fold in mdr1a(+/+) and mdr1a(-/-) mice, although the differences were not 
statistically significant (p>0.05; two-way ANOVA, Figure 4.5B). 
Osmotic Minipump Studies 
The vehicle, DMSO, up to 50% in water has been reported to be compatible with the 
minipump (www.alzet.com). The osmotic minipumps provided reliable delivery of 
cimetidine, alfuzosin, and dipyridamole (at dose of 1.28 mg/kg/day). However, with the 
dipyridamole administration rate of 12.8 mg/kg/day, precipitation was visible around the 
exit hole of the device at the end of the experiment. Cimetidine brain-to-plasma 
concentration ratios were 0.024 ± 0.005 and 0.020 ± 0.017 in C57BL/6 and Abcg2(-/-) 
mice, respectively (Student’s t-test, p>0.05). The plasma and brain concentrations were 
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highly variable with dipyridamole dose of 12.8 mg/kg/day, so only the brain-to-plasma 
concentration ratios of alfuzosin and dipyridamole (1.28 mg/kg/day) are shown in Figure 
4.6. Alfuzosin brain penetration was significantly higher (4.1-fold) in mdr1a(-/-) mice 
compared to mdr1a(+/+) mice (Student’s t-test, p<0.05). Alfuzosin and dipyridamole 
brain penetration was ~3.5-fold higher in Abcg2(-/-) mice compared to C57BL/6 mice, 
although these differences did not achieve statistical significance. In addition, 
dipyridamole brain penetration at 1.28 mg/kg/day was comparable between mdr1a(+/+) 
and mdr1a(-/-) mice (Student’s t-test, p>0.05). Although dipyridamole plasma and brain 
concentrations at a dose rate of 12.8 mg/kg/day were highly variable (no statistical 
analysis was conducted for these data), the trend suggested that brain concentrations 
exceeded plasma concentrations in all mouse strains. Overall, brain penetration of 
dipyridamole appeared to be higher at 12.8 mg/kg/day than at 1.28 mg/kg/day (data not 
shown). 
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Discussion 
Bcrp mediates intestinal and biliary secretion, substrate extrusion at mammary epithelia 
and in the placenta, and plays an important pharmacologic and toxicologic role in the 
absorption and disposition of xenobiotics and xenotoxins (Jonker et al., 2000; Jonker et 
al., 2005). However, the extent to which Bcrp might influence brain distribution of 
known Bcrp substrates has been unclear. The current study investigated the functional 
efficiency of Bcrp in vitro, in situ and in vivo using four model compounds: cimetidine, 
alfuzosin, dipyridamole and 14C-LY2228820. 
Asymmetric transport of cimetidine was mediated by Bcrp in transfected MDCK cell 
lines (Table 4.1), as evidenced by a B-A / A-B Papp ratio of 16. Under similar 
experimental conditions, a B-A / A-B Papp ratio of ~9 has been reported (Pavek et al., 
2005). Cimetidine was transported actively by Bcrp in an MDCKII-Bcrp1 cell line as 
well as in rat and mouse liver and rat placenta (McNamara et al., 1996; Merino et al., 
2005; Staud et al., 2006). However, in the current study Abcg2 gene knockout did not 
change the initial rate of brain uptake or steady-state brain distribution using in situ brain 
perfusion and in vivo brain penetration paradigms. In addition, cimetidine brain uptake 
was independent of P-gp and Bcrp inhibition by GF120918. Furthermore, cimetidine 
brain penetration was minimal during a 24-hr continuous subcutaneous infusion, and 
steady-state brain-to-plasma concentration ratios in C57BL/6 and Abcg2(-/-) mice were 
similar to a previously published value of 0.017 after i.p. injection of cimetidine (100 
mg/kg) in rats (Hough et al., 1986). The present results indicate that Bcrp does not pose a 
substantial barrier for cimetidine brain uptake, and that the poor brain penetration of 
cimetidine is primarily due to low passive permeability.  
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This study constitutes the first investigation of alfuzosin interaction with ABC efflux 
transporters. Alfuzosin Clup and brain-to-plasma concentration ratio in mdr1a(-/-) mice 
were 4.4- and 4.1-fold higher than those in mdr1a(+/+) mice, respectively. In addition, 
P-gp-mediated alfuzosin efflux was inhibited by GF120918 in mdr1a(+/+), C57BL/6 and 
Abcg2(-/-) mice, but not in mdr1a(-/-) mice, which confirmed that alfuzosin is a P-gp 
substrate at the BBB. In contrast, alfuzosin appears to be transported efficiently by Bcrp 
only when Bcrp is overexpressed in vitro. Alfuzosin Clup and brain-to-plasma 
concentration ratio was comparable between C57BL/6 and Abcg2(-/-) mice and co-
perfusion with GF120918 did not increase alfuzosin Clup in mdr1a(-/-) mice. Taken 
together, these data indicate that alfuzosin is not transported by Bcrp at the BBB. In all 
mouse strains, alfuzosin did not cross the BBB substantially, and brain concentrations 
were much lower than plasma concentrations. 
Dipyridamole has been reported to be a substrate of human Bcrp in both HEK and 
MDCK cell lines stably-transfected with human BCRP (Zhang et al., 2005b). The current 
study confirms that dipyridamole interacts with murine Bcrp and human P-gp in vitro 
(Table 4.1 and Figure 4.1). Brain uptake of dipyridamole was not concentration-
dependent in the range of 1-5 µM (a range selected based on a reported mean 
dipyridamole clinical plasma concentration of 3.5 µM (1.77 µg/mL; (Hervey and Goa, 
1999). In addition, brain penetration did not vary between mouse strains (C57BL/6 versus 
Abcg2(-/-) mice). Co-perfusion with GF120918 did not increase brain uptake in mdr1a(-/-) 
mice, animals that express Bcrp, but not P-gp, at the BBB. Thus, Bcrp cannot be an 
important factor in determining dipyaridamole brain uptake. In addition, the initial rate of 
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dipyridamole brain uptake did not differ between mdr1a(+/+) and mdr1a(-/-) mice, 
suggesting that dipyridamole is not transported by P-gp at the mouse BBB.  
Co-perfusion with GF120918 caused a modest but significant increase in dipyridamole 
Clup in C57BL/6 and Abcg2(-/-) mice, suggesting the possibility of an unknown 
GF120918-sensitive mechanism other than P-gp- or Bcrp-mediated transport, that 
influences dipyridamole flux across the BBB. Interestingly, brain penetration of 
dipyridamole following a 24-hr continuous subcutaneous infusion was dose-dependent 
(data not shown), while a tendency towards concentration-dependent uptake in Bcrp-
competent, but not Bcrp-deficient, mice during brain perfusion was not statistically 
significant (Figure 4.4). Under the current osmotic minipump experimental paradigm, 
dipyridamole plasma concentration at 24 hr was about 28.2 ng/ml (~56 nM), which was 
significantly lower than clinically-relevant concentrations ~3.5 µM (Hervey and Goa, 
1999) or the concentrations (1-5 µM) evaluated in the current brain perfusion study. 
Brain penetration increased when dipyridamole dose was increased from 1.28 mg/kg/day 
to 12.8 mg/kg/day, suggesting that dipyridamole brain penetration may be mediated by 
unknown saturable and high-affinity efflux transport mechanism(s), which likely is the 
same mechanism inhibited by GF120918 in situ. 
Efflux of 14C-LY2228820 was mediated by Bcrp in vitro. 14C-LY2228820 transport 
across the BBB was highly permeable, consistent with the rapid passive diffusion 
observed in in vitro cell monolayers. Brain uptake of 14C-LY2228820 was almost 
perfusion flow rate-limited in mdr1a(-/-) mice. In mdr1a(+/+) mice, 14C-LY2228820 
brain uptake decreased about almost 60%. 14C-LY2228820 brain uptake in Abcg2(+/+) 
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mice was comparable to C57BL/6 and Abcg2(-/-) mice, indicating that 14C-LY2228820 
brain uptake is not limited by Bcrp. 
Taken together, all four model compounds appeared to interact with Bcrp in the MDCK-
Bcrp cell line in vitro. However, none was transported by Bcrp at the mouse BBB, using 
the genetic knockout models, i.e., Bcrp-competent [C57BL/6, Abcg2(+/-)] and Bcrp-
deficient [Abcg2(-/-)], as well as P-gp-competent [mdr1a(+/+)] and P-gp-deficient 
[mdr1a(-/-)] mouse models for comparison, or chemical inhibition with GF120918, an 
inhibitor of P-gp and Bcrp. It is widely accepted that genetic knockout models are 
equivalent and essentially interchangeable with specific chemical knockout models, 
especially for cases in which the desired genetic knockout models are not available, as is 
most common in rat studies. However, the compensatory regulation of other transporter 
proteins following knockout of specific gene, as well as the specificity of inhibitors, are 
always fundamental concerns in the functional studies. Bcrp mRNA has been reported to 
be upregulated in mdr1a(-/-) mice, and was 3-fold higher than that in mdr1a(+/+) mice 
(Cisternino et al., 2004). Other evidence suggested that mRNA levels of mdr1a, Mrp1, 
Mrp4 and oatp2 were not changed in Bcrp knockout mice (Lee et al., 2005). Similarly, 
chemical inhibitors such as PSC833 for P-gp, probenecid for Mrps, and GF120918 for 
both P-gp and Bcrp are widely used in the literature. Cyclosporine A which has long been 
regarded as a specific P-gp inhibitor, has recently been demonstrated to inhibit Bcrp and 
OATPs (Xia et al., 2007). In a quercetin in situ rat brain perfusion study, co-perfusion 
with the P-gp inhibitor PSC833 did not change Clup of quercetin, while co-perfusion of P-
gp/Bcrp inhibitor GF120918 significantly enhanced brain uptake of quercetin (Youdim et 
al., 2004). The authors concluded that Bcrp was involved in quercetin brain uptake. In the 
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absence of appropriate comparisons with a genetic knockout model, or information 
regarding the specificity of a given inhibitor for a transporter, such a conclusion is 
potentially erroneous. 
In situ brain perfusion has been used efficiently to measure BBB permeability, which has 
been demonstrated to be dependent on the lipophilicity and protein binding in brain tissue 
for compounds that undergo solely passive diffusion at the BBB (Takasato et al., 1984; 
Summerfield et al., 2007). Figure 4.7A demonstrates that in the absence of P-gp, the Clup 
values for cimetidine, alfuzosin, dipyridamole and LY2228820 in mdr1a(-/-) mice were 
correlated (R2=0.956) with clogD7.4, the calculated logarithm of octanol water partition 
coefficient at pH 7.4 (the values of clogD7.4 are 0.12, 0.56, 3, 6.3 for cimetidine, alfuzosin, 
dipyridamole and LY2228820, respectively), which were obtained using Marvin and 
calculator plugin freeware (www.chemaxon.com, ChemAxon Kft, Budapest, Hungary). 
In addition, the in situ brain permeability has been found to be correlated with in vitro 
apparent permeability (Summerfield et al., 2007). There is a good correlation between the 
Clup values and the Papp,AB or Papp,BA in MDCKII-Bcrp cell line when Bcrp was 
completely inhibited by chrysin (Figure 4.7B). In addition, Clup is correlated with the 
cellular accumulation (R2=0.952, Figure 4.7C). These correlation analyses indicated that 
the cell line model may serve as a high-throughput in vitro system to predict passive 
permeability and contribute to improved compound selection in CNS drug discovery and 
development.  
A recent observation demonstrated that the protein expression of Bcrp in human and rat 
brain microvessel endothelial cells is much lower than in the in vitro overexpressed 
system (Lee et al., 2007). This difference in protein expression might explain the 
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discrepancies between the in vitro cell line model and in situ or in vivo animal models. As 
an overexpressed cell line model, good in vitro-in vivo correlation has been identified for 
P-gp efflux ratio in the brain (Adachi et al., 2001), in which P-gp is abundantly expressed.  
In summary, the results of the present study suggest that Bcrp plays a minor role in brain 
distribution of cimetidine, alfuzosin, dipyridamole and LY2228820, although each of 
these compounds interacted with Bcrp in transfected cell line models. Together with 
previously published data on prazosin, DHEAS and mitoxantrone (Cisternino et al., 2004; 
Lee et al., 2005), these results strongly suggest that Bcrp does not contribute significantly 
to murine BBB function. The present results also raise the related question of the specific 
role of organic anion transporters (Mrp1, Mrp2 and Mrp4) in the overall barrier function 
at the blood-brain interface. It has been shown that inhibition of Mrp2 and Mrp4 
significantly enhanced brain exposure of antiepileptic drugs, topotecan and nucleotides; 
however, the efflux effects observed were modest and all less than 2-fold (Potschka et al., 
2003; Leggas et al., 2004; Belinsky et al., 2007). The spectrum of reports to date suggest 
that is likely that P-gp, but not other ABC efflux transporters, provides the primary 
transport-mediated attenuation of brain uptake in the intact BBB. Caution must be taken 
in the design and interpretation of in vitro and in situ experiments prior to assigning 
specific functional importance to a given efflux transport system in the in vivo situation. 
In this regard, the current results with alfuzosin may serve as a useful template. These 
experiments demonstrated that alfuzosin is a P-gp substrate, with a 4-fold P-gp effect at 
the BBB. This P-gp effect was observed consistently among in vitro, in situ and in vivo 
experiments. This type of information set should be available for a given 
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substrate/transport protein pair prior to ascribing functional in vivo, and potential 
pharmacologic/toxicologic importance, to that transport protein in vivo. 
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Table 4.1:  Transport of 3H-cimetidine, alfuzosin, dipyridamole and 14C-LY2228820 (all 
at 5 µM) across MDCKII-Bcrp cell monolayer in the absence (-) or presence (+) of Bcrp 
inhibitor chrysin (20 µM). Mass recoveries were 92 to 112%. 
Papp ± SD (×10-6 cm/s) Compound 
Name Inhibitor A-B B-A 
B-A/A-B  
Papp ratio 
- 1.4 ± 0.2 23 ± 2 16 
Cimetidine 
+ 1.8 ± 0.2  3.6 ± 0.3 2.0 
-     1.9 ± 0.002 60 ± 1 31 
Alfuzosin 
+        25 ± 1 30 ± 2 1.2 
- 2.6 ±1 .0    90 ± 0.3 34 
Dipyridamole 
+        48 ± 1 70 ± 3 1.5 
- 3.9 ± 0.2       143 ± 1 37 
LY2228820 
+        44 ± 3 50 ± 8 1.1 
 
 148 
Table 4.2:  Initial brain uptake clearance (Clup, mL/min/100 g) for 3H-cimetidine and 
14C-LY2228820 in C57BL/6, Abcg2(-/-) mice, mdr1a(+/+) and mdr1a(-/-) mice. Data are 
presented as mean ± SD (n=3). Two-tailed student’s t-tests were used to determine the 
statistical significance of the Bcrp effect between C57BL/6 and Abcg2(-/-) mice, and P-
gp effect between mdr1a(+/+) and mdr1a(-/-) mice. Asterisk (*) represents a statistical 
difference (p<0.05) between mdr1a(+/+) and mdr1a(-/-) mice for 14C-LY2228820 initial 
brain uptake. 
Clup 
(mL/min/100g) C57BL/6 Bcrp(-/-) mdr1a(+/+) mdr1a(-/-) 
Cimetdine   0.8 ± 0.3   0.5 ± 0.1     0.7 ± 0.2 1.1 ± 0.4 
LY2228820 136 ± 33 131 ± 26 104 ± 8  239 ± 24 * 
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Figure 4.1:  Chemical structures of cimetidine (A), alfuzosin (B), dipyridamole (C) and 
LY2228820 (D). 
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Figure 4.2:  Apparent permeability (Papp, ×10-6 cm/s) of alfuzosin (AL) and dipyridamole 
(DP) across the MDCKII-MDR1 cell monolayer in apical-to-basolateral (A-B, solid bar) 
and basolateral-to-apical (B-A, open bar) directions in the absence (AL, DP) or presence 
(AL+I, DP+I) of P-gp inhibitor LSN335984 (2.5 µM).  
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Figure 4.3:  Initial brain uptake clearance (Clup, mL/min/100 g brain) of alfuzosin in the 
absence (solid bar) and presence (open bar) of co-perfusion with P-gp and Bcrp inhibitor 
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B 
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GF120918 in (A) C57BL/6 and Abcg2(-/-) mice, (B) mdr1a(+/+) and mdr1a(-/-) mice. 
Two-way ANOVA analysis was used to determine the statistical significance of 
GF120918 inhibitory effect and Bcrp effect [C57BL/6 vs. Abcg2(-/-)] or P-gp effect 
[mdr1a(+/+) vs. mdr1a(-/-)]. Asterisk (*) represents a statistical difference (p<0.05) with 
GF120918 inhibition ; dagger (†) represents a statistical difference (p<0.05) in the initial 
rate of alfuzosin brain uptake between mdr1a(+/+) and mdr1a(-/-) mice. 
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Figure 4.4:  Initial brain uptake clearance (Clup, mL/min/100 g) for dipyridamole at 
different concentrations (1, 2, and 5 µM) in C57BL/6 and Abcg2(-/-) mice. Two-way 
ANOVA analysis was used to determine the statistical significance of concentration-
dependence and Bcrp effect (p>0.05). 
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Figure 4.5:  Initial brain uptake clearance (Clup, mL/min/100 g brain) of dipyridamole in 
the absence (solid bar) and presence (open bar) of co-perfusion with P-gp and Bcrp 
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B 
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inhibitor GF120918 in (A) C57BL/6 and Abcg2(-/-) mice, (B) mdr1a(+/+) and mdr1a(-/-) 
mice. Two-way ANOVA analysis was used to determine the statistical significance of 
GF120918 inhibitory effect and Bcrp effect [C57BL/6 vs. Abcg2(-/-)] or P-gp effect 
[mdr1a(+/+) vs. mdr1a(-/-)]. Asterisk (*) represents a statistical difference (p<0.05) with 
GF120918 inhibition. 
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Figure 4.6:  Brain-to-plasma concentration ratios for alfuzosin and dipyridamole in 
C57BL/6 and Abcg2(-/-) mice, mdr1a(+/+) and mdr1a(-/-) mice following 24 hr of 
osmotic minipump administration. Data are presented as mean ± SD (n=3). Two tailed 
student’s t-tests were used to compare brain-to-plasma concentration ratios between 
C57BL/6 and Abcg2(-/-) mice, and between mdr1a(+/+) and mdr1a(-/-) mice. Asterisk (*) 
represents a statistical difference (p<0.05) between mdr1a(+/+) and mdr1a(-/-) mice for 
alfuzosin brain penetration. 
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Figure 4.7:  Relationship between the initial uptake clearance of substrates in mdr1a(-/-) 
mice [Clup(-/-)], and (A) calculated octanol-water partition coefficient at pH 7.4 (clogD7.4); 
and (B) the in vitro Papp in A-B (circles) or in B-A (triangles) direction; and (C) the 
percent dose of cellular accumulation [log(%Ccell)] in MDCKII-Bcrp cells incubated 
with 20 µM of chrysin. 
CHAPTER 5 
REGIONAL DIFFERENCES IN CAPILLARY DENSITY, PERFUSION RATE, 
AND P-GLYCOPROTEIN ACTIVITY: A QUANTITATIVE ANALYSIS OF 
REGIONAL DRUG EXPOSURE IN THE BRAIN 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted for publication in Journal of Cerebral Blood Flow and 
Metabolism and is presented in the style of that journal.  
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Abstract 
An adequate exposure of therapeutic agents to the relevant pharmacologic target within 
the brain is essential for the effective treatment of many central nervous system (CNS) 
disorders. Previous studies have indicated that the rate of regional blood flow, local 
cerebral vascular volume, regional blood-brain barrier (BBB) permeability and P-
glycoprotein (P-gp)-mediated efflux can influence regional drug exposure. In the current 
study, an in situ brain perfusion technique was used to assess the impact of local capillary 
density, blood flow rate and P-gp activity on regional drug exposure for the P-gp 
substrates colchicine, quinidine, verapamil, and loperamide, and the perfusion flow rate 
marker diazepam, and the vascular volume marker inulin, in mdr1a(+/+) and mdr1a(-/-) 
mice. Regional perfusion flow rate varied 7.5-fold, and capillary density (based on 
vascular volume) varied 3.7-fold, across the thirteen brain regions examined. The rate of 
regional flow, as well as P-gp-mediated colchicine efflux activity, was directly 
proportional to local capillary density. A decrease in perfusion rate attenuated verapamil 
brain uptake and had significant effect on P-gp-mediated efflux activity for this substrate 
in brain regions with lower capillary density. Regional brain uptake and calculated logD 
at pH7.4 were well-related in P-gp-deficient mice, suggesting that in the absence of P-gp-
mediated efflux, physicochemical properties of the compound (i.e., lipophilicity) serve as 
the primary determinant of regional brain uptake. Loperamide regional brain uptake 
during a 60-s brain perfusion or at 30 min after subcutaneous administration was 
significantly correlated with local capillary density. The highest P-gp-mediated efflux 
activity was consistently observed in cerebral cortex and midbrain regions for loperamide 
following short-term brain perfusion and at all time points following subcutaneous 
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administration. These results emphasize the complexity of factors that determine regional 
substrate exposure in brain, which may have pharmacologic consequences when the 
target receptor evidences regional expression. 
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Introduction 
For many cerebral disorders, such as brain tumors, Parkinson’s disease, stroke, and 
ischemia, the disease focus or the therapeutic target is localized in specific regions of the 
brain. In such cases, the efficacy of therapy will depend on adequate delivery of drugs to 
the brain region that contains the pharmacologically-relevant target. Regional drug 
exposure in the CNS is a function of many drug- and region-specific factors, including 
physicochemical characteristics (lipophilicity and ionization state), protein binding in 
blood and brain tissue, drug concentration in blood, local cerebral blood flow rate, brain 
capillary surface area, regional capillary transit time, cerebrospinal fluid (CSF) bulk flow, 
and the flux of drugs across the blood-brain barrier (BBB) that may include both passive 
and active (transport-mediated) components (Klein et al., 1986; Kalvass and Maurer, 
2002; Norinder and Haeberlein, 2002; Liu and Chen, 2005). For example, previous 
studies in this laboratory demonstrated that P-glycoprotein (P-gp)-mediated efflux at the 
BBB influences the distribution of 3H-verapamil within the brain following intranasal 
administration to P-gp-competent and P-gp-deficient mice (Graff et al., 2005; Appendix). 
Pharmacokinetic modeling of these data revealed that the apparent P-gp effect on 
verapamil exposure was negligible in some regions, and produced nearly a 100-fold 
attenuation of exposure in others. Knowledge of the regional cerebral vascular volume 
and blood flow rate, as well as regional P-gp activity, is of particular interest with regard 
to targeted treatment for cerebral diseases.   
The BBB and blood-cerebrospinal fluid barrier (BCSFB) are major interfaces between 
the CNS and peripheral circulation. The BBB is composed of brain capillary endothelial 
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cells, which are characterized by highly-developed tight junctions and a paucity of 
fenestrae and pinocytotic vesicles. In addition to this physical barrier to substrate flux, 
expression of efflux transport proteins and metabolic enzymes at the blood-brain 
interface further limit the penetration of substances into the CNS. P-gp, the most 
extensively studied BBB efflux transporter, is expressed at the luminal side of the brain 
capillary endothelium and mediates the flux of various endogenous compounds and 
xenobiotics in the brain-to-blood direction (Schinkel et al., 1994), thereby serving as an 
important barrier to the entry of P-gp substrates into brain. P-gp, a member of the ATP-
binding cassette (ABC) superfamily of transport proteins, is a 170-kDa membrane protein 
encoded by multidrug resistance gene (ABCB1 in human, Abcb1a and Abcb1b in rodents). 
Impaired BBB penetration represents the primary obstacle in CNS drug development 
since more than 98% of all new drugs evaluated for CNS applications do not cross the 
BBB (Terasaki and Pardridge, 2000). P-gp appears to be a significant factor in poor brain 
uptake of many agents. 
The mammalian brain is a highly specialized organ from both the structural and 
functional perspective. There are broad regional differences in neurophysiologic 
functions such as local neuronal activity, neurotransmitter distribution, and oxygen and 
glucose utilization. The rate of local cerebral blood flow under physiologic conditions 
varies about 18-fold among brain areas in the rat (Fenstermacher et al., 1991). In addition, 
the capillary blood volume and surface area of the BBB differ between brain regions; 
these differences may result in regional variations in drug exposure (Duelli and 
Kuschinsky, 1993).  
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Clinical practice has shown variations in sensitivity to the therapeutic effect or CNS side 
effects of drugs associated with different brain regions. For example, the hippocampus is 
especially vulnerable to ischemia and colchicine cytotoxicity (Goldschmidt and Steward, 
1980; Cavaglia et al., 2001). The administration of chemotherapeutic agents in 
combination with transient, reversible hyperosmotic opening of the BBB has been 
explored as an approach in the treatment of brain tumors; in vivo experiments and data 
generated with in situ rat brain perfusion techniques have demonstrated the variations in 
BBB disruption in different brain regions following hyperosmotic treatment, suggesting 
that the clinical efficacy of hyperosmolar disruption therapy may be affected by the 
location of the tumor within the brain (Chiueh et al., 1978; Brown et al., 2004). Region-
specific overexpression of P-gp has been reported to decrease phenytoin concentrations 
in the temporal hippocampus and parahippocampal cortex region in chronic epileptic rats 
(van Vliet et al., 2007).  
Brain uptake index, brain microdialysis, single-pass indicator-dilution, and PET imaging 
techniques have been used to study the impact of local cerebral blood flow rate and 
capillary density on the regional brain exposure of nutrients or therapeutic agents 
(Sokoloff et al., 1977; Fenstermacher et al., 1991; Rosen et al., 1991; Suzuki et al., 1998; 
Gee, 2003; Brown et al., 2004; Tohyama et al., 2004; Rambeck et al., 2006; Wyss et al., 
2007). For example, a close correspondence between local cerebral glucose utilization, 
local cerebral blood flow, and density of perfused capillaries has been identified in rat 
brain (Klein et al., 1986; Schrock and Kuschinsky, 1988). During in situ brain perfusion, 
uptake of the Oatp14 substrate thyroid hormone T4 into brain is 3-fold higher in the 
cerebral cortex than in the cerebellum (Tohyama et al., 2004).  
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In situ brain perfusion was first developed to evaluate BBB permeability in rats (Takasato 
et al., 1984), and was modified for use in mice (Dagenais et al., 2000a). This technique 
allows examination of single-pass permeability of molecules at the BBB without 
systemic contamination, with complete control of the composition and flow of perfusion 
buffer, and without other pharmacokinetic events (e.g., hepatic metabolism) confounding 
the experimental results. In the present study, the in situ brain perfusion technique was 
utilized to study the impact of local cerebral perfusion flow rate, vascular volume, and P-
gp activity on regional drug exposure. 14C-diazepam and 3H-inulin, selected as markers of 
functional perfusion flow rate and vascular volume, respectively, were perfused 
simultaneously, followed by microdissection of the brain to assess regional flow and 
capillary density. Subsequent experiments were directed towards examining regional 
brain exposure of the P-gp substrates colchicine, quinidine, loperamide and verapamil 
during perfusion in P-gp-competent and P-gp-deficient mice, allowing assessment of 
regional P-gp activity in P-gp-expressing animals. The in situ perfusion experiments were 
complemented by an in vivo evaluation of P-gp-mediated efflux activity over 12 hr 
following subcutaneous administration of loperamide to assess the potential time-
dependency of efflux activity estimates. 
 
Materials and Methods 
Adult CF-1 [mdr1a(+/+) and mdr1a (-/-)] mice (30-40 g, 6-8 weeks of age) were 
obtained from Charles River Laboratories (Wilmington, MA). All mice were maintained 
on a 12-h light/dark cycle with access to water and food ad libitum. All experimental 
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procedures were performed under full anesthesia induced with ketamine/xylazine (100/10 
mg/kg, i.p.). All procedures were approved by the Institutional Animal Care and Use 
Committee at the University of North Carolina at Chapel Hill and were conducted in 
accordance with “Principles with Laboratory Animal Care” (NIH publication No. 85-23, 
revised in 1985). 
14C-diazepam (56.0 mCi/mmol) was purchased from Amersham Biosciences 
(Buckinghamshire, UK). 14C-inulin (2.1 mCi/g) and 3H-quinidine (20 Ci/mmol) were 
obtained from American Radiolabeled Chemical Inc. (St Louis, MO). 3H-inulin (180.0 
mCi/g), 3H-colchicine (80.4 Ci/mmol) and 3H-verapamil (74.2 Ci/mmol) were purchased 
from PerkinElmer (Waltham, MA). Loperamide and fexofenadine were purchased from 
Sigma-Aldrich (St. Louis, MO). All of the other chemicals were commercially available 
and of reagent grade. 
In Situ Mouse Brain Perfusion Procedure 
In situ mouse brain perfusions were conducted as described by (Dagenais et al., 2000a). 
Briefly, P-gp competent- [mdr1a(+/+)] and -deficient [mdr1a(-/-)] mice (n=3) were 
anesthetized with ketamine/xylazine (100/10 mg/kg, i.p.). The perfusion buffer (Krebs-
bicarbonate buffer, with 9 mM of D-glucose, pH 7.4) was oxygenated with 95% O2 and 
5% CO2 and maintained at 37°C. The right common carotid artery was cannulated with 
PE-10 tubing (Braintree Scientific Inc., Braintree, MA) following ligation of the external 
carotid artery. The cardiac ventricles were severed immediately before starting perfusion 
for 60 s at 2.5 mL/min via a syringe pump (Harvard Apparatus, Holliston, MA). The 
experiment was terminated by decapitation immediately following perfusion. The right 
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cerebral hemisphere was removed carefully and placed on cold saline-soaked filter paper 
and dissected on ice. Approximately 150 mg of perfusate was collected through the 
syringe and tubing. 
Brain Perfusion Experimental Design 
In order to determine the regional cerebral capillary volume and functional perfusion 
flow rate, 14C-inulin (at 1.6 µCi/mL) and 14C-diazepam at (0.4 µCi/mL) as vascular 
volume and blood flow rate markers, respectively, were perfused simultaneously for 60 s 
in mdr1a(+/+) and mdr1a(-/-) mice (n=3). In separate studies, 3H-colchicine (at 1.6 
µCi/mL), 3H-verapamil (at 0.4 µCi/mL), 3H-quinidine (at 1 µCi/mL), or unlabeled 
loperamide (at 2 µM) was perfused for 60 s, followed by 15 s of cold saline washout to 
remove remaining perfusate in the vasculature. Additional groups of mdr1a(+/+) and 
mdr1a(-/-) mice (n=3) were perfused with 3H-verapamil at 1 mL/min to investigate the 
potential influence of changes in flow rate on apparent regional P-gp activity. 
Loperamide Subcutaneous Administration 
Loperamide was administered to mdr1a(+/+) mice (30 mg/kg, s.c.) and mdr1a(-/-) mice 
(1 mg/kg, s.c.), and animals (n=3 per group) were sacrificed by decapitation at 0.5, 1, 2, 4, 
6 and 12 hr post-dose. The doses were selected to produce approximately equivalent 
brain tissue concentrations in the two mouse strains. Trunk blood was collected and 
centrifuged at 3,000 rpm for 5 min. The plasma was transferred to a fresh microcentrifuge 
tube and stored at -20 °C until analysis by HPLC/MS/MS. The brain was carefully 
removed from skull, cleaned of meninges and choroid plexus, dissected on ice, and stored 
at -20 °C pending analysis.  
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Mouse Brain Microdissection 
To ensure the reproducibility of the dissection technique, bregma coordinates and 
anatomic boundaries defining each region were established based on the Franklin and 
Paxinos mouse brain atlas (Franklin and Paxinos, 1996). The microdissection procedure 
was conducted according to photographs and step-by-step instructions downloaded from 
a publicly-accessible relational database (www.barlow-lockhartbrainmapnimhgrant.org). 
For studies involving radiolabeled substrate, the perfused brain hemisphere was dissected 
into 13 regions (olfactory bulb, striatum, hippocampus, frontal cortex, parietal cortex, 
occipital cortex, superior and inferior colliculi, hypothalamus, thalamus, midbrain, pons, 
medulla, and cerebellum). Larger brain regions were required for accurate loperamide 
analysis. Accordingly, the perfused hemisphere for loperamide in situ studies, or brain 
tissue after in vivo administration of loperamide, was dissected into seven regions 
[olfactory bulb, striatum, hippocampus, cortex, midbrain (including midbrain, thalamus 
and hypothalamus), brainstem (including pons and medulla) and cerebellum]. 
Radioactive Sample Quantitation 
Samples containing radiolabeled substrate were digested with 0.3 mL of Solvable® 
(Packard, Boston, MA) at 50 °C for 4 hr. UltimaGold® scintillation cocktail (PerkinElmer, 
Wellesley, MA) was added (5 mL) and vortex-mixed. Total radioactivity (3H and/or 14C) 
was determined in a Packard Tri-carb TR 1900 liquid scintillation analyzer (Packard, 
Boston, MA).  
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Loperamide Sample Preparation and HPLC/MS/MS Assay  
Distilled water was added to brain samples (2:1 v/w) and homogenized with brief probe 
sonication. Plasma (for in vivo studies), brain homogenate, and perfusate (for in situ 
studies) samples were analyzed by HPLC/MS/MS (API 4000 triple quadrupole with 
TurboIonSpray interface; Applied Biosystems/MDS Sciex, Concord, ON, Canada). A 25-
µL aliquot of brain hemisphere homogenate or plasma was transferred to an HPLC vial, 
and protein was precipitated with 100 µl of methanol containing internal standard (10 
ng/mL fexofenadine), followed by a 25-µl aliquot of DMSO. The sample was vortex-
mixed and centrifuged. Standard solutions, ranging from 0.5-5000 nM were prepared 
similarly, i.e., 25 µl of blank plasma or brain matrix, 100 µl of methanol containing 
internal standard, and 25 µl of serially-diluted standard solution was mixed and 
centrifuged. Supernatant (3 µl) was injected by autosampler (Leap, Carrboro, NC). 
Loperamide and the internal standard, fexofenadine, were eluted from an Aquasil C18 
column (2.1 x 50 mm, dp = 5 µm; Thermo Electron Corporation, Waltham, MA) using a 
mobile phase gradient (A, 0.1% formic acid in water; B, 0.1% formic acid in methanol; 0-
0.70-min hold at 0% B, 0.70-3.12-min linear gradient to 90% B, 3.12-4.10 min hold at 
90% B, 4.10-4.20-min linear gradient to 0% B, 4.20-4.90-min hold at 0% B; solvent 
delivery system (Shimadzu); flow rate = 0.75 ml/min; 0.8-4 min directed to mass 
spectrometer) and were detected in positive ion mode using multiple reaction monitoring: 
fexofenadine: 502.4?466.4 m/z, loperamide, 477.4?266.0 m/z. The lower limit of 
detection was 0.5 ng/ml; inter-and intraday CVs were <15%.  
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Parameter Calculation 
The regional vasculature volume was calculated using the equation:  
inulin
inulin
vasc C
XV =  
where Xinulin and Cinulin are the amount of 3H-inulin radioactivity in the brain region and 
concentration in the perfusate, respectively. Regional 14C-diazepam brain uptake 
clearance (Clup), which is flow rate-limited and therefore serves as a surrogate marker of 
functional perfusate flow, was calculated using the equation:  
perf
vascbrain
up
C
)/TX-(X
Cl =  
for each brain region (Dagenais et al., 2000a). For each of the test compounds, regional 
Clup was calculated using  
perf
brain
up
C
/TXCl =  
No correction for substrate mass contained in residual was made as the vasculature 
substrate content was cleared via the 15-s cold saline washout at the end of the perfusion 
period. 
Statistical Analysis 
Data are reported as mean ± SD for 3 mice per condition. One-way or two-way ANOVA, 
where appropriate, was used to determine the statistical significance of differences among 
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two or more groups. The level of significance was corrected for multiple comparisons 
(e.g., Bonferroni test) or adjusted for unequal variance when necessary. In all cases, p < 
0.05 was considered to be statistically significant. 
 
Results 
Regional Cerebral Vascular Volume and Flow Rate 
During in situ mouse brain perfusion, the regional vascular volume and perfusion flow 
rate in mdr1a(+/+) and mdr1a(-/-) mice were comparable, so the data were pooled for 
each structure, as summarized in Table 5.1 (n=6, mean±SD). The regional vascular 
volume ranged from 0.62 mL/100 g in pons and medulla to 2.21 mL/100 g in colliculi. 
The perfusion flow rate ranged from 38.1 mL/min/100 g in medulla to 285 mL/min/100 g 
in colliculi. An orthogonal linear least-squares regression analysis between the local 
blood flow rate and vascular volume, with a correlation coefficient of 0.955, is illustrated 
in Figure 5.1. 
Regional P-gp Activity in Mouse Brain 
The regionality of brain uptake of 3H-colchicine, 3H-quinidine and 3H-verapamil in 
mdr1a(+/+) and mdr1a(-/-) mice is shown in Figure 5.2. Colchicine, quinidine and 
verapamil brain uptake were significantly higher in most of the brain regions studied in 
mdr1a(-/-) mice compared to wild-type animals, consistent with P-gp-associated 
impairment of brain uptake. In addition, a stronger relationship between Clup and regional 
vascular volume was observed in mdr1a(-/-) vs. mdr1a(+/+) mice. The actual regional P-
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gp efflux ratios were calculated as the ratios of Clup values in mdr1a(-/-) mice to wild-
type mice for each compound, and plotted against regional cerebral vascular volume 
(Figure 5.3). Approximately 67.9% of the variance in colchicine regional P-gp efflux 
ratio can be explained by the local cerebral vascular volume (Figure 5.3A). However, 
there is essentially no relationship between regional P-gp activity and vascular volume 
for quinidine or verapamil (Figure 5.3B and 5.3C, less than 1% of the variance in P-gp 
efflux ratio can be explained by the local vascular volume). The regression excluding 
pons, medulla and cerebellum (triangles in Figure 5.3C) for verapamil evidences a 
reasonable correlation between regional P-gp efflux ratio and vascular volume 
(R2=0.656). 
Effect of Flow Rate Perturbation on Brain Distribution 
To investigate the influence of regional cerebral perfusion flow rate on regional P-gp 
efflux of verapamil, mouse brain perfusions were performed at a lower flow rate (1 
mL/min). The resulting change in P-gp efflux ratio is plotted against the P-gp efflux ratio 
at the standard flow rate (Figure 5.4). Pons, medulla and cerebellum were excluded from 
the regression because in these areas the brain uptake was essentially flow rate-limited. A 
linear relationship (R2=0.861) was observed between the flow-related change in P-gp 
effect and local P-gp activity. In the brain regions that showed significant P-gp activity 
(such as parietal cortex and colliculi), changes in perfusion flow had little influence on P-
gp activity. In regions with limited P-gp activity, a change in perfusion flow rate had a 
more substantial impact on P-gp activity. A similar regression analysis also demonstrated 
a relationship between regional vascular volume and P-gp activity (R2=0.622, data not 
shown). 
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Regional P-gp Transport of Loperamide 
Loperamide samples were analyzed by HPLC/MS/MS. Seven larger brain regions were 
dissected to satisfy the requirement of sample preparation reproducibility and analytical 
sensitivity. Regional P-gp-mediated efflux of loperamide correlated well with regional 
vascular volume during in situ brain perfusion for 60 s in mice (R2=0.639; data not 
shown). Figure 5.5 illustrates the regional P-gp effect following subcutaneous 
administration of loperamide, with the P-gp efflux ratio at 0.5, 1, 2, 4, 6, 12 hr plotted for 
each region. The regional P-gp efflux ratio was statistically (R2=0.775) related to the 
regional vascular volume only at the earliest time point (0.5 hr). P-gp efflux ratios were 
always the highest in cerebral cortex and the midbrain regions at all time points (data not 
shown). 
Effect of Lipophilicity on Regional Brain Distribution  
Three-dimensional illustrations of the brain distribution of colchicine, quinidine, 
verapamil and diazepam in each brain region vs. clogD7.4 (the logarithm of the octanol 
water partition coefficient at pH7.4) are provided in Figure 5.6. The value of clogD7.4 for 
each compound was estimated using Marvin and calculator plugin freeware 
(www.chemaxon.com, ChemAxon Kft, Budapest, Hungary). The initial rate of brain 
uptake in mdr1a(-/-) mice [Clup(-/-), mL/min/100 g] was a function of lipophilicity. 
LogClup(-/-) increased with increasing clogD7.4 until Clup(-/-) approached the regional 
perfusion flow rate (for verapamil and diazepam). In pons, medulla and cerebellum, the 
functional perfusion flow rates were lower than in other brain structures (Figure 5.6A). In 
the presence of P-gp, the initial rate of colchicine, quinidine and verapamil brain uptake 
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was mitigated by P-gp-mediated efflux (Figure 5.6B). The P-gp efflux ratio was not a 
function of lipophilicity (Figure 5.6C). 
 
Discussion 
The BBB is a tightly regulated barrier that serves to maintain homeostasis of the 
microenvironment in the brain. BBB penetration is the first step in the access of CNS 
targets for therapeutic agents and toxicants in the brain. Most of the targets for treatment 
of brain disorders, e.g., neurodegenative disorders (dopamine receptors), epilepsy (e.g., 
GABA receptors) and neuropathic pain (µ-opioid receptors) are not homogeneously 
distributed in the brain (Heiss and Herholz, 2006). To achieve optimal therapeutic effect, 
adequate drug exposure at the site of action is important. Regional drug exposure in the 
brain is influenced not only by regional BBB permeability, but also by hemodynamic 
parameters such as local blood flow and capillary density.  
In situ brain perfusion has become an important technique for measuring BBB 
permeability (Takasato et al., 1984; Dagenais et al., 2000a). The advantages of the in situ 
brain perfusion technique include elimination of the confounding factors of systemic 
disposition (such as hepatic metabolism and plasma protein binding) and maintenance of 
the intact physiologic condition of the brain. 14C-diazepam and 3H-inulin were used as 
functional perfusion flow rate and capillary volume markers, respectively (Dagenais et al., 
2000a). In the current study, these two markers were used to study the local perfusion 
flow rate and capillary density in different brain structures. 
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A good relationship between local cerebral vascular volume and blood flow rate has been 
identified using various experimental techniques in conscious or anesthetized animals and 
humans (Klein et al., 1986; Suzuki et al., 1998; Wyss et al., 2007). In addition, 
heterogeneous cerebral vascular volume and blood flow have been found to be correlated 
with the local rate of neurophysiologic activity as expressed by glucose utilization. 
Structures with high glucose utilization, e.g., inferior colliculus, tend to have a high 
capillary density (Klein et al., 1986; Schrock and Kuschinsky, 1988). The current study 
demonstrated that brain structures such as colliculi, thalamus and parietal cortex have the 
highest vascular volume and functional flow rate, while the brainstem (pons and medulla) 
and cerebellum have the lowest vascular volume and functional flow rate. A significant 
correlation between local cerebral vascular volume (inulin volume) and local perfusion 
flow rate (diazepam Clup) was demonstrated (Figure 5.1). The mean transit time, 
calculated as the ratio of vascular volume to blood flow rate in each brain structure, was 
0.4-0.6 s among most of the regions. A notable exception was medulla, where the mean 
transit time was 1.0 s. These values are similar to the transit times (0.3-0.6 s) reported for 
various rat brain areas, as determined by an autoradiography technique following 
intravenous administration of 14C-iodoantipyrine (Fenstermacher et al., 1991). 
Brain capillary diameters are influenced by many factors such as CO2, O2 and electrolyte 
concentrations in blood. However, capillary diameters do not vary between different 
brain structures (Gjedde and Diemer, 1985; Duelli and Kuschinsky, 1993). Gjedde et al 
(Gjedde and Diemer, 1985) demonstrated that in brain regions with higher blood flow, 
there is a correspondingly larger capillary vascular volume, i.e., larger capillary density 
and total surface area. Thus the cerebral capillary is considered standard across the brain. 
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For example, the number of glucose transporters per unit capillary surface area is the 
same in all regions, and the apparent glucose permeability in all brain capillary beds are 
the same. Regional differences in the rates of blood flow and glucose uptake are the result 
of different capillary densities or the length of capillaries in the regions of the brain 
(Gjedde and Diemer, 1985). In the current study, the uptake clearance in mdr1a(-/-) mice 
[Clup(-/-)] for colchicine, quinidine, verapamil and diazepam correlated well with the 
local capillary density, with R2 values of 0.708, 0.862, 0.856, and 0.955, respectively, 
suggesting that the surface area in the regional BBB is very important for brain uptake 
(Figure 5.1 and 5.2). However, there was practically no such relationship in wild-type 
mice for colchicine (R2=0.019) and quinidine (R2=0.191). Both compounds are P-gp 
substrates, with brain uptake impaired by P-gp-mediated efflux. For verapamil, also a P-
gp substrate, brain uptake was correlated with capillary density (R2=0.726). This 
discrepancy can be explained by the fact that verapamil is quite permeable at the BBB. 
As its rate of brain uptake approaches the flow rate, verapamil uptake is influenced more 
significantly by flow than by P-gp activity. In addition, verapamil is a weaker P-gp 
substrate than quinidine, as reflected by the magnitude of P-gp efflux ratios (4.7 and 16.7, 
respectively). Thus, all other factors being equal, P-gp would be expected to have less of 
an effect on verapamil uptake than on quinidine uptake across the BBB. 
Figure 5.3A illustrates that the colchicine P-gp efflux ratio correlated with capillary 
density. The P-gp efflux ratio determined using in situ brain perfusion technique (ERB) 
has been shown to be directly proportional to P-gp efflux activity, using a mathematical 
three-compartment model in which P-gp efflux activity was directly proportional to 
functional protein expression level (Kalvass and Pollack, 2007). The present results with 
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colchicine suggest that the expression level of P-gp, a membrane-bound protein 
expressed in the brain capillary endothelium, is related to local capillary density. Thus, it 
is likely that the amount of P-gp per unit capillary surface area is the same in all regions 
and functions similarly. This is also consistent with the observations that P-gp is 
expressed in endothelial cells, with little or no expression in other brain cells (i.e., 
astrocytes and neurons) under normal conditions (Schinkel, 1999; Yousif et al., 2007). 
Surprisingly, there was not such a strong correlation between P-gp effect and capillary 
density for verapamil or quinidine. Verapamil P-gp efflux ratios were high in the pons 
and cerebellum. The pons, medulla and cerebellum are perfused by vertebral arteries 
under normal conditions, so are not perfused well with carotid artery perfusion under the 
current experimental technique (Takasato et al., 1984). Verapamil brain uptake in these 
areas is perfusion-limited. Regression analyses excluding these regions demonstrated a 
good correlation between the P-gp efflux ratio and capillary volume (R2=0.656, Figure 
5.3C). Regional P-gp efflux ratios following intranasal administration of verapamil also 
showed that the most substantial regional P-gp effects were in parietal cortex and the 
thalamas (Graff et al., 2005; Appendix), corresponding to the areas that have the highest 
capillary density and, by analogy, P-gp expression level. Other variables might contribute 
to quinidine brain uptake and its interaction with P-gp, such as more than one P-gp 
binding site for this substrate (unpublished data), and the interplay of passive 
permeability at the BBB with perfusion flow rate. 
In earlier studies, the apparent distributional volume (Vd) for colchicine, quinidine, 
verapamil and diazepam has been demonstrated to be a linear function of perfusion time 
over 60 s (Dagenais et al., 2000a; Dagenais et al., 2004). In the current study, all of the 
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perfusions were conducted for 60 s to maximize the brain exposure and analytical 
sensitivity while maintaining time-linear conditions. In addition, a final 15-s drug-free 
saline perfusion was utilized to wash out the residual perfusate remaining in the vascular 
space. This washout step is especially useful for poorly-permeable compounds such as 
colchicine, for which subtraction of vascular contamination might lead to appreciable 
variability in the estimated mass of substrate in brain. The Vd for colchicine in seven 
regions of rat brain ranged from 0.18 µl/g in cerebellum to 10.7 µl/g in the hippocampus, 
and was increased significantly upon pretreatment with P-gp inhibitor PSC833 and 
GF120918 in all regions (Youdim et al., 2004). In the present study, Clup (equivalent to 
Vd) ranged from 0.57 to 2.07 mL/min/100 g, with the lowest exposure in pons and 
medulla, and the highest exposure in hippocampus, olfactory bulb and colliculi, areas that 
have been reported to be selectively vulnerable to colchicine toxicity (Goldschmidt and 
Steward, 1982; Mundy and Tilson, 1990). One previous study using a perfusion 
procedure showed no regional differences (Drion et al., 1996). This discrepancy can be 
explained by the differences in the brain perfusion procedure, and in particular the 
presence or absence of a washout step in the perfusion protocol. Other experimental 
differences (e.g., the structures selected for evaluation) may have contributed to 
differences in results between the two studies. 
Among the P-gp substrates evaluated, verapamil is the most permeable at the BBB, with 
a brain uptake clearance in most brain regions approaching perfusion flow rate in 
mdr1a(-/-) mice. Verapamil brain uptake is expected to be sensitive to changes in 
perfusion flow rate. For this reason, verapamil was selected as a model compound to 
study the impact of blood flow on brain uptake and P-gp effect. A lower perfusion rate (1 
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mL/min) was selected for comparison to the standard flow rate (2.5 mL/min). Changes in 
blood flow cause capillary diameters to change, thus altering the surface area for regional 
uptake (Duelli and Kuschinsky, 1993). At a lower perfusion rate, a vasoconstricting 
effect occurs, and capillary diameter and surface area decrease. As expected, lower brain 
uptake was observed for verapamil at 1 mL/min compared to 2.5 mL/min. The P-gp 
efflux ratios also decreased, but to differing extents based on brain region, at the lower 
perfusion rate. The change in P-gp efflux ratio in response to a decrease in perfusion flow 
was found to be correlated with the basal (i.e., at 2.5 mL/min) regional P-gp effect. 
Changes in flow appeared to have a more substantial impact in areas that had a weaker P-
gp activity, but little or no effect in areas with stronger P-gp activity (i.e., areas that have 
larger capillary beds). A good correlation existed between the change in P-gp efflux ratio 
and the P-gp efflux ratio determined at 2.5 mL/min or regional cerebral volumes, when 
excluding pons, medulla and cerebellum regions for reasons described above. 
The in situ brain perfusion is an oversimplified system that only approximates intact 
systems. In the in vivo situation, factors such as plasma protein binding and non-specific 
binding in brain tissue, hemodynamic parameters such as pCO2, pO2, pH, and electrolyte 
concentrations influence the vascular volume, blood flow rate, and BBB permeability. At 
the earliest time point (0.5 hr) following subcutaneous administration, loperamide P-gp 
efflux ratio correlated with local capillary density, a result anticipated based upon the 
preceding in situ perfusion experiments. At all later time points, the apparent P-gp effect 
lost regionality, most likely due to inter-area diffusion and exchange, including 
distribution across the regional BBB. This explanation is kinetically sound because it is 
expected that the short-term perfusion in mouse brain represents in vivo situation prior to 
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attainment of distribution equilibrium (i.e., the initial phase of brain uptake, when the 
brain behaves as an approximate sink for substrate uptake). In contrast, later time points 
during in vivo distribution (i.e., when no net flux occurs between blood and brain tissue) 
brain-to-blood partitioning is determined primarily by relative protein binding in blood 
and brain tissue, not BBB permeability in isolation. A previous study resulted in a similar 
observation: short-term (up to 30 s) intravenous infusion of 3H-nicotine might be used to 
estimate local cerebral blood flow rate (initial rate of brain uptake determined by flow 
rate) and long-term (up to 4 min) infusion could be used to estimate density of cells and 
nerve endings, which was determined by the tissue binding of nicotine (Ohno et al., 
1979). 
Lipophilicity has been demonstrated to be one of the most important factors in 
determining brain exposure (Brodie et al., 1960). Experimental and modeling approaches 
demonstrated that the regional brain exposure of various compounds (antipyrine, 
verapamil, and diazepam) in dissected coronal brain slices is determined by lipophilicity, 
with the diffusivity factors directly proportional to logP values (Graff et al., 2005; 
Appendix). In the current study, the regional brain exposure of colchicine, quinidine, 
verapamil and diazepam in mdr1a(-/-) mice was a function of clogD7.4 in all brain regions. 
However, in the regions (pons, medulla and cerebellum) that were not well-perfused, 
brain uptake was limited by flow rate even with compounds with lower lipophilicity. This 
situation caused Clup to plateau for compounds with increasing lipophilicity. The regional 
brain exposure of colchicine, quinidine and verapamil (all P-gp substrates) in wild-type 
mice was impaired by P-gp-mediated efflux to different extents depending on the 
efficiency of P-gp effect. No correlation was observed between regional P-gp efflux ratio 
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and clogD7.4. Other variables such as the number of binding sites, or affinity towards the 
binding sites influence the nature of substrate interaction with P-gp. 
In conclusion, the current study used an in situ mouse brain perfusion technique to 
illustrate the interplay between regional brain capillary volume, blood flow, and P-gp 
activity, and the impact of these factors on regional drug exposure in mouse brain. The in 
vivo studies with loperamide confirmed that this in situ brain perfusion technique is an 
approximation to in vivo situation and is helpful in understanding the underlying 
mechanisms of regional brain exposure in the more complicated intact system. 
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Table 5.1:  Regional cerebral vascular volume (Vvasc) and perfusion flow rate determined 
by in situ brain perfusion at 2.5 mL/min for 60 s in mdr1a(+/+) and mdr1a(-/-) mice (n=3 
per strain). There is no statistical difference between these two strains (one-way ANOVA, 
p>0.05 for each brain region). The data in mdr1a(+/+) and mdr1a(-/-) mice are pooled 
and presented below (n=6). The Vvasc and flow rate in different brain regions are 
statistically different (one-way ANOVA, p<0.05) 
Region Vvasc (mL/100 g) Flow Rate (mL/min/100 g) 
olfactory bulb 1.1±0.3 155±52 
striatum 1.5±0.5 180±20 
hippocampus 1.6±0.3 200±4 
frontal cortex 1.5±0.3 167±21 
parietal cortex 1.7±0.3 223±11 
occipital cortex 1.7±0.4 215±24 
colliculi 2.2±0.5 285±49 
hypothalamus 1.5±0.4 214±21 
thalamus 1.9±0.4 238±39 
midbrain 1.6±0.3 198±20 
pons 0.6±0.1 65±45 
medulla 0.6±0.2 38±32 
cerebellum 1.1±0.2 122±40 
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Figure 5.1:  The relationship between regional flow rate (14C-diazepam Clup, 
mL/min/100 g brain tissue) and regional cerebral vascular volume (3H-inulin volume, 
mL/100 g brain tissue). Orthoganol linear least-squares regression (r2=0.955). ob, 
olfactory bulb; st, striatum; hp, hippocampus; fc, frontal cortex; pc, parietal cortex; oc, 
occipital cortex; cl, colliculi; hy, hypothalamus; th, thalamus; mid, midbrain; po, pons; 
md, medulla; cb, cerebellum.
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Figure 5.2:  The regional Clup (mL/min/100 g brain tissue) in mdr1a(+/+) (solid symbol) 
and mdr1a(-/-) (open symbol) mice versus regional cerebral vascular volume (inulin 
volume, mL/100 g brain tissue) for (A) colchicine, (B) quinidine, and (C) verapamil. The 
solid lines are orthogonal linear regression line in mdr1a(-/-) mice, the dashed lines are 
the arithmatic mean of Clup in mdr1a(+/+) mice. 
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Figure 5.3:  The observed relationship of regional P-gp efflux ratio and cerebral vascular 
volume (inulin volume, mL/100 g brain tissue) determined by in situ brain perfusion at 
2.5 mL/min for 60 s in mdr1a(+/+) and mdr1a(-/-) mice for (A) colchicine, (B) quinidine, 
and (C) verapamil. The orthogonal regression was carried out for colchicine and 
quinidine using all thirteen brain regions examined, and for verapamil using all brain 
regions (circles) excluding pons, medulla and cerebellum (triangles). 
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Figure 5.4:  The influence of perfusion flow rate perturbation in the regional verapamil 
P-gp efflux ratio. The Y-axis is the percent change of P-gp efflux ratio at 1 mL/min to 2.5 
mL/min; the abscissa is the regional P-gp efflux ratio at perfusion flow rate of 2.5 
mL/min. The orthogonal least-squares linear regression was conducted with all brain 
regions (circles) (R2=0.861). The triangles (pons, medulla and cerebellum) was not 
included into regression. ob, olfactory bulb; st, striatum; hp, hippocampus; fc, frontal 
cortex; pc, parietal cortex; oc, occipital cortex; cl, colliculi; hy, hypothalamus; th, 
thalamus; mid, midbrain; po, pons; md, medulla; cb, cerebellum. 
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Figure 5.5:  The relationship of regional P-gp efflux ratio of loperamide and regional 
cerebral vascular volume at (A) 0.5 h, (B) 1 h, (C) 2 h, (D) 4 h, (E) 6 h, and (F) 12 h 
following subcutaneous administration of 30 and 1 mg/kg of loperamide in mdr1a(+/+) 
and mdr1a(-/-) mice, respectively. 
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Figure 5.6:  The relationship of brain uptake of colchicine, quinidine and verapamil and 
diazepam (A) in mdr1a(-/-) mice [Clup(-/-)], (B) mdr1a(+/+) mice and (C) P-gp efflux 
ratios and the logarithm of octanol water patition coefficient at pH 7.4 (clogD7.4) in each 
brain region. ob, olfactory bulb; st, striatum; hp, hippocampus; fc, frontal cortex; pc, 
parietal cortex; oc, occipital cortex; cl, colliculi; hy, hypothalamus; th, thalamus; mid, 
midbrain; po, pons; md, medulla; cb, cerebellum.  
 
CHAPTER 6 
CONCLUSIONS 
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The blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB) are the 
major interfaces between the central nervous system (CNS) and the peripheral circulation. 
The BBB and BCSFB are formed by the brain capillary endothelial cells and epithelial 
cells lining the choroid plexus, respectively. Highly-developed tight junctions, lack of 
fenestrae, limited pinocytotic or transcytotic activities, and expression of numerous efflux 
transporters and metabolizing enzymes at both barriers limit brain penetration of many 
endogenous compounds and therapeutic agents (Begley 2003; Graff and Pollack 2004). 
The surface area of the BBB is approximately 3,000-times that of BCSFB, and 
consequently is the primary obstacle for CNS drug penetration. CNS pharmacologic or 
toxic response is determined by the rate and/or extent of drug presentation to the site of 
action, and the intrinsic ability of the agent to elicit a biologic effect.  
CNS exposure is determined by complex processes as illustrated in Figure 6.1. The CNS 
can be viewed as compartmentalized with respect to target localization. Depending on 
that localization, it is the unbound extracellular fluid (ECF), unbound intracellular, or, in 
limited cases, cerebrospinal fluid (CSF) concentration that drives the biologic response. 
Passive and active flux processes at the BBB and BCSFB, nonspecific binding (i.e., to 
non-receptor proteins) in plasma and brain tissue, metabolism at the BBB or BCSFB, and 
CSF turnover rate all can influence significantly the net brain exposure to therapeutic or 
toxic compounds (Brodie et al. 1960; Fenstermacher et al. 1981; Kalvass and Maurer 
2002; Kalvass et al. 2007a; Liu and Chen 2005; Liu et al. 2004; Schinkel et al. 1994). An 
additional complication is that therapeutic targets are not homogeneously distributed 
throughout the brain, but rather are region-specific. Regional physiologic factors such as 
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blood flow rate, brain capillary density, capillary residence time, and expression of 
transport proteins and metabolic enzymes will determine regional drug exposure.  
Studies focused on how various pathological conditions may influence the physical and 
functional aspects of the BBB have been somewhat limited in scope. Understanding the 
kinetics of drug uptake into brain (whether or not the compound cross the BBB and, if so, 
how fast and to what extent compound reaches the brain; the extent of drug exposure at 
the specific site of action; the relationship between dose, target site exposure, receptor 
occupancy and the pharmacologic response) is crucial to providing direction for drug 
design and development in the treatment of CNS disorders. However, the current 
understanding of many of these aspects is limited due to the complexity of the organ 
system and the techniques used to characterize brain distribution. For example, the 
functional efficiency of efflux transporters other than P-glycoprotein (P-gp) is mostly 
unknown and largely controversial. Similarly, the functional role of metabolizing 
enzymes expressed in the brain or at the blood-brain interface is only beginning to be 
appreciated. In the current dissertation project, a variety of experimental approaches, 
including in vitro, in situ and in vivo models were used to study: (1) the factors 
determining the BBB permeability; (2) the impact of P-gp and brain metabolism on brain 
exposure to a poorly permeable model compound, fexofenadine; (3) the potential role of 
breast cancer resistance protein (Bcrp) as a barrier transporter at the blood-brain interface; 
and (4) the mechanisms that dictate regional distribution of compounds within the brain. 
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The Rate of Brain Penetration 
The in situ brain perfusion technique was developed in 1984, and represents a powerful 
experimental tool for examining brain uptake kinetics under near-sink conditions. This 
model has many advantages over several older techniques (i.e., brain uptake index, 
systemic administration in vivo) in measuring the initial rate of brain uptake and BBB 
permeability (Takasato et al. 1984). The intact architecture of the BBB is maintained 
during perfusion, but confounding factors such as protein binding or systemic metabolism 
are avoided. The complete control of the composition of perfusion buffer and perfusate 
flow make this method applicable to studying several different aspects of CNS kinetics, 
such as the ability of compounds to cross the BBB, the potential modulation of 
transporter kinetics at the BBB, and regionality of substrate distribution. By adapting the 
perfusion technique for use in mice (Dagenais et al. 2000), the use of genetic knockout 
animal models became possible, providing invaluable information on the impact of efflux 
transport by P-gp on brain exposure (Dagenais et al. 2001a; Dagenais et al. 2004; 
Dagenais et al. 2001b; Graff and Pollack 2005; Zong and Pollack 2003).  
Lipophilicity has been recognized as one of the most important determinants for brain 
penetration due to the diffusion barrier presented by the plasma membrane of brain 
capillary endothelial cells. In previous studies (Smith 2003; Takasato et al. 1984), it has 
been demonstrated that the rate of brain uptake is proportional to lipophilicity at 
physiologic pH (clogD7.4). However, the compounds were mostly non-therapeutic agents 
with limited lipophilicity (clogD7.4<1). In Chapter 2, a sigmoidal relationship was 
demonstrated for twelve compounds with clogD7.4 in the range of 0-6. Compounds with 
low lipid solubility cannot penetrate the plasma membrane of the BBB endothelium, and 
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uptake is limited by permeability (i.e., the rate of uptake under approximate sink 
conditions in the brain is limited by the rate of diffusion through the membrane). For 
compounds with clogD7.4 higher than 3, the rate of brain uptake is limited by the blood 
flow (or, in the case of in situ perfusion, the perfusate flow rate) and therefore is not 
sensitive to passive permeability. For compounds with a clogD7.4 between 1 and 3, the 
rate of brain uptake is a function of permeability and flow rate.  
It is interesting to note that, for the 5 CNS-active drugs investigated in this study, the 
mean passive permeability was approximately 3-fold higher than the non-CNS active 
drugs in the compound set. Furthermore, none of the CNS-active drugs were subject to P-
gp-mediated efflux at the BBB, whereas the mean P-gp efflux ratio for the non-CNS 
active drugs was approximately 5.5. These results suggested that passive permeability 
and P-gp-mediated efflux activity at the BBB can differentiate the CNS and non-CNS 
drugs. From the drug design standpoint, a potential strategy for enhancing the probability 
of success in drug development is to design lipophilic agents that are not substrates of 
efflux transporters at the BBB. In addition, similar to the overall brain exposure, the 
regional distribution of drugs in different brain structures also was determined by 
lipophilicity and P-gp-mediated efflux (Chapter 5). 
The rate of brain equilibration with blood (i.e., the time to distribution equilibrium across 
the blood-brain interface) is an important aspect of CNS kinetics because it can influence 
the onset and offset of CNS activity. Some therapeutic indications, such as brain 
infections, stroke, epilepsy, neuropathic pain, and trauma, require a rapid onset of action, 
whereas other indications, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) 
and depression, can be treated effectively with drugs with a slow onset of action. The rate 
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of brain penetration is not only a function of permeability, but also of nonspecific binding 
in brain tissue. It is the difference in apparent brain distributional volume that contributes 
to the difference between the onset time of alfentanil and fentanil. Both compounds have 
similar systemic pharmacokinetics. Generally, BBB permeability increases with 
lipophilicity, whereas the brain tissue unbound fraction has an inverse relationship with 
lipophilicity. The apparent inverse relationship between PS and fu,brain makes the 
equilibration half-life a complex function of lipophilicity, with the most rapid 
equilibration for compounds with a clogD7.4 in the range of 1-3 (Figure 2.3). In the 
twelve compounds investigated in this portion of the dissertation project, alfentanil 
evidenced the most rapid equilibration. Both alfentanil and diazepam brain uptake were 
rapid and limited by perfusion flow rate. Alfentanil brain equilibrium was reached in 20 s, 
whereas diazepam brain uptake was still unidirectional after 60 s of brain perfusion. 
Diazepam binds more extensively than alfentanil to proteins in brain tissue, resulting in a 
larger apparent brain volume for diazepam than alfentanil, with a consequent longer time 
required to establish distribution equilibrium. Mathematical modeling and simulation, 
coupled with experimental results, demonstrated that the intrinsic equilibration half-life is 
an inverse function of product of permeability and brain tissue unbound fraction 
(PS×fu,brain) (Liu and Chen 2005; Liu et al. 2005). Colchicine, ritonavir, and fexofenadine 
demonstrated very slow equilibration across the BBB. The equilibration half-life varied 
widely among the different compounds studied. This result also can be inferred, and 
therefore supported at least indirectly, by in vivo pharmacodynamic studies that indicated 
a 70-fold difference in brain equilibration half-life (t1/2eq,brain) between alfentanil and 
morphine (Kalvass et al. 2007b). 
 202 
The Extent of Brain Penetration 
For compounds that distribute between blood and brain solely by passive diffusion, the 
plasma-to-brain unbound fraction ratio has been used successfully to predict in vivo 
brain-to-plasma concentration ratio at distribution equilibrium, under the assumption that 
unbound brain and plasma concentrations will be equal at steady-state or post-
distributional equilibrium. P-gp attenuates the extent of brain exposure by 2- to 65-fold 
for many therapeutic agents (Chen et al. 2003b; Kalvass et al. 2004). Previous efforts to 
predict brain penetration of P-gp substrates have demonstrated that this assumption still 
holds for most compounds. The brain partition coefficient Kp,brain is determined by the 
plasma and brain unbound fraction ratio and the magnitude of the P-gp efflux ratio at the 
BBB (Kalvass et al. 2007a; Summerfield et al. 2006).  
Sedative side effects are common for first-generation antihistamines, most of which have 
high passive permeability and are not subject to P-gp-mediated efflux at the BBB. 
Consequently, the unbound brain concentration is as high as the unbound plasma 
concentration. In contrast, brain penetration of the second-generation antihistamines 
fexofenadine and cetirizine is minimal, and these compounds do not cause sedation. In 
Chapter 3, fexofenadine brain penetration was almost completly restricted by P-gp-
mediated efflux at the BBB, and increased ~50-fold in P-gp-deficient mice. Following a 
continuous infusion with a subcutaneously-implanted osmotic minipump, not only 
fexofenadine brain penetration, but also P-gp efflux ratio, was found to increase over 
time. This temporal pattern was predicted by a two-compartment model with the passive 
diffusion and P-gp-mediated efflux mediating substrate flux between the systemic 
circulation and the brain compartment. In addition, following administration of the 
 203 
permeable prodrug terfenadine, fexofenadine brain exposure increased ~25-fold 
compared to fexofenadine administration due to the conversion of terfenadine to 
fexofenadine in the brain tissue.  
In addition to P-gp, which significantly decreases the rate and extent of brain penetration, 
Bcrp is another important efflux transporter expressed at the BBB. However, even though 
cimetidine, alfuzosin, dipyridamole and LY2228820 have been demonstrated to be 
transported by Bcrp in the MDCKII-Bcrp cell line, none of these compounds showed 
impaired BBB penetration in wild-type mice compared to the genetic knockout Abcg2(-/-) 
mouse model or to animals treated with co-perfusion of the chemical inhibitor GF120918 
(Chapter 4). Bcrp might only play a minor role, and P-gp is the predominant efflux 
transporter at the BBB in limiting drug brain exposure.  
Taken together, these results suggested that the extent of brain exposure, and ultimately 
the pharmacologic or toxicologic profile, might be influenced by passive diffusion, active 
transport, nonspecific binding in plasma and brain tissue, and metabolic deactivation or 
activation at the blood brain interface and/or inside the brain tissue.  
Regional Distribution Among Brain Structures 
Effective neurotherapeutics depend on the ability to achieve adequate drug exposure at 
the site of action. The brain is a highly structurally- and functionally-specialized organ, 
and therapeutic targets are not distributed homogeneously throughout the brain (Heiss 
and Herholz 2006). For example, regional blood flow rate in rat brain spans an 
approximate 18-fold range, and has been shown to correlate with regional brain capillary 
density (Fenstermacher et al. 1991; Klein et al. 1986). These local physiologic parameters 
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determine the surface area for substrate exchange between blood and brain, the rate of 
mass delivery to serve as the driving force for such exchange, and the residence time in 
different brain structures allowing substrate diffusion across the capillary endothelium of 
interaction with transport protein or enzymes expressed at the blood-brain interface. Each 
of the factors will potentially contribute to the consequent regional drug exposure. In 
regions such as cerebellum and brain stem, the blood supply comes from vertebral 
arteries, whereas the remainder of the brain is supplied by the carotid arteries under 
normal physiologic conditions. Drug exposure typically is low in cerebellum and brain 
stem, which causes problems in the treatment of diseases reside in these brain regions. 
In Chapter 5, the regional brain capillary vascular volume and blood flow rate were 
determined with in situ brain perfusion and microdissection techniques, using 3H-inulin 
and 14C-diazepam as the brain capillary vascular volume and blood flow rate markers, 
respectively. The results of this study demonstrated that brain capillary density (inferred 
from vascular volume) and perfusion rate range approximately 3.7- and 7.5-fold, 
respectively, in thirteen dissected brain structures (olfactory bulb, striatum, hippocampus, 
frontal cortex, parietal cortex, occipital cortex, colliculi, hypothalamus, thalamus, 
midbrain, pons, medulla and cerebellum). Regional functional perfusate flow rate, as 
inferred from the uptake clearance of diazepam, which is known to be flow rate-limited 
(Dagenais et al. 2000; Takasato et al. 1984), strongly correlated with local capillary 
density. In general, brain structures with a more dense capillary bed and richer blood flow 
(e.g., inferior and superior colliculi, parietal cortex and thalamus) have more available 
surface area for drug uptake into brain. However, an increase in available surface area 
does not necessarily lead to a proportionate increase in uptake clearance. It would be 
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reasonable to hypothesize that regions with more dense capillaries also would have a 
higher level of expression of barrier transporters such as P-gp. Indeed, brain perfusion 
with structurally-diverse drugs (P-gp substrates colchicine, quinidine, and verapamil and 
non-P-gp substrate diazepam) indicated that regional drug exposure varied about 3.0- to 
5.5-fold in P-gp-deficient mice. Colchicine demonstrated the highest exposure in inferior 
colliculus and olfactory bulb, consistent with the earlier report that these regions in 
experimental animals and human were most vulnerable to colchicine-induced CNS 
toxicity (Goldschmidt and Steward 1982; Mundy and Tilson 1990). 
The regionality of P-gp-mediated efflux at the BBB has been demonstrated in murine 
brain following intranasal verapamil administration (Graff et al. 2005; Appendix I). 
Although the conclusions were based on rather sophisticated mathematical modeling of 
the data, the results clearly suggest a marked regionality in the influence of P-gp on 
distribution of verapamil within the brain. P-gp is principally expressed in the brain 
capillary endothelial cells, and therefore the regional P-gp expression level is determined 
by regional brain capillary density. In Chapter 5, during brain perfusion, P-gp-mediated 
efflux decreased brain penetration by 2- to 20-fold for different P-gp substrates 
(colchicine, verapamil and quinidine) in mdr1a(+/+) mice compared to mdr1a(-/-) mice. 
Brain exposure was attenuated by P-gp to differing extents based on both substrate and 
brain region; regional P-gp efflux ratios varied ~ 2.5- to 4.0-fold in different brain 
structures for colchicine, verapamil and quinidine. The P-gp-mediated colchicine and 
verapamil efflux activity was directly proportional to local capillary density (Figure 5.3). 
In addition, verapamil brain uptake was determined in part by the perfusate flow rate, and 
decreased with decreasing flow. Changes or differences in perfusate flow did not only 
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affect verapamil brain uptake by altering the rate of substrate presentation to the brain 
vasculature, but also by modulating P-gp-mediated efflux activity in brain regions with 
lower capillary density (i.e., regions with weaker P-gp activities). In contrast, virtually no 
effect of alterations in flow were noted in regions with the highest capillary densities (i.e., 
regions with stronger P-gp activities). For poorly-permeable compounds such as 
colchicine, the change in flow rate had no effect on BBB permeability. This is 
understandable because flow is not the rate-limiting step in either permeation across the 
endothelial cell membrane or access to the efflux transport site (presumable a binding 
domain on P-gp that resides within the endothelial cell membrane) (Begley 2004; Raub 
2006; Sharom et al. 2005). 
Drug Metabolism in the Brain 
Drug metabolizing Phase I enzymes (cytochromes P450) and Phase II conjugating 
enzymes are expressed in the CNS (Ghersi-Egea et al. 1994; Strobel et al. 2001). The 
blood-brain and blood-CSF interfaces provide a metabolic barrier, in addition to the 
physical and transport barriers often considered, for penetrating lipophilic compounds. 
The expression of metabolic enzymes within the brain is cell- and region-specific (Meyer 
et al. 2007). In some brain regions, the expression level can be as high as, or even higher 
than, that in the liver. Biotransformation machinery is present in the brain in part to 
detoxify or decrease xenobiotic exposure, thereby protecting the organ from chemical 
insult. However, as with the liver, xenobiotic metabolism in brain also can result in 
bioactivation of compounds, resulting in the possible formation of pharmacologically 
active or neurotoxic products. Experiments performed as part of this dissertation project 
(Chapter 3) demonstrated that terfenadine was metabolized to fexofenadine in murine 
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brain. Administration of terfenadine caused a 25-fold higher fexofenadine brain exposure 
as compared to exposure following administration of pre-formed fexofenadine.  
As discussed earlier in this dissertation, most models of CNS pharmacokinetics and 
pharmacodynamics are based on the assumption that unbound substrate concentrations 
are equivalent at distribution equilibrium. This equivalence of unbound concentration 
(i.e., driving force) is a hallmark characteristic of substrate distribution by passive 
processes across a blood:tissue interface. When asymmetrical transport is present (i.e., 
when flux is dominated by protein-mediated transport in either the uptake or the efflux 
direction) the unbound concentration of substrate on either side of a diffusional barrier, 
such as the BBB in the case of fexofenadine, may not be equal even at presumed 
distribution equilibrium. Because fexofenadine flux from the systemic circulation into 
brain is limited by both poor permeation and efflux transport, it would be reasonable to 
hypothesize that unbound concentrations in brain would be less than or equal to, but 
certainly would not exceed, unbound concentrations in blood. However, when 
fexofenadine is formed from terfenadine within the brain, the situation changes quite 
significantly; the unbound brain concentration of fexofenadine was approximately 1.6-
fold higher that the unbound concentration in plasma. Earlier studies demonstrated that 
codeine was metabolized by brain CYP2D6 to morphine, leading to a consequent 
analgesic effect (Chen et al. 1990; Pai et al. 2004). Similarly, ceterizine brain exposure 
increased ~7-fold following hydroxyzine administration as compared to direct 
administration of the pre-formed substrate (Chen et al. 2003a). Thus, local metabolism 
clearly can play an important role in drug exposure in brain, and might be the most 
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important causative factor in pharmacologic or toxicologic events in the CNS for certain 
substances. 
In addition to the foregoing observations, mounting evidence has shown that brain P450s 
are inducible by therapeutic agents, also in a region- and cell-specific manner (Volk et al. 
1991). For example, phenytoin induces expression of CYP3A11 and CYP19 in murine 
brain, which leads to increased testosterone metabolism in the brain (Meyer et al. 2006). 
Thus, drug-drug interactions may lead to altered CNS pharmacodynamics via a variety of 
mechanisms: substrate displacement from protein binding sites in plasma and/or brain, 
inhibition of protein-mediated transport in either the uptake or the efflux direction, 
inhibition of deactivation or activation biotransformation processes in the brain, and 
potential induction of either transport or local metabolism. It is imperative to understand 
the prevailing mechanism or mechanisms of interaction in any given case in order to 
develop appropriate therapeutic guidelines for the management of such interactions. 
Furthermore, several P450 isoforms are responsible for the endogenous biochemical 
pathways, such as the local synthesis and regulation of steroid hormones, arachidonic 
acid metabolism (whose metabolites are cerebrovascular regulator, and in turn, 
pharmacological intervention of blood flow rate) and neurotransmitters synthesis and 
metabolism. These represent additional sites and mechanisms of potential unanticipated 
outcomes of drug therapy. 
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Experimental Models to Study BBB Kinetics   
For CNS drug discovery and development, choosing the best experimental models of the 
BBB depends on many factors, including cost, time, and how closely a model needs to 
resemble in vivo conditions. In vitro modeling of the BBB is a simplification of the in 
vivo situation. While cell-based BBB assays are more cost- and time-efficient 
experimental tools than in situ and in vivo methods, they lack three-dimensional 
architecture, blood flow, and sometimes lose the morphology and functional efficiencies 
of physical and transport barriers as they are elaborated in the intact organism. In situ 
brain perfusion offers a very accurate method to studying the rate of BBB penetration, 
although it requires technical expertise and raises the issue of interspecies comparisons of 
distributional events. In vivo disposition studies also provide direct measurement of BBB 
penetration, but are labor-intensive and animal-consumptive. In situ and in vivo methods 
have become especially useful for the study of transporter kinetics due to the emergence 
of various gene knockout animal models and the availability of, in some cases, selective 
or specific chemical inhibitors.  
All experimental models have specific advantages and limitations. It is not possible to 
develop an ideal model that represents all aspects of BBB penetration. An alternative 
approach is the combined use of several models to study different aspects of BBB 
kinetics, including both mechanistic and quantitative information domains. MDCK cells 
have been used successfully to rank order the ability of compounds to cross the BBB 
based on passive permeability across the cell membrane. Passive permeability determined 
in this cell-based models correlated well with the in situ brain permeability (Summerfield 
et al. 2007). Experiments performed in this dissertation project also demonstrated good 
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correlation between passive membrane permeability in MDCK cells and BBB 
permeability in mouse brain (Figure 4.7B and 4.7C, Chapter 4). Recently, primary brain 
capillary endothelial cell culture and immortalized cell lines have been developed as the 
alternative in vitro BBB model. For example, permeability in cultured bovine brain 
microvessel endothelial cells is predictive of in vivo BBB permeability based on in vivo 
brain microdialysis (Hansen et al. 2002). Furthermore, P-gp-mediated efflux kinetics also 
have been studied using cell lines that express endogenous P-gp (i.e., Caco-2) or stably 
transfected P-gp (MDCK and LLC-PK1 cells). The in vitro P-gp effect determined in 
these models was correlated among the different cell lines, and all cell lines correlated 
with the P-gp effect determined using in situ and in vivo methods (Adachi et al. 2001; 
Hochman et al. 2002; Yamazaki et al. 2001). Marketed CNS and non-CNS drugs can be 
differentiated by membrane permeability and P-gp-mediated efflux in P-gp-transfected 
MDCK cells, indicating that the drug candidates with passive permeability > 150 nm/s 
and non-P-gp substrates are more likely to be successful CNS therapeutics (Mahar Doan 
et al. 2002). The passive permeability and P-gp-mediated efflux at the BBB also 
differentiated the CNS- and non-CNS drugs in the present studies (Chapter 2).  
In addition to observational experimentation, the theoretical relationship between in vitro, 
in situ and in vivo transport kinetics has been quantitatively evaluated using a three-
compartment modeling and simulation approach. The different model systems can be 
characterized equivalently by the parameter “efflux ratio” which is a function of efflux 
activity and passive membrane permeability (Kalvass and Pollack 2007). A good 
correlation between in vitro (regardless the cell origins or P-gp expression levels) and in 
vivo (Kp,brain ratio in P-gp-deficient mice to wild-type mice) P-gp efflux ratios was 
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observed for 55-member compound set (Chen et al. 2003b). These studies suggested that 
under certain conditions in vitro models are predictive, quantitatively and mechanistically, 
of some elements of in vivo transporter kinetics at the BBB.  
Various experimental models have established P-gp as a gatekeeper at the BBB to 
maintain the homeostasis of the neuronal environment. However, discrepancies between 
different model systems are observed frequently, which cast doubt on the validity and to 
what extent the in vitro model can resemble in vivo situation. The differences can be 
many fold, although the underlying reasons for these differences have not been fully 
explained. One likely contributor is blood flow, which is an important characteristic of 
the in vivo BBB that is absent in cell-based models. Lipophilic compounds cross the BBB 
readily, and are limited in uptake by blood flow. In addition, the molecular mechanisms 
of P-gp-mediated efflux, and even the substrate interaction site(s) of P-gp, are still 
unknown. Access to the binding site that resides inside the plasma membrane can be the 
rate-limiting step for hydrophilic compounds, and transport efficiency might be 
influenced by residence time at or near the binding site. This residence time is, in turn, 
influenced by the rate of blood flow through the vessel, at least for substrates of 
intermediate permeability.  
An additional experimental complexity is that the expression level, localization, and 
functional efficiency of P-gp at the BBB all may vary among different animal species, 
including human (Ohtsuki and Terasaki 2007; Yamazaki et al. 2001). P-gp in rodents was 
reported to be principally expressed in the luminal side of the brain capillary endothelial 
cells, whereas P-gp is expressed in brain capillary endothelial cells, astrocytes, and 
neurons in human (Bendayan et al. 2006; Golden and Pardridge 1999). The inhibitory 
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effect of P-gp inhibitors showed significant species differences with different affinity 
toward P-gp in different species (Katoh et al. 2006; Suzuyama et al. 2007). Such 
differences make the extrapolation from in vitro and animal research to clinical studies 
quite difficult. Previous studies have demonstrated that other efflux transport proteins 
expressed at the BBB might be upregulated when P-gp was knocked out. For example, 
Bcrp mRNA level increased 3-fold in mdr1a/1b(-/-) mice (Cisternino et al. 2004). 
However, the functional efficiency of this compensatory mechanism at the BBB is still 
unknown. In addition, some presumably “specific” P-gp inhibitors have been found to be 
non-specific in studies of transport kinetics, e.g., cyclosporin A has been found to inhibit 
Bcrp and Oatp (Gupta et al. 2006; Xia et al. 2007). 
With P-gp as the most extensively-studied efflux transporter at the BBB, increasing 
attention has been paid to the potential role of Bcrp at the BBB due to the immense 
similarity of expression pattern and substrate specificity between these two proteins. 
However, while Bcrp mRNA and protein have been reported to be expressed at the BBB, 
the functional efficiency of Bcrp at the blood-brain interface remains controversial. Some 
studies have suggested that Bcrp is functional at the BBB (Breedveld et al. 2005; 
Enokizono et al. 2007), while others indicate a minor role of this transporter at the BBB 
(Cisternino et al. 2004; Lee et al. 2005). In the present studies (Chapter 4), Bcrp 
substrates (cimetidine, alfuzosin, dipyridamole and LY2228820) were identified in 
MDCKII-Bcrp transwell transport screening assays. None of these substrates evidenced 
increased brain penetration following knockout of Bcrp gene or chemical (GF120918) 
inhibition.  
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As with many other aspects of BBB function, the reasons underling the discrepancies 
between in vitro (MDCKII-Bcrp in this case) and in vivo (brain perfusion in Bcrp-
competent versus Bcrp-deficient mice; brain perfusion in Bcrp-competent mice with and 
without a chemical inhibitor) models are unknown. Such discrepancies also have been 
observed in previous studies (Cisternino et al. 2004; Lee et al. 2005). A recent 
observation demonstrated that Bcrp protein in human and rat brain capillary endothelial 
cells is expressed at a much lower level than in in vitro overexpressed system (Lee et al. 
2007). In addition, the compensatory mechanism (e.g., increased Mrp4 protein expression 
in spleen and thymus) has also been demonstrated for Bcrp knockout mice (Takenaka et 
al. 2007).  
Other efflux transporters such as multidrug resistance associated proteins (Mrps) have 
been reported to be expressed at the BBB, and the functional efficiency in effluxing 
organic anions out of the brain has been speculated. However, organic anions and 
nucleotide drugs are mostly hydrophilic compounds and ionized at physiologic pH. In 
vivo BBB penetration was primarily restricted by passive permeability of such 
compounds. Even though some evidence has demonstrated that in vivo BBB penetration 
of these compounds (e.g., PMEA, AZT) was further impaired by Mrps, brain penetration 
is not significant even in Mrp-knockout animals (Belinsky et al. 2007). 
BBB Characteristics under Pathological Conditions  
Potentially interrupted BBB integrity under pathological conditions such as HIV infection, 
meningitis, traumatic brain injury, Alzheimer’s disease, multiple sclerosis, gliomas and 
metastatic brain tumors, epileptic seizures, hypertension, and stroke has been implicated. 
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The compromised BBB might lead to increased brain penetration of therapeutic agents 
(e.g., increased morphine concentrations in injured brain) and even macromolecules such 
as albumin (Ederoth et al. 2004). This potential has been exploited for presumed 
therapeutic gain with the hyperosmotic disruption of the BBB in the case of CNS cancer 
chemotherapy (Hsieh et al. 2005). 
Several physiologic parameters may be influenced by disease states or by the untoward 
effects of therapeutic agents. Ischemia affects the BBB integrity and decreases cerebral 
glucose uptake even in the presence of increased glucose transporter GLUT1 mRNA 
level (Cavaglia et al. 2001; Suzuki et al. 1998). Changes in arterial pCO2 influence the 
diameter of brain capillaries, thus modulating the surface area for exchange at the blood-
brain interface (Duelli and Kuschinsky 1993). A high fat diet alters the cerebral blood 
flow rate and/or brain capillary density (Hasselbalch et al. 1996; Puchowicz et al. 2007). 
Cerebral blood flow rate may be increased pharmacologically, as is the case with nicotine 
administration or consumption (Hans et al. 1993). 
In addition, overexpression of efflux transporters has been reported in epileptic brain. For 
patients with refractory epilepsy, MDR1, MRP2 and MRP5 were upregulated in epileptic 
tissue. P-gp was induced in glial cells and neurons in epilepticus region, whereas P-gp is 
majorly expressed at the endothelial cells under normal conditions. The overexpression is 
also region- and cell-specific (van Vliet et al. 2007). 
Prediction of BBB Distribution Kinetics for Investigational Molecules 
CNS drug discovery and development is especially important due to the large unmet 
needs in clinical therapeutics, and in large part due to an increasing aging population. 
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Most of the drug candidates for CNS therapeutics that have good in vitro efficacy cannot 
cross the BBB to reach the intended target in concentrations sufficient to exert a 
meaningful pharmacologic effect. Lipophilicity is the most important determinant of 
BBB penetration. In silico models are usually the only option for compound screening in 
terms of BBB permeability during the early phase of drug discovery process. In silico 
models can only characterize and predict passive permeability of the BBB based on the 
parameters determined in in vitro, in situ and in vivo models using the physicochemical 
properties (lipophilicity, pKa, polar surface areas, etc) of investigational molecules. 
Significant recent progress has been made towards rational CNS drug discovery (Feng 
2002; Goodwin and Clark 2005; Liu and Chen 2005). As generally-accepted “rules of 
thumb”, compounds with molecular weight less than 450 Da, polar surface area less than 
80 Å2, octanol-water partition coefficient 1-3 are favorable to cross the BBB (Clark 2003; 
Norinder and Haeberlein 2002).  
The extent of brain exposure (Kp,brain) of compounds that undergo passive diffusion at the 
BBB was successfully predicted by in vitro plasma-to-brain unbound fraction ratio 
determined with the equilibrium dialysis method (Kalvass et al. 2007a), and was used 
most often as the index parameter in BBB in silico model development and prediction. 
An in silico model also has been developed to predict brain tissue unbound fraction based 
on the chemical structures of compounds. The degree of protein binding was found to be 
related to compound lipophilicity (Wan et al. 2007). However, it is frequently stated that 
unbound drug concentration is more relevant for the pharmacologic and toxic effects in 
the CNS. Using Kp,brain  to predict and screen drug candidates therefore might be 
potentially erroneous and misleading.  
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A recent trend is to use passive permeability as a surrogate in model development. 
However, passive permeability is a parameter that describes the rate, but not necessarily 
the extent, of brain penetration. An index parameter that characterizes the extent of brain 
exposure Kp,free  has been proposed (Liu and Chen 2005). An additional complication is 
the fact that the therapeutic targets within the brain are not homogeneously distributed. 
Because the brain is a compartmentalized organ, drug exposure at the site of action is the 
most relevant parameter to assess and predict the pharmacologic effect. 
Compartmentalization, as shown in Figure 6.1, is a simple illustration of this 
characteristic. The therapeutic targets for most of CNS acting drugs are accessible from 
the brain extracellular fluid. Only for some diseases, such as brain tumor and HIV 
infection, will the effect site be inside the cell. The regional drug distribution in different 
brain structures is influenced by the local cerebral blood flow rate, capillary density, 
nonspecific binding and P-gp efficiency. It is very difficult to determine and predict the 
unbound brain concentration at the site of action. Combined use of different models has 
been employed to understand the underlying mechanisms and complex processes of brain 
distribution (Venkatakrishnan et al. 2007; Zhuang et al. 2006). Brain microdialysis, in 
vitro nonspecific protein binding assay, brain slices and CSF sampling are the most 
prevalent methods to determine the unbound brain concentration (Becker and Liu 2006; 
de Lange et al. 1997; Kalvass and Maurer 2002; Shen et al. 2004).  
However, it is important to bear in mind that the BBB is not only a physical barrier. 
Lipophilic compounds which in theory will be effective permeants of the lipoidal BBB 
also tend to be P-gp substrates. Thus, compounds that would otherwise be able to cross 
the BBB are subject to the efflux and/or metabolism at the BBB and BCSFB interfaces 
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and associated brain parenchymal cells. Uptake transporters also are present in the BBB. 
While these proteins in theory can be exploited for therapeutic gain, it has been difficult 
to design drugs as substrates of these proteins because of their high specificity for 
endogenous compounds and nutrients (Ohtsuki and Terasaki 2007).  
From a practical standpoint, the most effective strategy is to design compounds with 
adequate lipid solubility that do not interact with efflux transporters at the BBB. However, 
the effort to predict P-gp substrates based on physicochemical properties or chemical 
structure alone has been frustrating, and the attempt to establish structure-activity 
relationships to identify P-pg substrates and inhibitors has been unsuccessful. So, P-gp 
substrates still need to be identified via screening with selected in vitro and in vivo 
methods. The non-cerebral origin, P-gp transfected MDCK or LLC-PK1 cell lines, are 
relatively high-throughput screening methods. Together with in situ brain perfusion 
technique and in vivo brain distribution method, in vivo P-gp effect at the BBB can be 
revealed. 
The BBB is also a metabolic barrier, although limited knowledge has been gained in this 
area (Meyer et al. 2007; Strobel et al. 2001). Lipophilc compounds that permeate the 
BBB and escape efflux transport may be metabolized by enzymes expressed at the blood-
brain and blood-CSF interfaces, astrocytes and neurons. Specific experimental models 
need to be developed to investigate brain metabolic enzyme function and regulation, 
especially the region- and cell-specific aspects of this phenomenon. Cell culture systems 
from distinct neuronal populations and in vivo animal models with microdissected 
regions have to be developed. In addition, in silico models need to be developed to 
predict the substrates, inhibitors and inducers of specific enzyme isoforms, and the 
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consequences of brain metabolism on the pharmacologic and toxic effects need to be 
considered. 
The predictive accuracy of in silico model, in the present context whether they are 
developed to address issues of distribution, transport, or metabolism, is directly 
determined by the quality of the experimental data used for model development and 
validation. The recent shift from logBB to logPS or Kp,free  have made model development 
even more difficult because of the limited available database in the existing literature due 
to technical challenges, cost, time and labor-intensity associated with the relevant 
experimental paradigms. In general, the current models can produce reasonable 
prediction of in vivo passive brain uptake. More components, such as active transport and 
metabolic activity, nonspecific binding in blood and brain tissue, and factors that dictate 
regional distribution within the brain areas need to be added to the modeling strategy in 
order to predict effectively the multiplicity of aspects that ultimately determine CNS drug 
response. 
Summary 
Ideally, a comprehensive understanding of the primary mechanisms underlying and 
determining CNS pharmacokinetics and pharmacodynamics will be gained to facilitate 
description and prediction of the time-course of drug concentrations at the site of action 
in specific brain structures, as well as in specific compartments of the brain such as the 
extracellular fluid, intracellular fluid, and CSF. Ultimately, the kinetics of substrate flux 
through these various compartments of the brain will be important determinants of the 
magnitude and time-course of the pharmacologic/toxic effects in the CNS. Immense 
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progress has been made in the understanding of CNS kinetics at the level of BBB 
permeability. However, understanding substrate kinetics within the brain, that is, after the 
substrate has penetrated the BBB, represents an important frontier for CNS pharmacology 
research. Regional distribution in different brain anatomical structures, drug exposure at 
the target site, elimination by local metabolism and active transport from the brain are 
critical issues that have been understudied, and must be understood with some degree of 
precision if the development of new neurotherapeutic compounds is to become an 
efficient enterprise. The creation of new experimental BBB models, new and innovative 
methods of data analysis, novel use of simulation experiments based on known elements 
of system behavior, and integration of new data with the current knowledge base from in 
vitro, animal and human studies. all will be required to achieve this important goal. 
Additional aspects such as the change of BBB characteristics under pathological 
conditions, the potential contribution of polymorphisms of BBB transporters and 
metabolic enzymes to interpatient variability, metabolic enzymes as therapeutic targets, 
extrapolation of in vitro and animal data to human clinical studies, and in vivo therapeutic 
target efficacy all are important topics that require further investigation. 
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Figure 6.1:  A simplified illustration of central nervous system compartmentalization. ①, 
protein binding; ②, passive diffusion; ③, active transport; ④, metabolism; ⑤, CSF 
turnover.  
Abbreviations: BBB, blood-brain barrer; BCSFB, blood-cerebrospinal fluid barrer; CSF, 
cerebrospinal fluid; ECF, extracellular fluid; ICF, intracellular fluid.
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APPENDIX 
PHARMACOKINETICS OF SUBSTRATE UPTAKE AND DISTRIBUTION IN MURINE 
BRAIN AFTER NASAL INSTILLATION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published in Pharmaceutical Research and is presented in the style of that 
journal. 
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ABSTRACT 
 
Purpose:  This study was conducted to develop a physiologically-relevant mathematical model 
for describing brain uptake and disposition of nasally-administered substrates.  
Methods:  [14C]-antipyrine, [14C]-diazepam, [3H]-sucrose or [3H]-verapamil was administered 
nasally to CF-1 mice. P-gp-deficient mice also received [3H]-verapamil to probe the influence of 
P-gp on uptake/distribution. Mice were sacrificed at selected intervals, and 20 serial 300-μm 
coronal brain sections were obtained to determine radioactivity.  A series of compartmental 
pharmacokinetic models was developed and fit to concentration vs. time/distance data.   
Results:  After nasal instillation, substrate concentration was highest in the olfactory bulb and 
decreased with distance. In the absence of transport-mediated flux, peak brain exposure occurred 
at 6 hr.  A catenary pharmacokinetic model with slice-specific brain-to-blood efflux rate 
constants and slice-to-slice diffusivity factors was capable of fitting the data. P-gp limited 
fractional absorption of [3H]-verapamil via efflux from the nasal cavity and olfactory epithelium.  
P-gp also increased the rate constants associated with [3H]-verapamil efflux 1.5 – to –190-fold, 
depending on brain region. P-gp limited [3H]-verapamil uptake from the nasal cavity into brain, 
and facilitated removal of [3H]-verapamil from brain during rostral-to-caudal distribution.  
Conclusions: Taken together, the data and associated modeling provide a comprehensive 
assessment of the influence of P-gp on brain uptake and disposition of nasally-administered 
substrates. 
 
Key Words:  P-glycoprotein, Nasal administration, Blood-brain barrier, Pharmacokinetics, Brain 
Slices 
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INTRODUCTION 
Treatment of central nervous system (CNS) disorders remains challenging, primarily due to the 
inability of potential therapeutic agents to reach the relevant pharmacologic target.  The blood-
brain barrier (BBB) forms a nearly impenetrable barrier that excludes compounds based on their 
physicochemical properties and affinity for active efflux transport (1).  P-glycoprotein (P-gp) is a 
barrier transporter that limits brain uptake of substrates from a variety of therapeutic classes, 
including protease inhibitors, anti-epileptics and anti-cancer agents (2-4).  P-gp is considered a 
prototypical multidrug resistance (MDR) transport protein, originally identified based on its 
ability to render cancer cells resistant to chemotherapy (5), and is the most well-characterized of 
the BBB efflux transport systems.  P-gp is a 170-kDa plasma membrane, energy-dependent 
efflux protein that is a member of the ABC superfamily of transport systems (6, 7), and is 
expressed on the luminal side of the brain capillary endothelium (8). P-gp expels a wide range of 
functionality and structurally unrelated compounds from the endothelial cell.  In general, P-gp 
substrates are hydrophobic, amphipathic molecules with a planar ring system, a molecular weight 
>400 kDa, and a positive charge at pH 7.4 (9).  However, due to the complexities involved with 
multiple substrate and ATP binding sites and conformational changes secondary to substrate 
binding, no comprehensive structure-activity relationships have been established for P-gp (10).  
Due to the formidable obstacle imposed by the BBB, there has been increased interest in 
developing strategies to overcome this barrier.  It has been a widely held view that nasal delivery 
provides a means to circumvent the BBB and thus may allow increased CNS penetration of 
compounds that otherwise display limited CNS exposure (11).  In general, there are three 
pathways that a drug administered into the nasal cavity may travel.  These routes include entry 
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into the systemic circulation directly from the nasal mucosa (12), entry into the olfactory bulb via 
axonal transport along neurons (13), and direct entry into the brain via the olfactory epithelium 
(14).  A drug that enters into the systemic circulation must be absorbed through the nasal mucosa.  
Administration via this route avoids hepatic/GI first-pass effects and therefore may provide more 
extensive systemic exposure for substrates that have poor oral bioavailability (15). However, this 
particular route does not represent an advantage for the delivery of agents to the CNS (as the 
substrate must traverse the BBB from the systemic circulation), and is thus not a focus of this 
paper.  A drug also may be carried along the olfactory neuron by intracellular axonal transport to 
the olfactory bulb. This olfactory nerve pathway would allow the drug to be taken up into the 
neuronal cell (located in the olfactory epithelium) by endocytosis and subsequently transported 
into the CNS.  This pathway is utilized by some metals, viruses, and proteins (13, 16, 17) and 
represents a path by which the BBB may be bypassed.  Despite the ability of this pathway to 
deliver agents to the olfactory bulb, transport to CNS sites beyond the olfactory system is unclear.  
Furthermore, this route is slow (requiring hours to days to reach certain brain regions), and thus 
cannot account for the immediate appearance (within minutes) of some solutes in the brain 
and/or CSF following nasal administration.  The mechanisms governing direct delivery of 
substrate to the brain via the olfactory epithelium are not well understood.  This pathway 
purportedly involves delivery of the substrate directly to the brain parenchymal tissue, to the 
cerebrospinal fluid (CSF), or to both (18).  While the BBB does not exist at the olfactory 
epithelium, P-gp (and likely other BBB transporters) is functional at this barrier (19).  The 
experiments reported in this communication were designed to explore the kinetics of brain 
uptake and distribution via this direct olfactory epithelial pathway. 
There is increasing evidence that a direct nose-to-brain pathway (resulting in rapid brain uptake) 
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exists and can be accessed by a variety of compounds, in both rodent models and humans (14, 20, 
21).  To exploit this direct olfactory epithelial route of delivery, a compound must cross the 
olfactory membrane via the transcellular pathway or via the paracellular pathway.  The former 
route is utilized by small lipophilic (primarily by diffusion) or large molecules (primarily by 
receptor-mediated endocytosis), while the latter route is utilized by small hydrophilic molecules 
(22).  There are a variety of factors that will affect the permeability of nasally-delivered drugs, 
including the biology of the system (i.e., structural features, pH, mucociliary clearance, and 
biochemical factors such as enzymes) and formulation factors [i.e., physicochemical properties 
of the drug and formulation (23)].  For instance, it has been shown that the uptake of drugs into 
the CSF and brain parenchyma is dependent on molecular weight and lipophilicity.  It is clear 
that a comprehensive understanding of the mechanisms governing this pathway is necessary in 
order to investigate the use of nasal administration as a practical means of delivering agents to 
the brain.   
Many of the studies examining brain uptake after nasal administration have utilized CSF 
concentrations as a surrogate for brain exposure.  This may not be an accurate representation of 
pharmacologically relevant CNS penetration since CSF is not necessarily in equilibrium with 
brain tissue.  Other experimental protocols have determined substrate in whole brain, which 
provides an estimate of overall brain exposure but gives no information regarding localization 
within the brain.  Although regional exposure has been addressed with microdialysis, this 
method provides information for only one discrete location per animal.  Previous studies in this 
laboratory utilized whole brain homogenate (24), and thus the potential distribution of substrate 
within the brain, and the pharmacologic implications associated with this distribution, were 
unclear (19).  Therefore, the purpose of the present study was to examine the kinetics of rostral-
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to-caudal distribution of nasally-administered compounds (in the absence of transporter-
mediated flux) and to develop a mathematical model to explain the disposition of these model 
compounds.  In addition, the impact of P-gp-mediated efflux on brain uptake and distribution 
was considered with the standard P-gp substrate verapamil. 
 
METHODS 
Materials 
Probe substrates were obtained from the following sources:  [3H]-(±)-verapamil (85 Ci/mmol), 
[14C]-diazepam (56 mCi/mmol), and [3H]-sucrose (10.2 Ci/mmol)  [NEN Life Science Products, 
Boston, MA]; [14C]-antipyrine (55 mCi/mmol) [American Radiolabeled Chemicals, St. Louis, 
MO]. All other reagents used in this study were of the highest grade available from commercial 
sources. 
Animals 
Adult CF-1 mice [mdr1a(+/+) and mdr1a(-/-), 30-40 g, 8-12 weeks of age] were purchased from 
Charles River Laboratories (Wilmington, MA) and maintained in a breeding colony in the 
School of Pharmacy, The University of North Carolina.  Male and female mice were housed 
separately (maximum of 4 animals per cage) in wire-mesh cages in a temperature- and humidity-
controlled room with a 12-h-dark/12-h-light cycle, and had unrestricted access to food and water.  
The Institutional Animal Care and Use Committee of the University of North Carolina approved 
the experimental protocols, and all procedures were conducted according to the “Principles of 
Laboratory Animal Care” (NIH publication #85-23, revised in 1985). 
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Nasal Administration  
Nasal administration was performed as previously reported (19).  Briefly, mice (n=4/group) were 
anesthetized by intraperitoneal injection of ketamine and xylazine (140 and 8 mg/kg, 
respectively).  The mice were placed in a supine position on a 37°C heating pad to maintain body 
temperature with the head held back and a dowel (~7 mm) under the neck to limit liquid flow 
down the trachea.  Solutions containing test compounds (pH 7) were warmed to 37°C in a water 
bath prior to instillation.  Tracers were added at a concentration of 0.5 mCi/mL.  The solutions (5 
μM, 5 μL/nostril) were administered via separate 10-μL gas-tight syringes (2 inch, 23 gauge 
needle) to each nostril.  Timing for the purpose of determining substrate uptake was initiated 
following completion of instillation. The animals were allowed free mobility upon awakening 
from the anesthesia. Brain uptake was terminated by decapitation at pre-determined time points 
(2, 4, 6, 8, 10, 12, 18 hr post-dose).  The brain was removed rapidly from the skull, blotted dry, 
and mounted on a platform with cyanoacrylate to allow coronal slicing. 
Systemic Administration 
Mice (n=4/group) were anesthetized as described above.  Substrates (5 mg/kg in 50% Methanol) 
with appropriate tracers (0.5 mCi/mL) were administered via tail vein injection (<0.01 mL/g).  
Brain uptake was terminated by decapitation at 2, 6, or 10 hr post-dose.  Following the 
experiment, the brain was removed and prepared for slicing as described above. 
Fresh Tissue Slicing  
After allowing the tissue to set for approximately 2 min, the platform was submersed in 2°C 
phosphate buffered saline (PBS) for slicing (Vibratome 3000, St. Louis, MO).  Coronal sections  
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(300 μm) were cut with a 35º-blade angle using Vibratome feather blades [low speed (setting 1), 
high amplitude (setting 8)]. Sequential slices were obtained in the rostral to caudal direction.  
Slices were removed from the buffer and placed in tared 8-mL glass scintillation vials and 
weighed.  The tissue was digested with 0.3 mL Solvable® (Packard, Boston, MA) at 50°C 
overnight. After cooling, samples were mixed with 5 mL scintillation cocktail (Ultimate Gold 
XR®; Packard) and total radioactivity was determined.  Scintillation counting (referenced to 
appropriate quench curves for single- or dual-label counting, depending on the experiment) was 
performed in a Packard Tri-Carb model 1900 TR (Packard).  Brain samples obtained from naïve 
mice were analyzed, and these blanks were subtracted from all samples to correct for apparent 
background. 
Data Analysis 
Data are expressed as mean ± SD (n=4) unless otherwise noted.  Where appropriate, a two-tailed 
Student’s t-test was used to evaluate the statistical significance of differences between 
experimental groups.  In all cases, P<0.05 was used as the criterion of statistical significance.  
The total fraction of radioactivity in the whole brain at each time point was calculated as the 
percentage of the total amount of radioactivity in the administered dose: 
100
(dpm) edadminister dose total
(mg)ht brain weig *brain) (dpm/mg,amount (%)fraction ×=  
The area under the slice concentration-time curve (AUC0→18 for nasal administration, AUC0→10 
for systemic administration) was calculated to assess the regional exposure from time zero to 18 
hr following nasal administration (and time zero to 10 hr following systemic administration) 
according to the linear trapezoidal method.   
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Pharmacokinetic Modeling 
Mean data for substrate concentration in each slice at each time point were fit simultaneously 
with the scheme depicted in Figure A.1A.  Because the substrate dose used in these experiments 
was low, linear conditions were assumed.  The model incorporated first-order absorption from 
the nasal cavity into brain (ka), with subsequent passive diffusion in the rostral-to-caudal 
direction between adjacent slices (k12).  It was assumed that the slice-to-slice diffusion rate 
constant was independent of brain region.  Flux from the nasal cavity (kn), as well as from each 
individual slice (koi) was included.  To account for the different physicochemical properties of 
the substrates (i.e., lipophilicity), diffusivity factors (Dfj for each compound j) were utilized as a 
modulator of the absorption rate constant (ka) and the rate constant for slice-to-slice diffusion 
(k12).   
The amount of [14C]-diazepam or [14C]-antipyrine in wild-type mice, and [3H]-verapamil in 
mdr1a(-/-) animals, in each brain slice was modeled vs. time with the following differential 
equations: 
In the nasal cavity, )()( nasalnnasalaj
nasal XkXkDf
dt
dX ••• −−=  
For the first slice, )()()( 111121 XkXkDfXkDfdt
dX
ojnasalaj ••••• −−=  
For all subsequent slices, )()()( 12)1(12 ijioiij
i XkDfXkXkDf
dt
dX ••••• −−= −  
For the last slice, )()( 20201912
20 XkXkDf
dt
dX
oj ••• −=  
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where at t=0, Xnasal = Fabs*X0 (X0 was the dose administered); for all subsequent slices, the initial 
value Xi (i=2→20) was equal to zero at time zero. 
To account for the impact of P-gp on [3H]-verapamil disposition, additional flux parameters were 
incorporated from the brain (k1p) and the nasal cavity (knp).  In order to determine the value of 
knp, kn was fixed at 1.87 hr-1, the value determined in the absence of P-gp-mediated efflux (i.e., 
from [3H]-verapamil disposition in mdr1a(-/-) mice).  
The amount of [3H]-verapamil in each brain slice of mdr1a(+/+) animals was modeled vs. time 
with the following differential equations: 
In the nasal cavity, )()(])[( 11 XkXkDfXkkdt
dX
pnasalajnasalnnp
nasal •••• +−+−=  
For the first slice, )()()()( 11211111 XkDfXkXkXkDfdt
dX
jopnasalaj •••••• −−−=  
For all subsequent slices, )()()( 12)1(12 ijioiij
i XkDfXkXkDf
dt
dX ••••• −−= −  
For the last slice, )()( 20201912
20 XkXkDf
dt
dX
oj ••• −=  
where the initial conditions for each slice were as defined above for mdr1a(-/-) animals. 
A model based on the scheme depicted in Figure A.1B was utilized to determine whether 
systemic concentrations contributed significantly to the brain uptake and disposition of model 
substrates.  This model was similar to Model A, but incorporated a first-order absorption into 
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blood from the nasal cavity (kb) and bi-directional flux from blood into the sequential slices (kpci, 
kcpi).  It also allowed for elimination of substrate from the blood compartment (kob). 
Model differential equations were fit to the mean data by nonlinear least-squares regression with 
WinNonlin Software (Pharsight, Palo Alto, CA, USA).  Assessment of the goodness of fit of the 
model to the observed data was based on coefficients of variation (CV%) and distribution of 
residual error.  Akaike’s Information Criteria (AIC) was used to compare the appropriateness of 
alternative model structures. 
 
RESULTS 
Brain Uptake Following Nasal Instillation 
For all of the compounds studied, the total amount present in the brain (expressed as % dose) 
following nasal instillation peaked at 6 hr post-dose (Figure A.2).  [14C]-diazepam had the 
highest amount in brain at 6 hr (3.58±0.28%), followed by [3H]-verapamil in the mdr1a(-/-) mice 
(3.16±0.74%) and [14C]-antipyrine (2.84±0.34%).  In general, the temporal profiles of these 
compounds were similar.  In contrast, [3H]-sucrose showed very limited uptake (0.91±0.22%), 
and although the amount in brain peaked at 6 hr, the profile evidenced little relationship with 
time. The mdr1a(+/+) mice exhibited much lower brain uptake of [3H]-verapamil compared to 
mdr1a(-/-) animals (1.2±0.31% at 6 hr; p<0.001), consistent with P-gp-mediated efflux.    The 
total amount delivered to the brain (expressed as AUC0→18) varied among the substrates 
examined, with [14C]-diazepam displaying the highest exposure (32.8±6.3 %dose*hr/mg), 
followed by [3H]-verapamil in the mdr1a(-/-) mice (29.5±5.3 %dose*hr/mg) and [14C]-antipyrine 
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(26.2±4.8 %dose*hr/mg).  [3H]-sucrose and [3H]-verapamil in the mdr1a(+/+) mice both 
displayed markedly lower brain exposure (8.3±2.3 and 10.2±2.1 %dose*hr/mg, respectively; 
p<0.01 for [3H]-verapamil compared to mdr1a(-/-) animals).  In the absence of an influence of P-
gp, the amount delivered to the brain correlated significantly (r2=0.95) with the log P values of 
the model substrates (Figure A.3). 
Brain Distribution Following Nasal Instillation 
Regional exposure (i.e., exposure in each brain tissue slice; dose-normalized and expressed as 
AUC0→18) differed among the model substrates (Figure A.4).  As was the case with total brain 
content, [14C]-diazepam exhibited the highest exposure in each slice, followed by [3H]-verapamil 
in mdr1a(-/-) animals, [14C]-antipyrine, [3H]-sucrose and [3H]-verapamil in mdr1a(+/+) animals.  
Exposure was highest in the olfactory region (slices #1-3) and decreased towards the more rostral 
portions of the brain.  In addition, [3H]-sucrose evidenced virtually no substrate exposure beyond 
slice #5. 
Brain Uptake and Distribution Following Systemic Administration 
To assess the difference in brain distribution following nasal administration compared to 
systemic administration, the model compounds also were administered systemically (i.v.) to mice, 
and both total amount delivered (% dose) and total exposure (AUC0→10) were determined.  
Systemic administration resulted in a larger fraction of the dose being delivered to the brain for 
each of the compounds, and the peak amount in brain occurred at 2 hr (compared to 6 hr for 
nasal administration).  The peak brain content was 11.7±2.6, 8.7±2.3, 5.9±1.8 and 1.3±0.4% for 
[14C]-diazepam, [3H]-verapamil in mdr1a(-/-) mice, [14C]-antipyrine and [3H]-verapamil in 
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mdr1a(+/+) mice, respectively.  There was no [3H]-sucrose detectable in the brain following 
systemic administration. 
The regional exposure also differed between systemic administration compared to nasal 
administration (Figure A.5).  Substrate content following systemic administration was relatively 
constant across the slices; certainly, preferential accumulation in specific slices was not evident.  
However, the amount of substrate in slices #7-10 was lower than in other areas of the brain.  
These slices correspond anatomically with regions containing the striatum, parietal cortex and 
thalamus, structures that have relatively low blood volumes (25).   
Pharmacokinetic Modeling 
Serial coronal tissue slicing was used in the present investigation to examine the distribution of 
substrates in the brain.  The primary objective of this study was to determine the effect of 
lipophilicity and P-gp-mediated efflux on substrate uptake into and distribution within the brain.  
Thus, a compartmental modeling approach was selected to analyze the data comprehensively.  A 
model based on the scheme depicted in Figure A.1A was fit simultaneously to the substrate 
concentration vs. slice and time data. Representative descriptions of the data for individual slices 
are shown in Figure A.6.  These panels illustrate the difference in [3H]-verapamil distribution 
between P-gp-competent and P-gp-deficient mice.  Final parameter estimates describing the 
brain distribution of substrates following nasal instillation in the presence and absence of P-gp 
are shown in Table A.1.  In the presence as compared to absence of P-gp, the efflux rate 
constants for [3H]-verapamil in each individual slice increased (1.4 to190-fold, depending on 
brain region), indicative of increased efflux mediated by P-gp within the brain.  The presence of 
P-gp also necessitated the inclusion of two additional flux components, one from the nasal cavity 
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(knp) and one at the olfactory epithelium (k1p).  These localizations are supported anatomically, 
given that P-gp has been identified in the nasal mucosa (26) and work in this laboratory has 
demonstrated the presence of P-gp in the olfactory epithelium (unpublished data).  The P-gp-
mediated efflux from the nasal cavity was larger than at the olfactory epithelium (8.92 vs. 4.32 
hr-1, respectively), consistent with the larger surface area of the nasal cavity compared to the 
olfactory epithelium.  The absorption of substrate (from nasal cavity to brain, ka) was decreased 
in the presence of P-gp (0.126 vs. 0.0835 hr-1), consistent with P-gp-mediated efflux at this 
barrier resulting in a reduced rate of absorption.  The slice-to-slice diffusional component of the 
model (k12) remained essentially the same regardless of the presence of P-gp, indicating that the 
difference in disposition was due primarily to the transporter mediating egress from the brain.  It 
is interesting to note that the diffusivity factors recovered correlated quite well with the reported 
log P values (and peak % dose absorbed) of these compounds (r2=0.98). 
Three-dimensional representations (comparing amount of substrate vs. time vs. slice number) of 
the model fit for the distribution of  [14C]-diazepam, [14C]-antipyrine and [3H]-verapamil (in 
mdr1a(-/-) and mdr1a(+/+) mice) are shown in Figures A.7-A.10, respectively.  These profiles 
clearly demonstrate that substrate exposure is dependent on time after administration, slice 
number (i.e., specific brain region), lipophilicity (by comparing different substrates), and 
transporter specificity.  In addition, each of these profiles evidenced a consistent plateau in slices 
obtained from the mid-brain. 
To consider the impact of P-gp beyond the olfactory epithelium, the [3H]-verapamil efflux 
parameters for individual slices in the presence vs. the absence of P-gp were compared, yielding 
slice-specific P-gp effects (Figure A.11).  The influence of P-gp on [3H]-verapamil efflux from 
brain was dependent on brain region, with the highest P-gp effects observed in slices #6-10.  
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Alternative models that included various combinations of rate constants and altered 
compartmental structure were evaluated.  For instance, the addition of a blood compartment for 
only slices #1-3 (corresponding to the olfactory region) was included with bi-directional flux to 
account for multiple routes of substrate input at this site (from nasal cavity and the systemic 
circulation).  In order to assess the potential for brain uptake occurring via the systemic 
circulation (following rapid absorption through the nasal mucosa), the model structure shown in 
Figure A.1B was considered.  The data did not support these alternative models, as evidenced by 
a poor distribution of residual error, increased coefficients of variation for model parameters, and 
increased AIC.  In addition, adjacent slices with similar substrate concentrations and common 
anatomical structures were grouped and included as lumped compartments.  Bi-directional 
passive diffusion between adjacent slices also was considered, as were various feedback loops.  
Ultimately, the model structure and data analysis approach (Figure A.1A) chosen were superior 
and provided the best description of the observed data. 
 
DISCUSSION 
The compounds selected for this study were chosen based on physicochemical properties 
(lipophilicity, molecular weight) and to probe the influence of P-gp on brain uptake from the 
nasal cavity and subsequent distribution in the organ.  Sucrose was selected to assess the 
feasibility of utilizing the nasal route to deliver a bulky hydrophilic compound that is unable to 
cross the BBB.  Diazepam was chosen as a highly lipophilic model compound, the brain uptake 
of which has been shown to be blood flow-limited (25).  Antipyrine was included in the 
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compound set due to its intermediate lipophilicity.  Finally, verapamil was chosen as a model P-
gp substrate to study the effects of P-gp-mediated efflux on brain uptake and distribution.   
In the absence of transporter-mediated flux ([3H]-verapamil in mdr1a(-/-) mice; all other 
compounds in wild-type animals) the peak fraction of the dose in brain correlated well with the 
log P values for this compound set (Figure A.3).  This observation suggests that brain uptake 
from the nasal cavity was mediated by the direct olfactory route, and is consistent with literature 
for nasal delivery of small molecules.  It has been shown previously that uptake of low molecular 
weight molecules across the olfactory epithelium is dependent on the physicochemical properties 
of the compound, and that CNS uptake by this pathway correlates with lipophilicity (21). 
Serial sectioning of the brain revealed that tissue exposure (i.e., AUC in discrete slices) 
following nasal delivery was dependent on the specific brain region.  Regardless of the substrate 
examined, nasal delivery resulted in preferential exposure in the rostral portions of the brain; 
exposure decreased consistently as the compound distributed caudally.  The profile for [3H]-
sucrose supports the premise that the direct olfactory epithelial pathway was being probed.  
Although [3H]-sucrose appeared in brain following nasal administration, it did not distribute 
beyond the olfactory region.  Furthermore, no [3H]-sucrose was detectable in the brain following 
systemic administration (Figure A.5).  Thus, the amount observed in brain following nasal 
administration was the result of a direct nose-to-brain transport.  The most lipophilic compound 
tested, [14C]-diazepam, had the highest total exposure, likely due to efficient diffusion through 
the olfactory epithelium into the brain.  The shape of the profiles for nasally-administered [14C]-
antipyrine and [3H]-verapamil (in the mdr1a(-/-) animals) were similar to that for [14C]-diazepam, 
although these compounds had a somewhat lower total exposure, consistent with a lower 
lipophilicity.  
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Compared to nasal administration, systemic administration resulted in a more homogenous 
distribution of substrate in brain.  The total exposure for the compounds was slightly increased 
(<1.5-fold) compared to nasal administration (43.8±8.9, 35.4±7.8 and 25.9±6.2 %dose*hr/mg for 
[14C]-diazepam, [3H]-verapamil (in mdr1a(-/-) mice) and [14C]-antipyrine, respectively).  
Interestingly, substrate persistence in brain appeared to be lower after systemic compared to 
nasal administration (data not shown), consistent with previous observations that nasal delivery 
results in increased residence time in the brain (27).  In addition, a distinctly lower exposure was 
noted for all compounds (except sucrose) between slices #7-10.  Anatomically, these slices are 
comprised of the parietal cortex, striatum and thalamus, which are brain regions with relatively 
low blood volume (25).  If resident blood volumes and blood flow are related, one would 
anticipate decreased exposure in regions with low blood volume prior to attainment of complete 
distribution equilibrium.  The ability to detect regional differences in substrate exposure that 
have a known physiologic correlate suggests that the coronal slicing method is sufficiently 
sensitive to reveal nuances in brain distribution. 
The presence of P-gp-mediated efflux resulted in significantly reduced net [3H]-verapamil 
delivered to the brain (Figure A.2).  Also, the profile for [3H]-verapamil distribution in  
mdr1a(+/+) brain compared to mdr1a(-/-) animals (Figure A.4) differed somewhat in shape with 
significantly reduced total exposure, suggesting that P-gp-mediated efflux influenced both initial 
brain uptake and overall brain distribution following nasal administration.   
Since it appeared that serial sectioning was sufficiently sensitive to explore compound 
distribution within the brain, rigorous mathematical modeling of the data was conducted to 
further explore and clarify this direct route of delivery.  The optimized model (Figure A.1A) was 
able to describe substrate distribution across time and brain region.  Given that [3H]-sucrose 
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failed to distribute significantly past the olfactory region, it was excluded from the modeling 
exercise. The data from each slice at each time point was modeled simultaneously to generate a 
comprehensive 3-dimensional representation of distribution within the brain as a function of time, 
distance and, in the case of [3H]-verapamil, interactions with an efflux transporter (Figures A.7-
A.10).  Attempts to consolidate the model by grouping adjacent slices provided inferior results, 
perhaps due to subtle differences in distribution kinetics between discrete brain regions.  The 
model recovered a single slice-to-slice distributional rate constant for all test compounds, which 
was modulated by a compound-specific diffusivity factor related to lipophilicity.  This result 
indicates that, in the absence of transporter-mediated flux, physicochemical properties of the 
compound (i.e., lipophilicity) serve as the primary determinant of brain uptake and distribution.   
The results of the modeling for [3H]-verapamil were consistent with earlier work indicating that 
P-gp is functional at the olfactory epithelium and serves to attenuate brain uptake after nasal 
administration (19).  These results also clearly show that P-gp operates throughout the brain to 
efflux substrates during rostral-to-caudal distribution.  However, the magnitude of the influence 
of P-gp on substrate residence in brain evidenced distinct regionality.  In contrast to compounds 
such as diazepam that rely solely on diffusional translocation, the brain distribution of substrates 
of efflux transporters (in this case, P-gp) is dominated by the transporter-mediated process.  
Incorporation of P-gp-mediated efflux into the model led to several interesting quantitative 
results. P-gp was modeled at the nasal mucosa and the olfactory epithelium (represented by the 
rate constants knp and k1p, respectively); both sites of expression influenced net uptake of [3H]-
verapamil into brain from the nasal cavity.  P-gp also was modeled throughout the brain 
(presumably at the BBB), facilitating loss of substrate from each slice.  However, the impact of 
P-gp on substrate distribution varied significantly among brain regions.  The koi ratio between P-
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gp-competent and P-gp-deficient animals defined the P-gp effect on substrate persistence in each 
slice.  Between slices #6-10 (anatomically corresponding to the thalamus, striatum and parietal 
cortex regions; Figure A.11), the P-gp effect was significantly higher than in other regions of the 
brain. This regionality in P-gp-mediated flux is consistent with recent literature suggesting 
preferential P-gp induction in the striatum and frontal cortex in a rat seizure model (28), and may 
suggest an increased basal expression of P-gp in this region.  The significance of this observation 
is not entirely clear, but the pharmacologic implications are apparent.  In order to be an effective 
CNS agent, a compound must be able to access its pharmacologic target.  Opioid receptors are 
concentrated in the thalamus and cortex (29), and the increased P-gp function in these regions 
suggests that this may serve a protective mechanism for these and perhaps other key receptors.  
Further studies are needed to elucidate the significance of the apparent regionality in P-gp 
function within the brain regions.   
Both the data and modeling support the direct pathway of delivery via the olfactory epithelium as 
the primary route of brain uptake for these compounds.  Although the present experiments 
cannot rule out the contribution of the olfactory nerve pathway, the modeling and time frame of 
the experiments suggest that the primary pathway of delivery being explored is likely direct.  It is 
possible that the direct pathway and the olfactory nerve pathway work coordinately, although 
such coordination has not been documented.  Alternatively, it is possible that exposure via the 
systemic circulation contributes to rapid substrate appearance in brain.  However, the 
mathematical modeling did not support the presence of significant drug uptake via this route.  In 
addition, it should be noted that this work examined total radioactivity and therefore might 
represent the disposition of both parent and one or more derived metabolites.  
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The fact that millions of people are afflicted with debilitating CNS disorders such as Alzheimer’s 
and Parkinson’s disease suggest that discovery and development of novel CNS agents will 
continue at a significant pace.  It is imperative that new therapeutic regimens are able to reach 
relevant pharmacologic target within the brain.  Nasal delivery may allow a drug to access a 
target in the brain more readily than by other routes of administration.  However, the 
mechanisms governing this uptake are only beginning to be understood.  In order to exploit this 
potential delivery route, efforts must be focused on increasing the fraction of the dose that 
reaches the CNS.  A comprehensive characterization of the potential transporters and metabolic 
enzymes present at the “nose-brain barrier” is required in order to maximize the potential that 
this delivery route may offer.   
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Table A.1:  Final model parameters associated with the brain distribution of [3H]-verapamil after 
nasal instillation. 
 Parameters in the 
absence of P-gp 
Parameters in the 
presence of P-gp 
Parameter  
Ratio 
Parameter (hr-1) Estimate  CV% Estimate CV%   
ka   0.126 6.82     0.0835 24.8 0.663 
k12       1.32 10.8        1.19 43.5 0.902 
ko1       5.48 129        7.62 113.8 1.39 
ko2       1.21 46.9        3.22 78.5 2.66 
ko3       0.496 47.7        1.75 62.3 3.53 
ko4       0.584 47.0        1.23 48.8 2.11 
ko5    0.610 56.2        1.12 32.5 1.84 
ko6    0.151 78.9        0.872 78.2 5.77 
ko7    0.216 62.3        3.27 48.2 15.14 
ko8      0.0204 212        2.24 198.8 110 
ko9      0.0110 168        2.11 223.6 192 
ko10      0.0831 150        2.87 143.4 34.5 
ko11  0.319 78.3        0.983 87.2 3.08 
ko12  0.521 59.3        1.23 56.8 2.36 
ko13  0.186 61.2        0.822 48.8 4.42 
ko14  0.394 78.2        1.29 112.5 3.27 
ko15  0.451 34.6        1.89 89.8 4.19 
ko16  0.649 48.8        1.24 65.7 1.91 
ko17  0.893 52.1        2.74 49.9 3.07 
ko18      1.27 57.3        3.21 123.4 2.53 
ko19      1.89 47.5        3.78 65.4 2.00 
ko20      4.89 68.9        7.13 43.4 1.46 
kn      1.87 168        1.87 187.7 1 
knp n/a -        8.92 72.3 n/a 
k1p n/a -        4.32 68.2 n/a 
Fabs (%)      2.03 78.5        2.03 84.8 n/a 
 Diffusivity Factors 
Diazepam      3.12 43.6 n/a - n/a 
Verapamil      2.52 58.8   2.52 84.3 1 
Antipyrine      1.13 38.6 n/a - n/a 
 
 
*[3H]-verapamil only 
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Figure A.1:  Panel A. Scheme of the model for brain uptake and disposition following nasal 
administration via the olfactory epithelium. Fabs represents the fraction of dose absorbed with X0 
representing the dose. ka represents the apparent first-order absorption rate constants into brain 
from the nasal cavity; kn represents the first-order rate constant for non-P-gp-mediated flux from 
the nasal cavity; k1p and knp are first-order rate constants representing P-gp-mediated flux from 
the brain and nasal cavity, respectively; k12 represents the first-order rate constant for passive 
diffusion between adjacent slice compartments (in a rostral-to-caudal direction only); koi 
represents the first-order rate constant for the passive diffusion out of the ith brain section.  
Diffusivity factors (Dfj for each compound j) were included in the final model structure to 
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account for the lipophilicity of each compound and were incorporated into ka and k12. Panel B. 
Scheme of the best model fit for brain uptake via systemic circulation following nasal 
administration. The parameters are the same as for model A with additional parameters 
representing absorption into blood (kb), absorption rate constants for flux between blood and 
brain (kpci and kcpi) and flux out of blood (kob). 
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Figure A.2:  Time course of [14C]-diazepam (triangles), [14C]-antipyrine (squares), [3H]-sucrose 
(diamonds) and [3H]-verapamil [circles, closed in mdr1a(+/+), open in mdr1a(-/-) animals] 
following nasal administration represented as % dose in brain. Symbols represent mean ± SD 
(n=4). 
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Figure A.3:  Relationship between reported log P values and the peak amount of drug delivered 
to the brain following nasal administration. Data represent mean ± SD (n=4) and the line 
represents the linear regression through those points (y=2.38x + 0.32; r2=0.95).  
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Figure A.4:  Regional exposure (expressed as AUC0→18) resulting from the distribution of 
substrates following nasal administration. Symbols represent mean ± SD (n=4). Panel A 
describes the distribution of [14C]-diazepam, Panel B describes the distribution of [3H]-sucrose, 
Panel C describes the distribution of [14C]-antipyrine, and Panel D describes the distribution of 
[3H]-verapamil [• in mdr1a(+/+) and o in mdr1a(-/-) animals].  
 
Slice Number
0 2 4 6 8 10 12 14 16 18 20
A
U
C
 (d
pm
*h
r/m
g)
0
100
200
300
400
500
600
Slice Number
0 2 4 6 8 10 12 14 16 18 20
A
U
C
 (d
pm
*h
r/m
g)
0
100
200
300
400
500
600
Slice Number
0 2 4 6 8 10 12 14 16 18 20
A
U
C
 (d
pm
*h
r/m
g)
0
100
200
300
400
500
600
Slice Number
0 2 4 6 8 10 12 14 16 18 20
A
U
C
 (d
pm
*h
r/m
g)
0
100
200
300
400
500
600
A
C
B 
D 
  258
 
  
Figure A.5:  Regional exposure of substrates (expressed as AUC0→10) following systemic 
administration. Triangles represent [14C]-diazepam, squares represent [14C]-antipyrine, and 
circles represent [3H]-verapamil [open in mdr1a(-/-) and closed in mdr1a(+/+) animals]. 
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Figure A.6:  Representative fit of the model to data from individual brain slices following nasal 
administration. Data are mean ± SD (n=4); the line indicates the model fit. Open symbols 
indicate [3H]-verapamil in mdr1a(-/-) animals and closed circles indicate [3H]-verapamil in 
mdr1a(+/+) animals. The individual slices shown are: slice #1 (Panel A), slice #3 (Panel B), 
slice #5 (Panel C), slice #9 (Panel D), slice #11 (Panel E) and slice #14 (Panel F). These slices 
were selected as representative of different brain regions and illustrate typical goodness-of-fit of 
the model to the data. 
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Figure A.7:  3D-representation of the brain disposition of [14C]-diazepam following nasal 
administration accounting for the influence of time and region on substrate exposure showing the 
influence of both brain region and time after administration on substrate accumulation.   
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Figure A.8:  3D-representation of the brain disposition of [14C]-antipyrine following nasal 
administration accounting for the influence of time and region on substrate exposure showing the 
influence of both brain region and time after administration on substrate accumulation.   
 
 
  262
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A.9:  3D-representation of the brain disposition of [3H]-verapamil (in mdr1a(-/-) mice) 
following nasal administration accounting for the influence of time and region on substrate 
exposure showing the influence of both brain region and time after administration on substrate 
accumulation.   
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Figure A.10:  3D-representation of the brain disposition of [3H]-verapamil (in mdr1a (+/+) mice) 
following nasal administration accounting for the influence of brain region, time after 
administration, and P-gp-mediated efflux on substrate exposure.   
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Figure A.11:  P-gp effect of [3H]-verapamil loss from individual slices (i = slice number). P-gp 
effect is expressed as the ratio of koi estimates in mdr1a(+/+) vs. mdr1a(-/-) animals. Note that 
the y-axis is shown as a log scale. 
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